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Abstract 
 
Chapter 1 provides a general introduction to organofluorine chemistry and focuses on 
recent developments in fluorination techniques. It also details how the C–F bond 
influences conformational and physiochemical properties of organic molecules.  
 
Chapter 2 highlights the biological role of the telomere, telomerase and quadruplex 
DNA in cells. It discusses the inhibition of telomerase with small molecules that 
stabilise quadruplex DNA as a treatment for cancer. An overview of the development of 
structurally related telomerase inhibitors and recent X-ray crystallographic structural 
data with BSU6039 and BRACO-19 telomeric DNA is presented.  
 
Chapter 3 discusses the synthesis of fluorinated BSU6039 analogues for the 
investigation of the conformational effects of fluorine in 5-membered rings and its 
influence on binding with quadruplex DNA. These compounds have been successfully 
co-crystallised with telomeric DNA and their relative stabilisation of telomeric DNA 
has been assessed. The latter half of this chapter focuses on the co-crystal structures 
between (S,S)- and (R,R)-144 with Oxytricha nova telomeric DNA, discussing the key 
differences between the two stereoisomers.  
 
Chapter 4 details the synthesis of fluorinated BRACO-19 analogues. The syntheses of 
such fluorinated analogues were achieved through a base mediated coupling between 
3,6-diaminoacridone and an α-fluorinated-β-amino ester. The α-fluorinated-β-amino 
ester was synthesised through a deoxyfluorination-mediated approach, using the 
stereochemistry of natural amino acids.  
 
Chapter 5 describes the stereo- and regio- selectivity of deoxyfluorination reactions 
with dipeptides bearing the β-amino alcohol functionality. Understanding this 
selectivity enabled the development of a method towards α-fluorination of tertiary 
amides. The application of this fluorination method with an orthogonally protected 
tertiary amide is described. 
  
Chapter 1 
 
Synthesis & properties of fluorinated 
compounds 
 
 
 
 
 
 
1.1 - A brief history 
 
Alchemists of the 17th century first harnessed the power of fluoric acids by treating 
fluorspar (CaF2) with strong acid to liberate hydrofluoric acid vapour. This vapour was 
used to etch glass for decorative purposes. However, the isolation of elemental fluorine 
remained elusive until the end of the 19th century, with many of great experimentalists, 
including H. Davy and A.-M. Ampère, dedicating their efforts. The Frenchman Henri 
Moissan finally isolated elemental fluorine (F2) in 1886, by the electrolysis of 
KHF2/HF, an accomplishment that contributed to Moissan being awarded the Nobel 
Prize for Chemistry in 1906.1 During his attempts to isolate F2, Moissan would often 
experience the apparatus exploding into flames, as the liberated gas reacted with silicon 
grease. Moissan took this to conclude that he had in fact produced F2 and proceeded to 
inform the National Academy with the following statement: “One can indeed make 
various hypotheses on the nature of the liberated gas: the simplest would be we are in 
the presence of fluorine”.2 
 
1.2 - Fluorination techniques 
 
Elemental fluorine will react with practically any organic material. In today’s chemical 
research environment, fluorine gas is still actively used by academic groups around the 
world, despite the requirement for rigorous safety considerations. Chambers and 
Sandford have developed a method employing microflow reactors to tame F2. With this 
approach, 1,3-diketones such as 1, can be mildly fluorinated with 10% F2 in N2, and 
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then subsequent cyclisation with hydrazine through to mono-fluorinated pyrazoles such 
as 3. These represent fluorinated structural motifs for medicinal chemistry applications 
(Scheme 1.01).3 This approach results in higher yields over direct fluorination of 
pyrazoles with electrophilic fluorinating reagents or with elemental fluorine. 
 
 
OO F2 in N2 (10%)
MeCN
F
O O
NH2NH2
MeCN
N
H
N
F
 
 
Scheme 1.01. Synthesis of pyrazoles employing a fluorination flow method. 
 
Despite controlling the reactivity of F2 with flow reactors, elemental fluorine remains 
difficult to handle and therefore in the last half-century, there have been many novel 
fluorination methods reported in the literature.4,5  
 
1.3 - Electrophilic fluorinating reagents  
 
In the 1960’s Derek Barton explored the development of the electrophilic reagent 
CF3OF. Fluoroxy-trifluoromethane can fluorinate activated enolates, but the reagent is 
toxic and difficult to use.6 Various second generation electrophilic fluorinating reagents 
initially inspired by the power of CF3OF have now become commonplace in organic 
chemistry (Figure 1.01).  
 
 
N+
F BF4
-
N
S
F
S
O
O
F3C
O
O
CF3
N+
N+
Cl
F
2 BF4
-
 
 
Figure 1.01. Common electrophilic fluorinating reagents. 
 
The first of these reagents were the N-fluoropyridinium salts 4 of Umemoto.7 The 
reactivity of these salts can be tuned through modification of the pyridinium ring with 
electron-withdrawing and -donating functional groups. The mode of fluorination is 
thought to proceed by a single electron transfer (SET) mechanism. 
 
 1  2 3 - 77% 
4 5 6 
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The sulfone amide, N-fluorobis[(trifluoromethyl)sulfonyl]imide 5 (NFSI), developed by 
Desmarteau, is among the most powerful electrophilic fluorinating reagent developed.8 
Differding and co-workers demonstrated the first enantioselective electrophilic 
fluorination with the chiral N-fluoro sultam 7 NFSI.9 Fluorination of cyclic enolates 8 
with sulfone 7, enabled a modest enantioselectivities of up to 70% ee (Scheme 1.02). 
 
N
S
O O
F
O
COOEt
Base O
COOEt
F
 
 
Scheme 1.02. The first example of an enantioselective fluorination reaction. 
 
More recently, however, there have been remarkable developments in enantioselective 
fluorination as demonstrated by MacMillan,10 Jørgenson11 and Barbas.12 In their 
separate approaches they have demonstrated how organocatalysts in the presence of 
NFSI can achieve α-fluorination of various aldehydes, with enantioselectivities of up to 
99% ee in the case of MacMillan’s system (Scheme 1.03). 
 
H
O
NFSI 
20 mol% 12
THF/iPrOH,
 -10 ºC, 12 h
Followed by 
NaBH4
OH
F
H
O
NFSI 
1 mol% 15
MeOtBu, rt, 2 h
H
F
H
O
NFSI 
1 eq 18
DMF, 4 ºC, 2 h
F
O
H
O
MacMillan
Jørgenson
Barbas
N NH
O Ph
HN
OTMS
CF3
F3C
CF3
CF3
NHN
tBu
O Ph
12
15
18
H
 
 
Scheme 1.03. Organocatalytic approaches to the α-fluorination of aldehydes with NFSI (5). 
 
8 
7 
9 
13 
16 
11 
90%, 99% ee 
14 
>90 %, 97% ee 
17 
74%, 96% ee 
10 
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In these examples, the formation of a chiral enamine intermediate results in a 
diastereoselective interaction with the fluorinating reagent (Scheme 1.04).  
 
R
N
N
H
(S)
O
Ph
H
O
R
N
N+
O
Ph
R
N
N+
O
Ph
N
N+
O
Ph
F
R
R (S) H
O
F
R NN+ O
Ph
N SS
F
O
PhO
O
PhO
H
Si-face
Re-face
NS S
F
O
Ph
O O
Ph O
Via
H
H
O
O
Cl
Cl
 
 
Scheme 1.04. Proposed catalytic cycle for fluorination where R = aryl or alkyl. The counterion for 
intermediates 20-22 is dichloroacetic acid.  
 
Transfer of fluorine from the bottom face (the Re-face) of the chiral intermediate is 
blocked by the bulky phenyl moiety (Scheme 1.04, red clash). Thus, NFSI approaches 
the Si-face of the enaminium intermediate 21 to furnish the α-fluoro iminium 22, which 
generates α-fluoro aldehyde 23 following hydrolysis.  
 
Jørgenson used the bulky proline derivative 15 at very low catalyst loading (1 mol%), 
much lower than that of MacMillan and Barbas. The MacMillan and Barbas catalysts 
both suffer from higher catalyst loadings, however in the system developed by 
MacMillan, the yields and level of enantiocontrol were significantly improved 
(Scheme 1.03).  
 
 
 
21 
 20 
 19 
23 
 12 
 22 
N+ N
R
H
Me
Me
OBn HRe-face
Si-face
NS S Ph
O
OPh O
O
F
N SS
Ph
O
O PhO
O
F
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The most widely used electrophilic fluorinating reagent is the 
1,4-diazabicyclo[2.2.2]octane based reagent, selectfluor (6) (Figure 1.01).13 Selectfluor, 
developed by Banks, is a highly stabile, versatile and reliable fluorinating reagent that 
has found wide application in synthesis.13,14 A recent publication in Science by Toste 
and co-workers demonstrated the applicability of selectfluor (6) in the enantioselective 
fluorocyclisation of dihydropyran based substrates such as 24 to fluorinated 
spiro-oxazoline, such as 26. (Scheme 1.05).15  
 
O NH
O
R
O
N
O R
F
5 mol% Cat*
1.25 eq Selectfluor
1.1 eq proton sponge
C6H5F, -20 ºC, 24 h
O
O P
O
OH
R'
R'
iPr
iPr
iPr
iPr
iPr
iPr
Cat* -
 
Scheme 1.05. Phase transfer catalyst with selectfluor to induce fluorocyclisation. R = H, alkyl, aryl, halide 
 
In this particular transformation, Toste et al. formed a chiral cationic fluorinating 
reagent in situ, with phosphoric acid catalyst 25. Selectfluor is insoluble in non-polar 
solvents and in this protocol the formation of the chiral selectfluor salt with 25 enables 
the reaction to proceed in a non-polar solvent and thus increases the substrate scope. 
Conducting the reaction in a polar medium was found to lead to multiple unidentifiable 
products.  
 
Ritter and co-workers have pioneered an approach to the fluorination of aromatic 
heterocycles through the use of the selectfluor PF6- salt 28.16 They demonstrated that 
treatment of aryl tributylstannanes (27) with silver triflate and selectfluor resulted in the 
isolation of aryl fluorides such as 29 within 20 min at room temperature (Scheme 1.06).  
 
 
 
24 26 
25 
6 
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tBu3Sn
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N+
N+ Cl
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acetone, 23 ºC, 20 min
F
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Scheme 1.06. Fluorodestannylation through a silver-mediated approach. 
 
This proceeds through a mechanistically complex process that preliminary experimental 
data demonstrates the involvement of two silver cations in the catalytically active 
species. Trans-metalation of the aryl stannane followed by oxidative insertion of the 
fluorine to form a speculative [(Aryl-Ag-F)Ag]n+ species is though to be key to the 
process. Reductive elimination to form the Aryl-fluorine bond completes the process.  
 
Gouverneur et al. have recently demonstrated this fluorodestannylation in the 
preparation of fluorine-18 labelled heterocycles with modest radiochemical yields of up 
to 18% for positron emission tomography (PET).17 
 
1.4 - Nucleophilic fluorinating reagents 
 
Fluoride ion is a hard nucleophile with high solvation energy. The use of polar 
coordinating solvents greatly diminishes its nucleophilicity.18,19 Typical nucleophilic 
sources of fluoride are: NaF, KF and CsF.20–22 These alkali metal fluorides can be used 
to displace activated alcohols, such as 30, to furnish the corresponding fluorinated 
derivatives 31 (Scheme 1.07).4  
 
R OMs
KF/18F
R F/
18F
 
 
 
Scheme 1.07. General nucleophilic displacement of an activated alcohol with KF. Radiolabelled K18F can 
be used for the generation of PET radiotracers. R = H, alkyl, aryl. 
 
Many nucleophilic fluorinating reagents are commercially available and offer an array 
of options for chemists to introduce one more fluorine atoms into organic molecules. 
30 31 R=alkyl or aryl 
27 29 where R=aryl, 
alkyl, halide or H 
28 
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One of the most powerful fluorinating reagents is sulfur tetrafluoride (SF4), which can 
convert alcohols, ketones and carboxylic acids through to their respective mono-, 
di- and tri-fluoro analogues.4 
 
The development of safer and easier to use sulfur-based fluorination regents was led by 
Middleton at DuPont in the 1970’s.23 Middleton developed diethylaminosulfur 
trifluoride 32 (DAST 32, Figure 1.02), which represented a convenient nucleophilic 
fluorinating reagent (Scheme 1.08) for the deoxyfluorination of alcohols, with wide 
applications in synthesis. 
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Figure 1.02. Nucleophilic fluorinating reagents.  
 
DAST 32 exists in equilibrium between the neutral form 32 and the charged activated 
species 32' with a fluoride counter ion. Nucleophilic attack of the lone pair of an 
alcohol (40), to the sulfur of the activated DAST 32' results in intermediate 41 
(Scheme 1.08). This activates the alcohol ready for nucleophilic displacement by the 
liberated fluoride to yield the fluorinated product 42 (Scheme 1.08). DAST 32 does, 
however, suffer from thermal sensitivity and can decompose exothermically at 
temperatures above 90 ºC.  
 
 
32 
DAST 
 
33 
Deoxo-Fluor® 
 
34 
MOST 
 
35 
XtalFluor-E® 
 
36 
XtalFluor-M® 
37 
Ishikawa’s  
Reagent 
38 
Yarovenko’s  
Reagent 
39 
DFI 
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Scheme 1.08. General mechanism for fluorination of alcohols (where R = aryl and alkyl) with DAST 32 or 
Deoxo-Fluor® 33. 
 
Deoxo-Fluor® 33 and MOST 34 were developed as thermally stable alternatives to 
DAST 32 (Figure 1.02).23 Sulfur trifluoride based fluorinating reagents can fluorinate a 
variety of substrates, however, they are mostly employed for the fluorination of 
alcohols. DAST 32 can also convert ketones into their respective gem-difluoro 
analogues.24  
 
Ishikawa’s reagent 37, Yarovenko’s reagent 38 and the 
2,2-difluoro-1,3-dimethylimidazolidine (DFI) 39 are nucleophilic fluorinating reagents 
that are less commonly employed.4 This lack of application can be explained through 
their propensity to form side products. For example, DFI 39 can be used to fluorinate 
alcohols and ketones such as 43 and 46, however, this often results in elimination to 
give vinyl and fluoro vinyl side products such as 44 and 48 (Scheme 1.09).25 
 
 
O F FF
+
OH
OH
F
F
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Scheme 1.09. Fluorination of alcohols and ketones with DFI 39. 
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The tetrafluoroborate salts, XtalFluorE ® 35 and M® 36 are recent additions to the list of 
nucleophilic fluorinating regents (Figure 1.02).26,27 These air and thermally stable solid 
salts have been shown to have similar selectivity to DAST 32 or Deoxo-Fluor® 33 with 
few elimination products observed. However, these reagents require promoter additives 
such as DBU or HF.Et3N to enable effective conversion to gem-difluoro 51, 
mono-fluoro 53 and acyl fluoride 55 derivatives (Scheme 1.10).27 These reagents, 
unlike DAST 32 and Deoxo-Fluor® 33, do not have free fluoride, therefore the 
promoters are important in generating fluoride for nucleophilic attack at the activated 
carbon centers.  
 
O
O
OH
+N SF2
BF4-
DBU or 
Et3N.3HF
F
FF
Ph
OH
Ph
Ph
O
FPh  
 
Scheme 1.10. Fluorination with XtalFluorE ® (35). 
 
1.5 - Trifluoromethylation of aromatic and heteroaromatic rings 
 
Recent high profile publications have appeared in the literature addressing the 
development of effective aromatic trifluoromethylation. The most notable of these are 
from the laboratories of Buchwald,28 Baran29 and MacMillan,30 appearing in Science, 
PNAS and Nature respectively. Buchwald et al., developed a low catalyst loading Pd 
phosphine based trifluoromethylation procedure that displayed wide substrate tolerance 
(Scheme 1.11). This method proceeds via a classic Pd catalysed mechanism with 
reductive elimination furnishing the Ar-CF3 product, such as 57, in yields >70%.  
 55  54 
53 
 51  50  
52 
35  
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Scheme 1.11. Recent advances in the trifluoromethylation of aromatic rings. 
 
The Buchwald palladium catalysed approach provides an efficient procedure for the 
trifluoromethylation of various building blocks for later assembly into structurally 
important compounds. The contributions by Baran29 and MacMillan30 employ radical 
trifluoromethylation approaches, which proceed at ambient temperature (Scheme 1.11). 
Baran et al., have shown that the Langlois reagent (NaSO2CF3),31 along with tert-butyl 
hydroperoxide can achieve radical trifluoromethylation of unactivated heteroaromatics 
such as 59 (Scheme 1.11). This occurs in a non-selective fashion under biphasic 
conditions with trifluoromethylation of 59 occurring at the 2/3- positions 
(Scheme 1.11). Extending this approach to the trifluoromethylation of medicinally 
active agents enabled the synthesis of trifluoromethylated analogues 64-66 with some 
selectivity for the more nucleophilic carbon center (Figure 1.03).  
N
N N
N
O
O
NH
N
O
HO
N N
2
5
N
H
CF3
CF3
F3C  
 
 
Figure 1.03. Selected products using the Baran’s trifluoromethylation method. 
57 58 56 
60 59 
62 61 
63 
65 (78%) 
CF3-Caffeine 
66 (50%), 4:1 (C5/C2) 
CF3 - Varenicline 
64 (49%) 
CF3-dihydroqunine 
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In a subsequent development, MacMillan et al. have demonstrated the applicability of 
Ru(phen)3 photocatalyst 63 for the initiation of radical trifluoromethylation with various 
unactivated heteroaromatics such as 61 (Scheme 1.11).30 This approach also works at 
ambient temperature and is highly suitable to late stage modifications of 
pharmacological relevant compounds such as 67-72 (Figure 1.04). The authors report 
both selective and promiscuous trifluoromethylation with this approach (Figure 1.04). 
While both outcomes are beneficial, the promiscuous trifluoromethylation is 
significantly more powerful, enabling the synthesis of various trifluoromethylated 
regioisomers for the systematic studies of their effects in vitro/vivo.  
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Figure 1.04. Typical products of the MacMillan’s trifluoromethylation procedure. 
 
 
Both of the procedures from the MacMillan and Baran laboratories represent significant 
advances in the trifluoromethylation of aromatic compounds with wide ranging 
applications. The application of these techniques to rapid profiling of 
trifluoromethylated drugs in a medicinal chemistry context will be a key aspect of their 
future application.32,33 
 
 
 
 
 
67 (92%) 
CF3-methyluracil 
68 (94%) 
CF3-Aricept 
69 (85% ) 
CF3-flavone 
72 (78%), 2:1 (C3/C4) 
CF3-lidocaine 
71 (78%), 1.4:1 (C3/C2) 
CF3-ibuprofen 
70 (82%), 5:1 (C2/C5) 
CF3-methylvanillin 
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1.6 - Properties of fluorine in organic molecules 
 
Organofluorine compounds have found a multitude of applications from functional 
materials34 to pharmaceuticals,35–37 and agrochemicals.38 They form a significant 
proportion of pharmaceutical compounds and agrochemicals, with organofluorine 
compounds representing approximately 20% of products on the market.39 
 
Fluorine has a small van der Waals radius (1.47 Å)40 and is often regarded as an isostere 
for hydrogen or oxygen, as its steric influence is intermediate between these atoms.41 
Due to its high electronegativity, fluorine holds onto valence electrons tightly, and as a 
result, it has a high ionisation energy potential of 1681 kJ mol−1 (cf. chlorine 1251 kJ 
mol-1). Fluorine has never been observed as a ‘fluoronium’ ion (F+), unlike other 
halogens.19 
 
The C–F bond is the strongest single bond in organic chemistry with a dissociation 
energy of 115.0 kcal mol-1, significantly higher than that of other carbon halogen bonds 
(cf. C–Br - 69 kcal mol-1, C–Cl - 79 kcal mol-1).42 This can be attributed to the 
electronegativity and relative size of the fluorine atom, with the carbon donating 
electrons to the fluorine such that the carbon becomes δ+ and the fluorine δ-. Therefore, 
it can be assumed that the single bond has some electrostatic character in addition to its 
covalent nature.42 
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1.7 - Acidity and basicity  
 
The strong C–F dipole alters the pKa or pKb of neighbouring functional groups 
(Table 1.1).43,44 For example, sequential introductions of fluorine on the α-carbon of 
acetic acid results in an increase of acidity of the carboxylic acid, with the pKa going 
from 4.76 in acetic acid to 0.52 for trifluoroacetic acid (Table 1.01). This can be 
explained by a greater electropositive nature of the α-carbon supporting the negative 
charge of the carboxylate through the inductive effect.  
 
Carboxylic acids pKa Alcohols pKa Bases pKb 
CH3CO2H 4.76 CH3CH2OH 15.9 CH3CH2NH2 10.7 
CH2FCO2H 2.59 CF3CH2OH 12.4 CH2FCH2NH2 8.97 
CHF2CO2H 1.34 (CH3)3OH 19.2 CHF2CH2NH2 7.52 
CF3CO2H 0.52 (CF3)3OH 5.1 CF3CH2NH2 5.70 
 
Table 1.01. pKa and pKb of non-fluorinated and fluorinated acids, alcohols and bases. 
 
This effect on acidity or basicity can affect a drugs ability to be transported through 
biological membranes such as the blood brain barrier. Thus, fluorine incorporation can 
be used to tailor properties to improve pharmacokinetic profile of a molecule.36 
 
1.8 - Fluorine in drug metabolism  
 
Within medicinal chemistry, the strong C–F bond has been used to limit the 
susceptibility of pharmaceuticals to P450 oxidation in the liver.35 This has been widely 
applied to the modification of aryl rings for example, in Ezetimibe 74 (Scheme 1.12). 
Lead optimisation of 73 resulted in an overall increase in potency and stability in vivo.45 
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Scheme 1.12. Metabolic stability introduced through lead optimisation resulting in greater potency. 
 
1.9 - Fluorine based suicide inhibitors 
 
One of the earliest and most successful applications of fluorine within medicinal 
chemistry was the antineoplastic drug 5-fluorouracil (5-FU) 75 (Scheme 1.13).46 5-FU 
acts by inhibiting the enzyme thymidylate synthase disrupting the biosynthesis of 
nucleotides for DNA synthesis resulting in cell death (Figure 1.13).  
 
HN
N
H
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O
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 biosynthesis interrupted- 
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Thymidylate 
Synthase
 
Scheme 1.13. 5-FU inhibition of thymidylate synthase through the irreversible covalent blocking of the 
active site. 
 
Inhibition of the enzyme occurs during the methylation stage. To release the methylated 
nucleotide, the fluorine must leave as ‘F+’, which cannot happen, and so the 5-FU 
becomes covalently bound in the active site, thus leaving the enzyme inactive 
(Scheme 1.13).47 
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F
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1.10 - 19F NMR probes in chemical biology 
 
1.10.1 - General applications  
 
The use of fluorine NMR has been particularly important in chemical biology for 
example, during the elucidation of the metabolism of fluoro-containing 
pharmaceuticals,48,49 or following the biosynthesis of fluorinated natural products 
in vitro.50,51 The power of 19F NMR signals in these systems is that the chemical shift of 
fluorinated compounds varies over a large range (~ 300 ppm) and their spectral 
complexities are lower compared with 1H NMR spectra. 19F NMR has been extended to 
the study of small molecule-protein or DNA binding studies.52,53 The synthesis of 
proteins containing fluorine modified amino acids, offers a route to monitor the binding 
of small molecules to an active site by observing the chemical shift changes in the 
19F NMR spectrum.54 
 
1.10.2 - rRNA conformation probes  
 
The application of 19F NMR in the study of small molecule probes for determining 
RNA tertiary structure was reported in 2010 by Micouin and co-workers.55 Based on 
previous work, they demonstrated that small diaminocyclopentanes 77 (Figure 1.05) 
were able to bind to various transfer RNAs without altering the global structure of 
specific tRNAs.56,57 
 
H2N
NH2
F
H2N
NH2
F  
 
Figure 1.05. Small fluorinated NMR probes for RNA structure. 
 
Monitoring the chemical shift differences of the two diastereoisomers of 77 upon 
binding to tRNA sequences demonstrated the formation of a diastereomeric pair with 
tRNA (Figure 1.06). The relative chemical shift was found to be tRNA dependent. In 
each case this shift was dependent on the tertiary structure of the tRNA, as confirmed 
by variable temperature-NMR (VT-NMR).55  
(R)-77 (S)-77 
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Δδ1
Δδ2
19F NMR
 
Figure 1.06. Changes in the 19F NMR chemical shift of rac-77 in response to RNA addition.  
 
This technique allows a potential method to investigate the topological changes in 
tRNA structure, however the future assessment, in a complex biological environment, 
may be complicated by non-specific binding of 77. 
 
1.10.3 - Membrane transport kinetics  
 
19F NMR has also been used to explore the transport of the fluorinated glucose analogue 
α/β-78 across erythrocyte (red blood cells) membranes (Figure 1.07).58  
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Figure 1.07. Trifluoro-glucose analogues α/β-78 as a 19F NMR probes to study efflux enzymes through 2D 
EXSY experiments. 
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In the study by O’Hagan et al., membrane transport kinetics were assessed by 2D 19F 
Exchange Correlation Spectroscopy NMR (EXSY NMR).59 The 19F NMR signals for 
both of the intra- and extra-cellular populations of the trifluoroglucose anomers’ α/β-78 
were distinguishable. In the EXSY experiment, the intensity of the cross peaks formed 
from the retained polarisation from internal to external populations could be correlated 
to the transmembrane rate constant. It was found that this method generated rate 
constants that were similar to glucose itself.60  
 
1.11 - Conformational effects of fluorine 
 
1.11.1 - The gauche effect 
 
The incorporation of a carbon-fluorine bond into organic molecules can have an 
influence on molecular conformation. A well-documented case is the gauche effect in 
1,2-difluoroethane 79 (Scheme 1.14). It has been shown that the gauche conformers are 
favoured over the anti-conformer by approximately 0.8 kcal mol-1.19 
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Scheme 1.14. The gauche effect in 1,2-dihaloethanes.  
 
This is in contrast with 1,2-dichloroethane 80, which does not show conformational 
preference and with 1,2-dibromoethane 81, which has an anti-conformer preference. In 
the case of 1,2-difluoroethane 79, the gauche-conformer is stabilised through 
hyperconjugative interactions (Figure 1.08).  
g- 
80 
81 
79 
g+ 
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F
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Figure 1.08. Hyperconjugation in 1,2-difluoroethane 79. 
 
This donation of electron density from the σCH orbital antiperiplanar to the σ*CF orbital 
stabilises the gauche conformer.61,62 The σ*CF orbital is low in energy and a good 
acceptor of electron density compared to the other halogens.63 In the case of 
1,2-difluoroethane 79, there are two hyperconjugative interactions with both C–F bonds 
orientating antiperiplanar to C–H bonds. The gauche effect is also observed in 
1,2-fluorohydrins and in other systems whereby the fluorine has a vicinal arrangement 
with various electron withdrawing groups.64 
 
Stereoelectronic effects are important in the molecular preorganization of linear 
fluoroalkanes containing multiple contiguous vicinal fluorine atoms.65 The synthesis of 
the all-syn tetra-, penta- and hexa-fluoroalkanes, 82-8467–69 respectively, results in a 
defined conformation arising from gauche effect contributions and most significantly 
1,3-fluorine-fluorine repulsion of ~3.0 kcal mol-1 (Figure 1.09).66 
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Figure 1.09. The all syn-vicinal fluorinated alkane motifs. 
 
This is particularly striking in the hexa-fluoroalkane 84, where a helical structure is 
observed in both the solid and solution states (Figure 1.10).69 
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Figure 1.10. X-ray crystal structure of the all-syn hexa-fluoro alkane demonstrating the helicity induced by 
1,3-fluorine-fluorine repulsions.  
 
In a systematic study with various fluorohydrin stereoisomers 87-90 of the HIV-1 
protease inhibitor Indinavir 85, the gauche effect has been used to stabilise the preferred 
extended binding conformation (Figure 1.11).70  
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Figure 1.11. Fluorinated Indinavir 85 and epi-Indinavir 86 demonstrating a conformational preference for 
target specificity. 
 
The optimal conformation is achieved in the syn,syn isomer 87, which has the same 
efficacy as Indinavir 85. This conformation is not accommodated in the anti,anti isomer 
89, which has a lower activity (10 fold decrease). There is a more significant effect in 
the fluorinated stereoisomers of the less active epi-Indinavir 86. Interestingly the 
syn,anti isomer 88 reverses the loss in activity in 86 over 85 by 8 fold, whereas, the 
anti,syn 90 shows a dramatic decrease in activity into the millimolar 
range (Figure 1.11).70 
85 
85 86 
87 88 
89 90 
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1.11.2 - The α-fluoroamide effect  
 
α-Fluoro amides have a clear conformational preference as a result of the C–F bond 
dipole (1.85 Debye in fluoromethane).71 In α-fluoro-amides there is a strong preference 
for the C–F bond to lie antiperiplanar to the dipole of the amide carbonyl 
(Scheme 1.15).72–74 This is particularly striking for 91 and 92 where there is a 
stabilisation of 7.5 and 8.0 kcal mol-1 respectively for the anti conformation.72 
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Scheme 1.15. The α-fluoroamide effect with anti-preference relative to the amide carbonyl.  
 
Molecular orbital (MO) calculations by O’Hagan et al., demonstrated this preference in 
N-methyl-2-fluoropropionamide.72 The rotational energy profile for this system is 
shown in Figure 1.12. There is a clear energy well of ~8.0 kcal mol-1 when the C–F 
bond and amide carbonyl are anti to each other.72 
 
Figure 1.12. Rotational energy profile for α-fluoroacetamide 92 showing a conformational well for the 
trans- (anti) conformation. 
7.5 kcal mol-1 - 91, R = H  
8.0 kcal mol-1 - 92, R = Me  
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This strong preference arises from at least three stabilizing factors: primarily the 
relaxation of the dipoles from the C–F and the C=O bonds, such that their combined 
vectors cancel (Figure 1.13, A); a favourable C–F⋯H-N electrostatic interaction 
(Figure 1.13, B); and finally, a stabilising orbital interaction between the amide 
π*C(O)N orbital and the F np orbital (Figure 1.13, C).75 
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Figure 1.13. Stabilising factors for the anti-conformation in α-fluoroamides. 
 
A study of the Cambridge Structural Database (CSD) by Seebach et al., reveals that 
this conformational preference is reflected across a range of open chain compounds in 
the solid state with typical F–C–C–O dihedral angles of 147º<φ<190º (Figure 1.14).76 
 
Figure 1.14. Dihedral angle prevalence in α-fluoro amides. 
 
The notable exception to this is the synclinal example with a dihedral angle ~50-60º. 
Seebach et al., also observed this deviation from the anticipated antiperiplanar 
orientation in a study of fluorinated β-amino acid conformational effects on peptide 
conformation.76 They demonstrated through NMR analysis of the 4JHF coupling 
constants that the C–F bond orientates perpendicular to the amide plane in the 
tridecapeptide 93 if it can not adopt an anti orientation, thus destroying the helicity of 
the peptide (Figure 1.15, A).77 In this example, it was reasoned that the global energy 
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minimum of the peptide was enough to ‘override’ the local stabilisation of the C–F 
bond, which was forced into its next favoured conformation (Figure 1.15, B). This 
energy preference is apparent in the rotational energy diagram (Figure 1.12) with a 
plateau around 60º.72 
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Figure 1.15. The fluorinated tridecapeptide has a favoured solution structure with the C–F bond orientating 
90º relative to the carbonyl of the amide. 
  
1.11.3 - The Charge-dipole effect 
 
If the C–F bond is located proximal to a positive charged species, a conformational 
preference arises resulting from a strong electrostatic interaction.78 This favours a 
conformation that might otherwise be unfavourable. For example, in 
2-fluoroethylammonium 94, the C–F and C–NH3+ orientate preferentially in a gauche 
rather than an anti alignment (Scheme 1.16).  
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Scheme 1.16. Charge-dipole effect in 2-fluoroethylammonium 94.  
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DFT calculations on 2-fluoroethylammonium 94 have demonstrated that the gauche 
conformation is preferred by about 5.8 kcal mol-1 (Figure 1.16), thus, exerting 
significant stabilisation for that particular conformation.78,79 This conformational 
preference is also observed for protonated alcohol 95 and the N-fluoroethylpyridinium 
ion 96 (Figure 1.16).  
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Figure 1.16. Conformational preference as a result of the charge-dipole interaction.  
 
In studies by Lankin and Synder80 the charge-dipole effect was shown to result in a 
strong axial orientation of the C–F bond in 3-fluoropiperidinium rings 97-99, where the 
stabilisation is ~5 kcal mol-1. The axial preference was confirmed by NMR and DFT 
calculations, in addition to X-ray crystallographic analysis of selected compounds. The 
3,5-difluoropiperidinium 100 also demonstrated an axial preference, clearly overcoming 
the repulsive 1,3-diaxial fluorine-fluorine interaction (Figure 1.17).  
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Figure 1.17. Charge-dipole effect in fluorinated piperidinium systems with their respective DFT 
(Becke3 LYP/6–311G(d,p)) calculated energies. 
 
Following from these studies, Gooseman et al. demonstrated the charge-dipole effect in 
4-and 5-membered rings, 101 and 102 respectively (Figure 1.18), which have no 
particular conformational preference in their non-fluorinated forms unlike six 
membered rings.81,82 
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Figure 1.18. Charge-dipole effect in small and large fluorinated nitrogen containing heterocycles. 
 
This was confirmed through DFT and X-ray crystallographic analysis, both of which are 
in strong agreement with that observed in six-membered rings. The effect in larger rings, 
such as 103 (Figure 1.18), was also found to favour the axial orientation of the C–F 
bond.81 It follows that the incorporation of the C–F bond into protonated nitrogen 
heterocycles offers a way to influence the conformation in a non-covalent manner, 
which could have an application in drug discovery.  
 
1.12 - Applications of the charge-dipole effect 
 
1.12.1 - Organocatalysts 
 
The charge-dipole effect has been explored in both medicinal and organocatalytic 
arenas.83 In a study by Gilmour et al.84 an exocyclic C–F bond situated pendant to a 
pyrrolidine ring (104) was shown to induce stereocontrol in the epoxidation of 
α,β-unsaturated aldehydes such as 105a/b (Scheme 1.17) with excellent enantiomeric 
control, up to 96% ee in 107b with good to excellent diastereomeric excess. 
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Scheme 1.17. Organocatalytic epoxidation of α,β-unsaturated aldehydes with the C–F charge-dipole 
effect driving enantiocontrol. 
107a R=Ph 92% 
82:18 dr, 96% ee  
 
107b R=iPr 90% 
>95:<5 dr, 90% ee  
 
106a/b 104 -10 mol% 
105a/b 
106a/b 
101 102 103 
9.2 kcal mol-1 
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In this reaction, the intermediate C–F-iminium dihedral angle in 106 was shown 
to be 58º, thus directing the phenyl moiety to shield one face of the π-system 
(3.8/4.3 kcal mol-1 gauche stabilisation for the E-/Z- geometry in 106a/b). This 
therefore delivers the nucleophile to the opposite Si-face. The non-fluorinated catalyst 
108 proceeds with 23% ee, albeit under different conditions (Scheme 1.18).85 
N
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Scheme 1.18. Demonstration of the fluorine charge dipole effect and its application in organocatalysis.  
 
1.12.2 - Biological exploitation of the C–F bond 
 
The charge-dipole effect has also been used to probe the molecular binding 
conformation of GABA 109 to GABAA/C receptors and GABA metabolising enzymes 
(Figure 1.19).  
 
F
CO2-+H3N
F
CO2-+H3NCO2-+H3N  
 
Figure 1.19. Fluoro-GABA analogues.  
 
Deniau et al. demonstrated that GABA transaminase could discriminate between 
(R)-and (S)-3-fluoroGABA 110.86 The preferred transaminase binding conformation is 
readily adopted by (S)-110, however, this conformation is unfavoured in (R)-110 
(Figure 1.20, A).86 Both (R)- and (S)-110 exhibited a similar efficacy for the GABAA 
receptor87 (Figure 1.20, B), however (R)-110 was more active at the GABAC receptor 
(Figure 1.20, C).88 
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Figure 1.20. Preferred binding conformations of the fluorinated GABA analogues 110 to the GABAA 
receptor and GABA transaminase. 
 
The charge-dipole effect governs these conformations leading to the observed activities. 
These studies demonstrate that the fluorine charge-dipole effect is significant in a 
biological context and can offer information on the favoured binding mode of small 
molecules to large proteins (Figure 1.21).  
 
-OOC H
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Figure 1.21. Binding conformation to GABAA/C receptors of GABA based on fluorinated probes.  
 
It also demonstrated the applicability of this approach in the development of probes to 
study binding conformations of bioactives in complex molecular environments; thus 
providing information for the development of new inhibitors to target these receptors.89  
 
 
 
(R)-110 
(S)-110 
109 109 
   A B C 
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In a comprehensive study by Hunter et al., the α-fluoro amide, charge-dipole and 
fluorine-fluorine gauche effects were collectively considered for a conformational study 
on α,β-difluoro-γ-amino amides 111 and 112 (Figure 1.22).90 
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Figure 1.22. Conformational differences between syn- and anti-isomers of the α,β-difluoro-γ-amino 
amides 111 and 112. 
 
In this study, it was possible to demonstrate through NMR solution studies and by 
X-ray crystallography that both 111 and 112 exhibited an antiperiplanar orientation of 
the C–F bond relative to the amide carbonyl and that the vicinal C–F bonds are gauche 
to each other. The β-C–F and γ-C–N bonds are also gauche in the solid and solution 
state. The accumulative effect of these interactions results in two distinct and 
predictable conformations for 111 and 112.90 From these compounds, the vicinally 
2,3-difluorinated GABA analogues 113-116 were prepared and assessed for their 
respective activity on GABAC receptors.91 It was found that the syn-isomers exhibited 
potent activity over the anti-isomers (Figure 1.23).  
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Figure 1.23. The four stereoisomers of 2,3-difluorinated GABA analogues and their activity for the GABAC 
receptors.  
 
In the syn-isomer series, 113 acts as an agonist, whereas 114 was an antagonist. 
Molecular docking studies of the energy-minimised structures of 113 demonstrate it 
could adopt the correct binding conformation to accommodate the key contacts 
important for GABAC binding, thus supporting its agonist response. Docking of 114 
also demonstrated the ability of the carboxylate and amine groups to orientate in the 
correct manner, however, this also highlighted additional steric interactions with the 
113 114 115 116 
111 112 
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receptor that may explain its antagonist activity. The predicted conformation of 113 
corresponds with the binding conformation proposed earlier for GABA 109 
(Figure 1.21) to the GABAC receptor. Interestingly 113 and 114 did not exhibit any 
GABAA activity whereas 115 and 116 did.91 
 
From these studies, it is clear that the charge-dipole and other conformational effects 
can be used to influence the conformation of otherwise flexible organic molecules. This 
predictable preorganization has enabled detailed studies on the binding of GABA to its 
receptors. It is envisaged that this information will enable a better understanding of how 
to design tailored inhibitors for these receptors.  
1.13 - Synthesis of fluorinated β-amino acids 
1.13.1 - General methods 
 
The most common way of incorporating a fluorine substituent into an amino acid 
involves deoxyfluorination reactions with DAST 32. Takei et al., have employed 
DAST 32 in the synthesis of α-fluoro-β2,3-homophenylalanine 118 in studies exploring 
the inhibition of chromotrypsin (Scheme 1.19, A).92  
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Scheme 1.19. The application of DAST 32 to the synthesis of α-fluorinated-β-amino acids.  
 
DAST 32 was first used in this context in a synthesis of benzyl protected 
α-fluoro-β-alanine 120 by Shomek (Scheme 1.19, B).93 This method has been widely 
used by Seebach et al. for studies on the influence of α-fluorinated-β-amino acids on 
β-amino peptide structures and exploring their metabolic stability.94 In example B 
(Figure 1.19), the fluorination proceeds through an aziridinium intermediate, a 
mechanism, which will be discussed in more detail in Chapter 4.95 
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These methods rely on stereospecific reactions manipulating the existing 
stereochemistry of the starting material. Other methods have used stereoselective 
fluorination reactions to generate new stereogenic centers with fluorine. This approach 
is discussed in sections 1.13.2 and 1.13.3. 
 
1.13.2 - Evans oxazolidine approach 
 
In 2008, Abell et al. demonstrated an Evans oxazolidinone based strategy for the 
construction of mono-fluorinated β2,2-amino acids bearing a quaternary stereogenic 
center (Scheme 1.20).96 In this approach they were able to fluorinate the oxazolidine 
derivative of cyclohexyl and phenyl propanoic acids, 120a/b respectively, by 
deprotonation and treatment with N-fluorobenzenesulfonamide. This gave 121a/b in 
high diastereomeric excess and in good yield (>90% de, 79%).  
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Scheme 1.20. Evans auxiliary approach to the synthesis of mono-fluorinated quaternary centers 
 
The alkylation of 121a/b was achieved with benzyl chloromethyl ether in the presence 
of base and TiCl4 (Scheme 1.20). Further transformations with 122 enabled the 
synthesis of 124a/b in >95% diastereomeric excess (Scheme 1.21). This was the first 
synthesis of a mono-fluorinated β2,2 substituted amino acid and offered a versatile 
approach to the synthesis of diverse fluorinated amino acids (Scheme 1.21).  
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Scheme 1.21. Functionalisation of the fluorinated Evans auxiliaries 122a/b mono-fluorinated β2,2 amino 
acids. 
122a - 70% 
122b - 69% 
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1.13.3 - Davies’ lithium amide approach 
 
In a modification of the Davies’97 diastereoselective addition of lithium amides 126 to 
α,β-unsaturated esters 125, Duggan and co-workers have demonstrated that quenching 
the intermediate enolates 127 with NFSI 5 results in the isolation of 
α-fluorinated β2,3-amino acids 128 with high diastereoselectivity (Scheme 1.22).98  
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Scheme 1.22. Chiral lithium amide addition to α,β-unsaturated esters in the tandem approach to 
α-fluorinated β2,3 amino acids. R = alkyl, aryl. 
 
Various α,β-unsaturated esters 125 could be employed with the chiral lithium amide 126 
to provide synthetically useful β-amino acids 128 through this tandem approach. In a 
proof of concept study, a stepwise addition-fluorination protocol via 129a/b 
demonstrated that the isolated β-amino acids 128a/b were of low diastereomeric excess 
(Figure 1.23). Thus, demonstrating the power of their tandem approach (Figure 1.22). 
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Scheme 1.23. Stepwise approach with poor diastereomeric control of the fluorination step.  
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Using the tandem approach, the orthogonally protected α-fluoro-β2,3-lysine derivative 
130 starting from 128c was synthesised (Scheme 1.24).  
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Scheme 1.24. Further functionalisation through to an orthogonally protected α-fluoro-β2,3-lysine for 
synthesis applications. 
 
This method offers a route for generating an array of structurally diverse fluorinated 
β-amino acids for the incorporation into medicinally relevant compounds or for the use 
as chemical probes.  
 
The synthesis of fluorinated amino acids has received a significant level of attention as 
indicated by the number of reviews and publications in the field.99 Structural and 
biological applications of the conformational influence of the C–F bond continue to 
appear, and the role of the C–F bond in this context may become more widely 
recognised.  
 
1.14 - Conclusion  
 
It is clear, from the discussion in this chapter, that the strategic incorporation of a C–F 
bond into an organic molecule can result in a conformational bias. This has enabled the 
elucidation of binding modes of small molecules to enzymes and large receptors.  
 
The following chapter will address the development of quadruplex DNA stabilizing 
ligands and will offer a biological context for investigating the conformational influence 
of the C–F bond in a drug-DNA complex.  
 
128c 
 
130 
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Telomeres, telomerase and quadruplex DNA 
 
 
 
 
2.1 - The 2009 Nobel prize to telomeres  
  
In 2009, the Nobel Prize for Medicine was awarded to Elizabeth H. Blackburn, Carol 
W. Greider and Jack W. Szostak for their contributions towards our understanding of 
the telomere and telomerase.100 Their contributions have budded what is now a very 
active research area. Blackburn and Szostak were first to demonstrate that the telomeric 
sequence was conserved across a range of distantly related organisms and that it was 
fundamental in cell biology.101 Following this, Blackburn and Greider provided 
evidence for the enzyme telomerase (Christmas Day 1984), which is responsible for 
elongation of the telomere.102 They later demonstrated that telomerase required an RNA 
component to be catalytically active.103 These discoveries underpin many of the 
biochemical and genetic studies focused around the telomeres and its role in cancer, 
ageing, and inheritable diseases, amongst many others. The following will provide a 
general review of the telomere and inhibitors of telomerase. 
 
2.2 - Telomeres and telomerase  
 
One of the major limitations of replication in eukaryotic cells is for the replication 
machinery to completely copy to the 3' end of DNA. This is known as the end 
replication problem.104 Thus, with each round of replication, a short section of DNA is 
cleaved from the chromosome. DNA sequences coded at the end of chromosomes are 
not faithfully copied and this jeopardises genomic stability following each round of cell 
division. To guard against this, chromosomes have a protective ending known as the 
telomere (Scheme 2.01).  
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Scheme 2.01. Generalised scheme for telomere erosion and elongation at the chromosome end. Knitted 
chromosomes copyright Science Museum/Science and Society Picture Library 2012. 
 
The telomere is a non-coding sequence of DNA consisting of tandem hexanucleotide 
repeats dTTAGGG, with an approximate length of 5-8 kilobase pairs.105 Therefore, each 
round of cell division results in the loss of approximately 50-200 bases from this 
non-coding DNA.106 The cell will replicate until the length of the telomere reaches a 
critical length, its Hayflick limit,107 before entering a state of replicative senescence 
(G0 state), which then initiates p53-mediated cell death.108 Therefore, the average 
telomeric length in a colony of cells will decrease over time until it reaches its Hayflick 
length, unless the cells are replenished by their respective stem cell, which generally 
have longer, maintained telomeric DNA lengths.  
 
The telomeres in stem and germ-line cells are maintained by an RNA-dependent DNA 
polymerase.102,109 This reverse transcriptase adds the TTAGGG nucleotides to the 3' end 
of the telomere following each round of cell division. The RNA component (hTR) is 
critical for activity and anneals the 3' end of the telomere,110,111 templating it into the 
active site of the catalytic subunit, hTERT. The hTR component is found expressed in 
somatic cells, however hTERT expression is silenced through various transcriptional 
regulators,106 thus somatic cells contain no constitutively active telomerase.112–114 Both 
hTR and hTERT components are expressed in stem and germ-line cells, thus active 
telomerase can maintain the telomeric length in these cells.113 
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2.3 - Telomerase and cancer  
 
The nature of the telomere in somatic cells, with its critical length, raises a question 
around its role in cancer. Cancer cells typically replicate without control and so it would 
be natural to assume that the average telomeric DNA length in cancer is critically low. 
However, this is not observed and the telomere lengths in cancers are maintained. This 
telomeric maintenance can be attributed to the loss of the transcriptional control of 
hTERT, with 85% of cancers expressing this catalytic domain.115,116 With both hTR and 
hTERT found in cancer cells, an active telomerase maintains the telomere length and 
these cells subsequently avoid activation of cell death pathways. Targeting the action of 
telomerase offers a unique method of cancer therapy with the bulk of non-cancerous 
cells not affected by this approach.108  
 
Even though the telomere is a section of non-coding DNA, its maintenance and function 
is controlled by a multitude of protein interactions.117 The majority of the telomere 
adheres to normal topological parameters of duplex DNA, with the exception of 
approximately 200 nucleobases at the 3' end.118–120 These nucleobases form a single 
stranded overhang and it is this section of the telomere where the most interesting 
biological interactions occur and structures form.  
 
2.4 - Shelterin complex at the telomere 
 
Single-stranded DNA (ssDNA) in other regions of the genome are quickly recognised 
as damaged by the cell.121–123 Detection of ssDNA results in the activation of repair 
mechanisms or causes the cell to activate apoptotic pathways. To circumvent this for the 
telomere, there are various proteins that interact with the 3' single stranded overhang 
and protect it.117,124 These core protective proteins form the complex known as shelterin 
and specifically bind the TTAGGG repeat of the telomere. Shelterin is comprised of 
eight core protein units, TRF1/2, TIN2, TPP1 and POT1 (Figure 2.01), with five 
domains available to recognize the telomeric DNA sequence, making it highly specific 
for telomeric DNA. Knockout studies of the shelterin component POT1, resulted in 
cell-cycle arrest and chromosomal end-to-end fusion as a direct result of shelterin 
complex disruption.125 For telomerase to elongate the telomere following cell division, 
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the telomere must be linear and free of any tertiary structure to enable the association of 
the catalytic and recognition domains of telomerase.126 
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Figure 2.01. A simplified representation of shelterin proteins associating with telomeric DNA. 
 
2.5 - Self-assembly of guanosine 
 
In the 1960’s, it was established that solutions of guanosine-5'-monophosphate 
(5'-GMP) base 131 formed gel-like solutions upon standing (Scheme 2.02).127 These gel 
solutions resulted from the formation of square planar quartets of hydrogen-bonded 
ionophores, which rapidly formed in the presence of monovalent cations.  
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Scheme 2.02. The self-assembly of guanosine nucleotides 131 into quartet structures in the presence of 
mono-valent counter ions. Quartet representation extracted from PDB 1I1H (Ref.-128) with the image 
created using PyMol.129 Distances are in Å. 
 
These monovalent cations, primarily Na+ and K+, increase the stability of G-quartets by 
favourable electrostatic interactions with the O6 atoms of each base. 5'-GMP 131 can 
form four hydrogen bonds per base by utilizing its Hoogsteen edge along with the 
131 
Hoogsteen 
face 
Watson-Crick 
face 
M+ 
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typical Watson-Crick edge as shown in 131 (Scheme 2.02). The hydrogen bond 
acceptors N7 and O6 on the Hoogsteen edge form hydrogen bonds with the hydrogen 
bond donors, N1 and N2, on the Watson-Crick edge. Therefore, four individual 5'-GMP 
131 nucleotides can form a G-quartet with eight hydrogen bonds in total. 130 
 
Multiple G-quartets can self-assemble into a G-quadruplex structure through favourable 
π-π stacking interactions and stabilisation brought about by a bipyramidal antiprismatic 
bound cation, primarily K+.131 A further thermodynamic driving force for this assembly 
is found from the displacement of water that forms unfavourable interactions with each 
G-quartet. G-quadruplex self-assembly motifs can be between 8 to 30 nm long with 
each G-quartet rotated round the central axis (Figure 2.02).132–134 
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Figure 2.02. Representation of guanine tetrads stacking to form a self-assembled G-quadruplex.  
 
2.6 - Quadruplex DNA folding and topology  
 
It is likely that guanine-rich telomeric sequences in the human genome will form 
quadruplexes in vivo.135-137 There are two main types of quadruplex structures that can 
form with guanine-rich sequences, intramolecular (unimolecular) and intermolecular 
(bimolecular) forms. Sequences of the type Go·Xp·Go form intermolecular structures 
and Xn·Go·Xp·Go·Xp·Go·Xp·Go·Xn form intramolecular folds (where Xn is any 
number non-guanine nucleotide, Go is any number of guanine nucleotides and Xp is 
any number non-guanine nucleotides involved in loop formation).135 The topology that 
one sequence may form over another is firstly governed by the linking nucleotide length 
and by the presence of different monovalent cations. 138 Go·Xp·Go sequences, such as 
the Oxytricha nova telomeric sequence, G4T4G4, will form bimolecular quadruplexes 
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where two sequences associate to form the quadruplex structure (Figure 2.03). In these 
structures, Xp will orientate relative to the guanine nucleotides to accommodate their 
assembly into a quadruplex (Figure 2.03).  
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Figure 10 Schematic diagrams showing potential linking loop arrangements and resulting
topologies for bimolecular quadruplexes. (a) Lateral loops connecting anti-
parallel strands arranged on the same face; (b) lateral loops connecting anti-
parallel strands arranged on either end. (c) Diagonal loops connecting opposite
anti-parallel strands. (d) External chain reversal loops connecting parallel
strands together; (e) Diagonal loops connecting opposite anti-parallel strands
18 Chapter 1
a) b) c)
d)
External
Loop
Diagonal
Loop (D)
e)
Lateral
Loop (L)
External
Loop (E)
Lateral
Loop
Figure 10 Schematic diagrams showing potential linking loop arrangements and resulting
topologies for bimolecular quadruplexes. (a) Lateral loops connecting anti-
parallel strands arranged on the same face; (b) lateral loops connecting anti-
parallel strands arranged on either end. (c) Diagonal loops connecting opposite
anti-parallel strands. (d) External chain reversal loops connecting parallel
strands together; (e) Diagonal loops connecting opposite anti-parallel strands
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In the forming of dimeric quadruplexes we first need two strands to be linked
together. If we link two of the strands by a lateral loop the strands will be
constrained to be anti-parallel and require an inversion of one of the paired
bases and the glycosidic torsion angle, in order to retain an appropriate
hydrogen bonding arrangement. This is usually accommodated in one of the
two ways, either each strand has a run of alternating syn, anti glycosidic angles
for the guanine bases, or one strand has exclusively syn and the other strand
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Figure 9 Schematic diagrams showing potential strand polarity and related glycosidic
torsional angles for intermoleculer quadruplexes. (a) Parallel with all anti
glycosidic torsional angles; (b) parallel all syn glycosidic torsional angles; (c–
e) alternating strands arrangements with the corresponding mixed syn anti
relationships
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Figure 2.03. Arrangement of gua in s d linking nucl otides in bimolecular quadruplexes.139 
 
The Xp nucleotides can either form external, diagonal or lateral links relative to the 
quadruplex core, which can result in many complex and diverse quadruplex 
structures.130,140 In addition to this, the glycosidic bond in the DNA monomers will also 
reverse from the favoured anti to syn bo d angl , in an attempt to accommodate the 
formation of hydrogen bonded quartets.138 In the O. nova sequence, G4T4G4, the 
thymine linking nucleotides associate in a diagonal manner (Figure 2.03, e) relative to 
the guanine nucleotides (Figure 2.04).141–143 
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Figure 2.04. Crystal structure of the O. nova G4T4G4 bimolecular quadruplex with two aspect views. Image 
created with PyMOL129 using PDB file 1JPQ.141  
 
However, the mutant O. nova sequence, G3T4G4 forms a mismatched quadruplex, which 
results in a distinct fold compared to G4T4G4, with the thymine nucleotides associating 
in a lateral and diagonal manner.144 A small sequence change can result in a significant 
structural modification, highlighting the complexity of quadruplex folds in the solid 
state, and clearly the dynamics in solution. A further example of this structural 
complexity is exemplified by reducing the number of nucleotides available for 
cross-linking. For example, the G4T3G4 sequence forms a bimolecular structure with 
lateral thymine linkages.145 In this case, two quadruplex structures in the unit cell are 
observed with both the head-to-head (Figure 2.03, a) and head-to-tail (Figure 2.03, b) 
quadruplexes formed (Figure 2.05).  
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Figure 2.05. The two quadruplex DNA structures formed from the G4T3G4 sequence. Images created with 
PDB codes 2AVH & 2AVJ respectively using the PyMOL package.129 
 
Unimolecular quadruplexes also form different topological structures (Figure 2.06).138 
Such unimolecular quadruplexes are biologically relevant and are likely to form in vivo 
at the ssDNA ends of the telomere, in addition to regions throughout the genome that 
have a high guanine content.146 
 
1.3.1 Loop Length, Sequence, and Stability
An additional constraint for the folding topologies for bimolecular and inter-
molecular quadruplexes relates to the number (length) of the linking nucleo-
tides. Short linker lengths, two or less, will prevent diagonal loops from
forming due to the distance to be spanned across G tetrad. However, the short
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Figure 11 Schematic diagrams showing potential linking loop arrangements and resulting
topologies for intramolecular quadruplexes. (a) Lateral loops connecting anti-
parallel strands arranged on the same face; (b) mixed lateral and diagonal
loops connecting anti-parallel strands. (c) External chain reversal loops con-
necting parallel strands together. (d) Mixed external and lateral loops con-
necting strands; (e) Mixed external, diagonal, and lateral loops connecting
strands together; (f) Mixed external and diagonal loops connecting strands
together
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forming due to the distance to be spanned across G tetrad. However, the short
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Figure 11 Schematic diagrams showing potential linking loop arrangements and resulting
topologies for intramolecular quadruplexes. (a) Lateral loops connecting anti-
parallel strands arranged on the same face; (b) mixed lateral and diagonal
loops connecting anti-parallel strands. (c) External chain reversal loops con-
necting parallel strands together. (d) Mixed external and lateral loops con-
necting strands; (e) Mixed external, diagonal, and lateral loops connecting
strands together; (f) Mixed external and diagonal loops connecting strands
together
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Figure 2.06. Arrangement of guanines and linking nucleotides in unimolecular quadruplexes.139 
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In addition to the various ways that the linking polynucleotides can arrange relative to 
the guanine core, there is also a structural effect from the presence of different 
monovalent cations.147 For example, Na+ ion coordinates within the plane of the 
G-quartet while the larger K+ ion coordinates offset between two G-quartets. As a result, 
as shown by solution NMR (Figure 2.07, A)148 and X-ray149 crystallographic studies 
(Figure 2.07, B), structures for the human telomeric sequence d(TG3(T2AG3)3) adopt 
very distinct folds. In the Na+ NMR structure the T2A linking nucleotides associate in a 
lateral and diagonal fashion relative to the guanine tetrads (Figure 2.07, A). In contrast, 
the linking nucleotides assemble in a diagonal manner (Figure 2.06, C) in the crystal 
structure with K+, resulting in a distinctive propeller like structure (Figure 2.07, B). 
  
 
 
 
  
 
 
 
 
 
 
 
Figure 2.07. Unimolecular quadruplex DNA with different counterions A – d[AG3(T2AG3)3] sequence with 
Na+ counter ion & B – with K+ counter ion. Images created from PDB codes 143D (Ref.-148) and 1KF1 
(Ref.-149) with PyMol.129 
 
Structural studies of the human telomeric DNA sequences are starting to provide a 
strong foundation in the understanding of how quadruplex DNA topologies arise. This 
information is important for the rational design of drugs that may interact with these 
sequences.140  
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2.7 - Telomerase inhibition  
 
Zahler and co-workers observed that increasing the K+ concentration induced an 
inhibitory effect on telomerase action in vivo.150 They concluded that the increased [K+] 
stabilises quadruplex folds in vivo and in vitro, and that this may act as a negative 
feedback mechanism for the maintenance of telomere length. This inhibition of 
telomerase can be attributed to the disruption of the association between the telomere 
and telomerase, with the interaction critically dependent on the 3' ssDNA overhang 
being free and linear. This free topology is required such that the hTERT RNA subunit 
can anneal with the telomere, thus stable quadruplex DNA structures will inhibit the 
action of telomerase as they will not uncoil.151 
 
2.8 - Assessing telomerase inhibition and quadruplex stability  
 
The development of quadruplex DNA stabilising ligands has called for the development 
of standardised techniques to assess their action in vitro and in vivo. The following 
section is a brief overview of the current techniques used.152  
 
Circularly polarised light spectroscopy is used to assess the topological arrangement of 
guanine-rich sequences. Circular dichroism (CD) is a powerful tool to probe and 
monitor structural changes of quadruplex DNA upon altering the nature and 
concentration of counter ions.153,154 CD can also be used to monitor structural changes 
upon binding of drugs that interact with quadruplex DNA.152 Other spectroscopic 
techniques such as NMR155,156 and X-ray crystallography157 play significant roles in the 
structural evaluation of how quadruplex stabilising ligands bind to quadruplex DNA. 
These techniques taken together provide information on the interactions between drugs 
and quadruplex DNA and can be used for the systematic development and rational 
design of new agents.  
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Fluorescence resonance energy transfer (FRET) assays are used to quantify the level of 
stabilisation that specific ligands provide to the quadruplex folds.158 For this technique, 
modified quadruplex DNA sequences are attached with fluorescent donor and acceptor 
chromophores at the 3' and 5' ends (Scheme 2.03). Commonly used chromophores are 
6-carboxyfluorescein 132 (FAM) and 6-carboxytetramethyl rhodamine 133 (TAMRA) 
(Scheme 2.03). When the donor and acceptor are in close contact, such as when the 
quadruplex is folded, the excitation of the donor ligand results in FRET transfer to the 
acceptor which results in emission of a different wavelength (Scheme 2.03).159 An 
increase in temperature will unfold the quadruplex structure to its linear form, thus 
increasing the distance between the two chromophores, resulting in poor energy transfer 
with subsequent fluorescence decrease. The addition of a stabilising ligand will cause an 
increase in the melting temperature of the quadruplex DNA, and the increased 
stabilisation of the fold results in a higher melting temperature.  
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Scheme 2.03. General overview of FRET-based analysis of quadruplex stability. 
 
Telomerase inhibition assays provide specific values for the inhibition of telomerase 
activity in vitro. The protocol for this is known as TRAP - Telomeric repeat 
amplification protocol.160 The use of a fluorescent primer for the telomerase enzyme 
enables the evaluation of telomerase inhibition by quadruplex-stabilising drugs. This is 
Donor Acceptor 
 132 133 
 488 nm 
 520 nm 
 
 
 
 488 nm 
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a widely employed protocol in the literature providing telIC50/telEC50 values for a range 
of ligands.  
 
Good experimental correlation between the FRET and the TRAP assays are observed 
and generally a higher melting temperature results in better inhibition of the telomerase 
enzyme. However, a direct correlation and prediction of one value based on the other 
cannot easily be made.  
 
2.9 - Quadruplex DNA stabilising ligands 
  
Various quadruplex DNA stabilising ligands have been identified.106,161 These include 
natural products along with various other motifs arising from structure based design 
strategies.140,161 A concurrent theme arises with these stabilising ligands, as many are 
based on a large polyaromatic core with various peripheral cationic side chain 
substituents. These side chain substituents often interact with the negatively charged 
phosphate grooves and polynucleotide linkages, while the flat polyaromatic cores 
capitalise on favourable π-π stacking with a free G-tetrad at the end of the quadruplex 
DNA fold. It has been observed that larger aromatic cores give rise to greater selectivity 
of quadruplex DNA over that of duplex DNA, due to the greater π-bonding surface 
available from the quadruplex.135  
 
A critical evaluation of quadruplex DNA ligands is in their classical cytotoxicity. For an 
effective quadruplex DNA stabilising ligand, the level of cell cytotoxicity should be at 
least 10 times higher than the telEC50. Classical anti-cancer/proliferative drugs work on 
being cytotoxic to the cell, this is not the case for quadruplex DNA ligands. Typically 
the use of a drug that inhibits telomerase through the stabilisation of quadruplex 
structures will not demonstrate any signs of activity until multiple rounds of cell 
division. This would lead to the gradual erosion of the telomere, initiating expression of 
proteins associated with short or damaged telomeres, resulting in characteristics protein 
foci at the chromosomal ends. The use of other anti-cancer agents would accelerate this 
process by targeting the cancerous cells from two approaches, with each agent working 
synergistically with one another.  
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2.9.1 - Natural products and analogues 
 
The natural product telomestatin 134 is currently the most efficient telomerase inhibitor 
known, with an telIC50 of 5 nM and is often used as the benchmark for assessment of 
other telomerase inhibitors (Figure 2.08).162,163 Telomestatin 134 was isolated from 
Streptomyces anulatus and is comprised of seven oxazole rings with one 
dehydrothiazole ring.162 A subsequent total synthesis identified the natural configuration 
of telomestatin 134 as the (R)-enantiomer, in-line with the natural configuration of the 
amino acid cysteine.164 
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Figure 2.08. The natural product telomestatin, a potent inhibitor of telomerase. 
 
Telomestatin has a 70-fold binding selectivity for quadruplex DNA over that of duplex 
DNA.163 Quadruplex selectivity is critical for non-specific binding of the ligand to other 
regions of genomic DNA, with unspecific binding resulting in unwanted cytotoxic 
effects. Synthetic analogues of telomestatin 134, such as 135a/b (Figure 2.09) have 
been shown to be entirely quadruplex selective over duplex DNA, with the acetate 
analogue 135b demonstrating a 2 µM inhibition of telomerase (Figure 2.09).165,166 
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Figure 2.09. Analogues of the natural product telomestatin. 
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2.9.2 - Porphyrin based inhibitors  
 
Porphyrin based inhibitors such as TMPyP4 136 have poor selectivity for quadruplex 
DNA, however CD and NMR based studies have shown that porphyrin 136 
significantly stabilises quadruplex DNA (Figure 2.10).167,168 TMPyP4 136 was shown to 
inhibit telomerase with an telIC50 of 6.5 µM as determined by the TRAP assay and a ΔTm 
of 17 ºC from FRET analysis.169 Subsequent X-ray crystallographic studies of TMPyP4 
136 with bimolecular quadruplex d(TAG3T2AG3) detailed an unusual major groove 
complexation between the ligand and the DNA rather than complexing to the G-tetrad 
face.170 This may offer an explanation for the poor duplex/quadruplex selectivity.167,171 
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Figure 2.10. Structure of the porphyrin based quadruplex DNA stabilizing ligand, TMPyP4 136. 
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ΔTm = 17.0 ºC telIC50 = 6.5 μM 
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2.9.3 - Quinacridine ligands 
 
Dibenzophenanthroline ligands such as 137a-c have been shown to have good 
stabilisation potential for quadruplex DNA. Assessing their stabilisation through FRET 
analysis, found that 137a and 137b stabilized the human telomeric sequence by 
+19.7 ºC and +12.8 ºC respectively (Figure 2.11).158 In TRAP assays, 137a and 137b 
have also showed an inhibitory effect on telomerase with telIC50 values of 0.028 µM and 
0.5 µM respectively. These values correlate with the FRET-based observations with the 
higher stabilising ligand resulting in a greater inhibition of telomerase. The cyclic 
derivative 137c was shown to bind by both π-stacking and groove intercalation with 
quadruplex DNA with a ΔTm of 28 ºC and telIC50 of 0.13 µM (Figure 2.11).172 
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Figure 2.11. Structures of the quinacridine based quadruplex DNA stabilizing ligands. 
 
 
 
 
 
 
137b - ΔTm = 12.8 ºC telIC50 = 0.5 μM 
137a - ΔTm = 19.7 ºC telIC50 = 0.028 μM 
137c - ΔTm = 28.0 ºC telIC50 = 0.13 μM 
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2.9.4 - Anthraquinone and fluorenone ligands 
 
Quadruplex DNA-stabilising ligands developed by Neidle, Hurley and co-workers have 
led to a plethora of papers detailing the improvements and achievements of designing 
new ligands based on their early work.173 Initially, bisamidoanthraquinone ligands 
138a-h had attractive telEC50 values for telomerase inhibition (Figure 2.12). 
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Figure 2.12. Structures and telEC50 values of the anthraquinone and fluorenone based ligands. 
 
Systematic studies on the substitution patterns of anthraquinones 138a-h through the 
1,4- 1,8-, 2,6- and 2,7- regioisomers identified the 2,7-regioisomer 138a as the most 
potent, with an inhibitory value of 2.0 µM. The side groups are protonated at 
physiological pH with the exception of morpholine 138c. The detrimental effect of 
neutral ligands can be observed in the telEC50 value for 138c (>>50 µM), thus this ligand 
does not appear to form strong interactions with quadruplex DNA folds. Interestingly, 
the generation of the N+−Me salts 138b/d/f/h resulted in an increase in telEC50 values. 
This may be due to the removal of hydrogen bonds between the ligands and the 
quadruplex DNA. However, the metabolic cytotoxic effects of 138a-h were problematic. 
This lead to the development of fluorenone analogues 139a-h, which do not suffer the 
same metabolic fate as 138a-h. Fluorenones 139a-h demonstrated telIC50 values between 
8-12 µM and a decrease in metabolic related cytotoxicity compared to the 
anthraquinones 138a-h (Figure 2.12). 
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2.9.5 - Acridone and di- and tri-substituted acridine ligands 
 
Subsequent development of acridone-based ligands 140a-h,174 demonstrated that the 
incorporation of a nitrogen in the aromatic core results in an increased interaction with 
quadruplex DNA (Figure 2.13). Following these observations, the acridine-based 
compounds 141a-h175,176 were developed in an attempt to arrange the central protonated 
acridine nitrogen over the negatively polarised central quadruplex core (Figure 2.13). 
However, the acridine series 141a-h had low selectivity (1.3:1) for quadruplex DNA 
over duplex DNA.177 Of the series, BSU6039 141a, which exhibited a telEC50 value of 
5.2 µM, was chosen for subsequent studies. 
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Figure 2.13. Structure and telEC50 values for the acridone and acridine 3,6-disubstituted ligands.  
 
Molecular modelling with BSU6039 141a suggested that substitution at the 9-position 
would result in further interactions with a third phosphate groove in the quadruplex fold 
(Figure 2.14).177,178 The tri-substituted series 142a-f was synthesised and it was found 
that 142a (BRACO-19) exhibited the most favourable inhibitor characteristics. 
BRACO-19, with the 4-(dimethylamino)aniline substituent in the 9-position, was 
31-fold more selective for quadruplex over duplex DNA and also showed a 44-fold 
increase in inhibition of telomerase (telEC50 0.115 µM) when compared to BSU6039.174 
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Figure 2.14. 3,6,9-Trisubstituted acridine ligands. TelEC50 values are underneath for each 9-position 
substituent. 
 
2.10 - BRACO-19 142a in vitro & in vivo studies  
 
BRACO-19 142a (Figure 2.15) has good in vitro efficacy against the prostate cancer 
cell line DU145.179 It was shown that after incubation over 7 days with sub-cytotoxic 
doses of BRACO-19 142a that half of the cells entered the G0 phase. After 21 days there 
was an increase in the expression of the apoptosis associated proteins p21 and p16. It 
was also noted that non-homologous end-joining (NHEJ) events were occurring during 
the metaphase of the cell cycle, a feature of dysfunctional telomeres.121 The data 
presented here suggests that BRACO-19 142a acts as a telomerase inhibitor through 
quadruplex DNA stabilization and also competes with telomeric binding proteins such 
as POT1. It has been demonstrated in vivo that BRACO-19 142a has efficacy towards 
xenographed uterine cancers in a murine model.180 
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Figure 2.15. Structure of BRACO-19 142a and Paclitaxel 143 (Taxol). 
 
Further studies with BRACO-19 142a and the established clinical anti-cancer agent 
paclitaxel 143 (Figure 2.15) have shown promising synergistic activities.151 The 
treatment of A431 human epithelial carcinoma with BRACO-19 142a results in an 
insignificant decrease in tumour size upon intraperitoneal dosage. However, dosing of 
BRACO-19 142a post paclitaxel 143 treatment in these carcinomas resulted in greater 
tumour shrinkage, with a shortening of the average telomere length, than with paclitaxel 
alone.181 This was the first proof of principal study of quadruplex DNA stabilisation as 
a method for anti-cancer therapy.  
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2.11 - X-ray crystallographic studies with acridine based ligands 
 
2.11.1 - BSU6039 141a and O. nova DNA 
 
The crystal structure between BSU6039 141a and the bimolecular quadruplex DNA 
sequence G4T4G4 was solved to 1.75 Å and provided an insight into how the acridine 
based ligands 141a-h interact with quadruplex DNA (Figure 2.16).128  
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Figure 2.16. Crystal structure of BSU6039 141a bound to the bimolecular quadruplex fold from the 
Oxytricha nova sequence. A – BSU6039 structure, B – standard representation with BSU6039 binding in 
the top section and C – Surface representation to show binding cleft. Images created from PDB 1L1H 
using PyMol.129 
 
In this structure, BSU6039 141a binds with one quadruplex fold with the thymine 
linking residues orientating in a diagonal manner across the top face of the quadruplex 
(Figure 2.16, B). This topology is the same for the native crystal structure (Figure 2.4) 
with potassium ions and generates two wide phosphate grooves with complementary 
narrower phosphate grooves along the sides of the quadruplex.141 The glycosidic angles 
of the guanine nucleotides in the sequence alternate syn-anti, such that the G-tetrad has 
a syn-syn-anti-anti glycosidic arrangement, which enables the hydrogen bonds from the 
 B  
 
C 
 
A 
 
141a 
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Hoogsteen and Watson-Crick faces to be accommodated (Figure 2.3). Between the G-
tetrads, potassium ions are coordinated to the O6 carbonyls of the G-tetrads, thus further 
stabilizing the quadruplex structure (Figure 2.16, purple crosses). The diagonal 
orientation of the thymine loops generates a binding cleft into which BSU6039 141a 
can orientate and π-π stack with the top G-tetrad (Figure 2.16, C). In contrast to the 
native crystal structure (Figure 2.4), one of the thymine nucleotides twists out of the 
loop plane and interacts with the central nitrogen and one amide carbonyl of 141a, 
forming two hydrogen bonds (Figure 2.17).  
 
 
 
Figure 2.17. Top orientated view of the binding between BSU6039 141a and the quadruplex fold. 
Distances are in Å. Image generated from PDB file 1L1H using PyMOL.129 
 
Another thymine nucleotide also forms a π-π interaction with the acridine, further 
stabilising the fold. In the phosphate grooves, there is a highly ordered water lattice. 
However, the charged pyrrolidino rings of 141a do not interact through salt bridges with 
the phosphate backbone and only on one side does the substituent form a hydrogen 
bond with a water molecule (Figure 2.17). This specific water molecule forms a 
hydrogen bond with the guanine tetrad. There are no other direct hydrogen bonds in the 
crystal structure between the quadruplex and the ligand. It has been rationalised that the 
substituents interact in an electrostatic manner as demonstrated in a range of crystal 
structures of 3,6-substituted acridines 141a-h with the O. nova sequence.182 
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2.11.2 - BRACO-19 142a and human DNA 
 
A subsequent study on the mode of binding of the 3,6,9-substituted acridine ligand 142a 
has been published.183 The crystal structure of BRACO-19 bound to the bimolecular 
human telomeric G-quadruplex sequence, d(TAG3T2AG3T), was resolved to 2.5 Å by 
X-ray crystallography (Figure 2.18).183 
 
  
Figure 2.18. BRACO-19 bimolecular quadruplex DNA co-complex X-ray crystal structure. A – BRACO-19 
in a space filling representation sandwiched between two quadruplex folds, B – Structure of BRACO-19 for 
comparison and C – Surface representation of the bottom quadruplex clearly demonstrating the phosphate 
grooves. Images created from the PDB file 3CE5 using PyMol.129  
 
This crystal structure and the binding between the quadruplex DNA and the ligand 142a 
are very different to that of the O. nova structure presented earlier. Each bimolecular 
quadruplex has propeller linkages, similar to those observed in the native G3(T2AG3)3 
sequence (Figure 2.07, B), with an assembly of three planar stacked guanine tetrads. In 
contrast to the BSU6039 141a crystal structure, BRACO-19 142a is complexed 
between two quadruplex folds, forming π-π stacking interactions with the 3' end 
guanine tetrad of one quadruplex and TA nucleotides of the 5' end from another 
quadruplex. One linking thymine base is rotated such that it interacts through hydrogen 
bonding and water-salt bridges with the acridine core of BRACO-19 142a (Figure 2.19).  
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Figure 2.19. Top orientated view of the binding between BRACO-19 142a and quadruplex DNA. Distances 
are in Å. 
 
This rotated thymine plays a critical role in the interaction and stabilisation of 
BRACO-19 142a with the quadruplex. The charged 3- and 6- substituents do not form 
hydrogen bonds with the negatively charged phosphates and interact in an electrostatic 
manner. The propeller TTA linkages between the guanine tracks generate size specific 
grooves that accommodate smaller substituents. This is in contrast to the O. nova 
sequence where the diagonal loops generate a cleft able to accommodate a variety of 
substituents.182 The overall mode of binding of BRACO-19 142a is typically mediated 
through hydrogen bonding with water to the quadruplex rather than through direct 
interactions. The synthesis of BRACO-19 142a analogues with longer alkyl substituents 
results in decreased stability.184 It is likely that the conformational flexibility in these 
analogues results in a less ordered binding ligand that will not orientate correctly to 
form hydrogen bonds, even with the water lattice in the phosphate grooves. The 
interaction between BRACO-19 142a and two quadruplex folds is a significant 
observation and may represent a realistic in vivo model. It is reasonable that quadruplex 
folds occur in a contiguous fashion with one or more quadruplex folds occurring at the 
ssDNA telomeric end. Therefore, the binding of BRACO-19 142a to one quadruplex in 
vivo may induce another quadruplex to ‘fold back’ and interact similar to that observed 
in the crystal structure. To date, however, there are no crystal structures of extended 
telomeric sequences, such as with d(AG3(T2AG3)n) where n≥7, that demonstrate two or 
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more quadruplexes per sequence.151 The generation of such structural data would be a 
significant advance in the current understanding of how quadruplex ligands are likely to 
interact with quadruplex DNA in vivo. 
 
2.12 - Conclusions  
 
This chapter has provided a brief overview of the biological and structural aspects of 
telomeres in the cell. It has also discussed the implication of inhibiting enzymes 
involved in the maintenance of telomere length. The structures of several classes of 
small molecule inhibitors of telomerase that act through the stabilisation of quadruplex 
DNA in vivo have been described. Detailed assessment of their interaction in the solid 
state by X-ray crystallography has enabled the development of a generalised view of 
their mode of action.  
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Synthesis and evaluation of fluorinated BSU6039 
analogues 
 
 
 
 
3.1 - Introduction 
 
It is common practice in drug discovery to vary the substituents on the 
pharmacophore to explore structure activity relationships for a particular inhibitor. In 
the case of BRACO-19 142a and BSU6039 141a, it is clear that small ring substituents 
on the alkyl amino side chains led to a more efficacious inhibitor (Chapter 2.14).161 
These rings are accommodated within the hydrophobic pocket formed by the DNA 
sequence. The size of the hydrophobic pocket is highly dependent on the individual 
sequence of the quadruplex DNA used for crystallisation, with the various linker 
nucleotides assuming different conformations in space (Chapter 2.6).157 In the case of 
the O. nova sequence, crystallography indicates that the thymine residues allow for a 
variety of alkyl substituents to be accommodated.182 
 
 As highlighted in Chapter 1.11, modification of small nitrogen containing 
heterocycles with β-fluorine substituents results in a ring conformation whereby the 
fluorine-carbon bond dipole moment interacts favourably with the N+–H bond dipole on 
the protonated nitrogen (Figure 3.01).19 
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Figure 3.01. The charge-dipole effect in 5- and 6-membered rings. 
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This is a dipole-dipole through space interaction. The possibility of incorporating 
fluorine in this manner into BSU6039 would enable an investigation into the mode of 
binding and the importance of ring conformation to the stability of quadruplex DNA. In 
addition, the C–F bond will be expected to lower the pKaH of the protonated amine and 
increase the acidity of the hydrogen for hydrogen bonding. In general, however, a 
smaller ΔpKa between the donor and acceptor results in a stronger hydrogen bond.185  
 
Therefore, the aim of this research was to investigate the effect of substituting the 
pyrrolidino rings of BSU6039 141a with a C–F bond at the 3-position and to assess the 
structural influence by X-ray crystallography of co-crystals with O. nova bimolecular 
quadruplex DNA (Chapter 2.6/2.11).  
 
In order to investigate these effects, it was necessary to synthesise the enantiomers of 
the fluoro- and hydroxyl- analogues 144 and 145 of BSU6039 (Figure 3.02). These 
analogues would then be co-crystallised with the T4G4T4 O. nova quadruplex DNA 
sequence. 
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Figure 3.02. 3-Fluoro- and 3-hydroxyl pyrrolidine analogues of BSU6039 141a. 
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3.2 - Synthesis of BSU6039 141a analogues  
 
To access the synthetic targets it was required to prepare the bis-chloro intermediate 146 
from which 144 and 145 could be synthesised (Scheme 3.01). This intermediate can be 
accessed by treating proflavin 147 with 3-chloropropionyl chloride 148. 
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Scheme 3.01. Retrosynthetic approach to 146. 
 
Treatment of diamine 147 with neat 3-chloropropionyl chloride (148) under forcing 
conditions generated the known bis-chloro substituted acridine 146 in an excellent yield 
of 90% (Scheme 3.02).175 
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Scheme 3.02. Reagents and conditions: a) 3-Chloropropionyl chloride (neat), 140 ºC, 4 h, 90%. 
 
The solubility of bis-chloro 146 in common solvents was very low, thus it was 
particularly difficult to purify. In the event, bis-chloro 146 was often contaminated with 
acid chloride 148. This pungent smelling contaminant remained even after 
recrystallisation and washing with ethanol and then drying under high vacuum. 
However, the contamination (NMR analysis) was low and so the product was taken on 
without further purification. In order to access (R,R)-144, it was required to treat 
bis-chloro 146 with (3R)-fluoropyrrolidine 149 (Scheme 3.03).  
 
147 146 
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Scheme 3.03. Reagents and conditions: a) NaI, EtOH, 80 ºC, 3-5 h, 63%.  
 
Treating pyrrolidine (R)-149 with bis-chloro 146 in ethanol and with sodium iodide 
generated (R,R)-144. Purification of the product mixture by column chromatography 
required up to 5% triethylamine to obtain a pure sample of (R,R)-144 (63% yield). 
Repeating the procedure with (S)-149 enabled the isolation of (S,S)-144 also in a 
satisfactory yield of 65% (Scheme 3.04).  
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Scheme 3.04. Reagents and conditions: a) 146, NaI, EtOH, 80 ºC, 3-5 h, 65%. 
 
 
In order to obtain (S,S)-145 and (R,R)-145, the reactions were repeated with (S)- or 
(R)-150. Products (S,S)-145 and (R,R)-145 could be isolated in satisfactory yields for 
both ligands (Scheme 3.05).  
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Scheme 3.05. Reagents and conditions: a) 146, NaI, EtOH, 80 ºC, 3-5 h, 59%. 
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3.3 - Characterisation of (S,S)- and (R,R)-144 
 
The proton resonances of the 3-fluoropyrrolidine ring in (S,S)- and (R,R)-144 in the 
1H NMR are well defined and can be assigned based on the correlations in the 1H–1H 
COSY spectrum (Figure 3.03).  
 
 
 
Figure 3.03. 1H-1H COSY (500 MHz, d6-DMSO/CD3OD) analysis of (S,S)-144.  
 
It is likely that the C–F bond does not exhibit a strong preference for a pseudo- axial or 
equatorial C–F bond conformation. Therefore, the unambiguous assignment of 
pseudo-axial and equatorial proton resonances cannot be made and have been 
designated as Ha and Hb for each resonance. Thus, starting from the distinctive 2JHF 
coupling constants, it was possible to assign the resonance at 5.28 as H-7' in 
144 (Figure 3.03, blue line). The cross peak pattern from H-7' enabled the putative 
assignment of the resonances belonging to H-6'a/b and H-8'a/b. The relative chemical shift 
of the resonances at 3.15 and 2.84 ppm and their cross peak isolation (Figure 3.03, 
purple line) support the assignment of these as the H-6'a/b resonances. Therefore, the 
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resonances at 2.29 and 2.10 ppm can be assigned as H-8'a/b. The remaining resonances 
corresponding to H-9'a/b are confirmed through the clear cross peaks with 
H-8'a/b (Figure 3.03, orange lines).  It is clear from the analysis of 144 that distinct 
resonances for each proton on the pyrrolidino ring can be observed. The 1H–1H COSY 
assignments were supported by a 1H–13C HSQC analysis (Figure 3.04). 
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Figure 3.04. 1H–13C HSQC (500/125 MHz, d6-DMSO/CD3OD) analysis of (S,S)-144. 
 
Again, the distinctive 1JCF and 2JCF couplings in the 13C NMR spectrum, along with 
their relative chemical shifts enabled the assignment of C-7' (1JCF = 175 Hz). The 
resonances at 52.5 and 36.5 ppm in the 13C NMR spectrum were assigned to C-3' and  
C-4' respectively through cross peaks with the triplets at 3.02 and 2.75 ppm of the 
1H NMR spectrum. Of the remaining resonances in the 13C NMR spectrum, two 
exhibited distinctive couplings of 22.8 and 22.3 Hz at 61.4 and 33.5 ppm respectively, 
corresponding to 2JCF through bond coupling. Distinguishing between these resonances 
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was possible by referring to the 1H–1H COSY spectrum (Figure 3.03), with the signal at 
61.4 ppm corresponding to C-6' (Figure 3.04, purple line) and that at 33.5 ppm to C-8'. 
The remaining resonance, without any JCF coupling could be assigned to C-9'. The close 
proximity of the C-9' signal to the strongly correlating peak of C-3' (Figure 3.04, red 
line) obscured the H-9'a – C-9'correlation (Figure 3.04, green line), however, this could 
still be observed as a shoulder peak. These assignments were further supported by 
HMBC and 1H–19F HMBC analyses. The aromatic quaternary carbons of the acridine 
ring were assigned based on DEPT-Q, HMBC and HSQC analyses. It was possible to 
assign the spectrum of (R,R)-144 using the same combination of techniques detailed 
above. The spectra for diols (R,R)-145 and (S,S)-145, were less complex and more 
readily assigned. 
 
3.4 - Fluoropyrrolidine ring conformation in 144.HCl 
 
To assess the conformation of the 3-fluoropyrrolidine ring in 144, the HCl salts were 
prepared. Acridine (S,S)-144 was dissolved in methanol and treated with 
HCl (1 M diethyl ether soln.), such that the nitrogen of the pyrrolidino rings were 
protonated (Scheme 3.06). This resulted in the precipitation of (S,S)-144 as the 
hydrochloride salt, and thus the salt had to be dissolved in d6-DMSO for NMR analysis. 
 
NN
H
N
H
O
N
O
NF F
N+N
H
N
H
O
N+
O
N+F F
H
HH
a)
Cl-Cl- Cl-  
 
Scheme 3.06. Reagents and conditions: a) HCl (1 M in Et2O), MeOH, rt.  
 
The 1H NMR spectrum of (S,S)-144.HCl showed significantly broadened signals as a 
result of further coupling to the N–H of the pyrrolidino ring and no coupling constants 
could be extrapolated. Interestingly, the 19F NMR of (S,S)-144.HCl, split into two 
well-defined resonances at -171.9 ppm and -173.4 ppm, upfield from that of the free 
amine (Figure 3.05). 
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Figure 3.05. A -19F NMR (470 MHz, d6-DMSO) of (S,S)-144. B - 19F NMR of (S,S)-144.HCl &                      
C - Expanded section of B.  
 
The two resonances (Figure 3.05, C) must reasonably correspond to the formation of a 
diastereomeric pair, as protonation of the nitrogen can occur from either side of the 
rings, syn or anti to the axially orientated C–F bond (Figure 3.06). The equal 
distribution of protonation states was supported by DFT calculation, with the relative 
energy difference insignificant enough to influence the distribution of the two isomers 
(Figure 3.06).  
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Figure 3.06. Protonation creates diastereomers of the pyrrolidine ring, which can be clearly observed in 
the 19F NMR. The relative energy difference was calculated by DFT (B3LYP/6-316(D)) by Dr Tomas Lebl, 
St Andrews. R = H.  
 
The coupling constants from the two resonances (Figure 3.05, C) can be used to 
demonstrate an axial solution conformation of the C–F bond, consistent with the 
literature.79-81 The 2JFH and 3JFH coupling constants could be extracted from the 
resonance at -171.9 ppm , although the 4JFH couplings are small and could not be 
B C 
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quantified (Figure 3.07, A). In (S,S)-144.HCl four 3JFH coupling constants at -171.9 ppm 
could be determined with values of 39.4, 33.0, 25.8 and 19.5 Hz. The experimental 
coupling constants were entered into a NMR simulation package (iNMR) and the 
simulated spectrum (Figure 3.07, B) provided a good fit with the experimental data 
(Figure 3.07, A). The same treatment could not be repeated with the resonance 
at -173.4 ppm, however this signal was of similar width. 
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2JFH = 52.8
3JFH = 39.4
3JFH = 33.0
3JFH = 25.8
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Figure 3.07. A - Expanded region of 19F NMR spectrum (470 MHz) for (S,S)-144.HCl & B - Simulated 
spectrum at 470 MHz.  
 
A comparison of the coupling constants observed for (S,S)-144.HCl with the literature 
was made.186 Thibaudeau et al., have reported trans 3JHF relationships (H–C–C–F 
torsion angles 160-180º) of between 30-45 Hz in ribose rings. In these systems, the size 
of the coupling constant is dependent on the substituents. The 3J values of 39.4 and 
33.0 Hz suggest an H–C–C–F torsional angle approaching 180º, indicative of a 
pseudo-axial/axial coupling. The remaining two 3JFH values correspond well with 
torsion angles in the range 0-60º respectively, suggesting a pseudo-axial/equatorial 
conformation. These large coupling constants support the view that the 
fluorine-ammonium interaction in (S,S)-144.HCl leads to a highly ordered conformation 
with the C–F bond orientating in axial conformation (Figure 3.08, A).  
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Figure 3.08. Representations for the pseudo-axial (A) and equatorial (B) orientation of the C–F bond.  
 
If the C–F bond was orientated in a pseudo-equatorial conformation (Figure 3.08, B), 
for this particular signal, then the 3JFH coupling constants would be between 10-20 Hz. 
This is consistent with torsion angles approaching 60º, corresponding to a 
pseudo-equatorial-equatorial coupling. These coupling constants would result in a 
resonance with a smaller spectral width and less definition, similar to that of the 
non-protonated system (Figure 3.05, A). 
 
3.5 - Co-crystallisation with quadruplex DNA 
3.5.1 - Background and crystallisation  
 
Co-crystallisation trials with (S,S)- and (R,R)-144 and 145 with quadruplex DNA were 
conducted in collaboration with Prof. Steven Neidle’s laboratory at the UCL, School of 
Pharmacy. The approach used the hanging drop vapour-diffusion method (Figure 3.09).  
 
Mother liquor 
Cover Slip
Grease
A B C D
 
Figure 3.09. A - Hanging drop vapour diffusion method for growing crystals, B - Top view of crystals 
growing on the top cover slip, C - Crystal tray with various conditions attempted such as altering the 
mother liquor concentrations & D - Attempted trays stored at 16 ºC.  
 
By this method the ligand and quadruplex DNA are added in various concentrations to a 
buffer solution, which is placed on a cover slip (Figure 3.09, A/B). This cover slip is 
then suspended over a concentrated salt solution, forming a closed system with grease 
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generating a tight seal. Evaporation of the buffer solution containing the ligand and 
quadruplex DNA results in super-saturation. Optimisation of this evaporation process 
by changing variables can result in the crystallisation of DNA-ligand crystals that are 
suitable for X-ray diffraction. The variables are: crystallisation temperature; buffer 
constituents; stock buffer concentrations; DNA to ligand ratio; and/or concentration 
relative to the buffer. Negative results such as DNA precipitation can be used to tune 
the crystal growing conditions.157 
 
After an extensive exploration of variables by Dr. Nancy Campbell (School of 
Pharmacy) the optimal conditions for crystal growth were found, resulting in 
rhombohedral co-crystals of (R,R)-144 and (S,S)-144 with quadruplex DNA. The 
crystals (Figure 3.10) were subject to X-ray analysis on a synchrotron at the Diamond 
Light source (Oxfordshire, UK).  
 
 
Figure 3.10. Photograph of diffracted ligand-DNA crystals. 
 
The diffraction data was fitted and refined, providing crystal structures at a highly 
refined 1.18 Å and 1.10 Å resolution for (R,R)-144 and (S,S)-144 respectively. The 
resulting unit cell for crystals of (R,R)-144 is shown in Figure 3.11.  
0.2 mm 
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Figure 3.11. Unit cell of the co-crystal of (R,R)-144 with O. nova bimolecular DNA.  
 
This representation and that shown in subsequent figures were created from the files 
deposited in the Protein Data Bank (PDB) with file names 3NYP and 3NZ7 for 
(R,R)-and (S,S)-144 respectively. Images were generated using the COOT187 and 
PyMol129 crystal visualisation packages.  
 
The high level of resolution of these co-crystals enabled a detailed assessment of 
interactions of these ligands with O. nova DNA and they could be compared to the 
co-crystal structure previously solved with BSU6039 141a to 1.75 Å (Figure 2.16). 
Thus, the co-crystals with the fluorinated analogues (R,R)- and (S,S)-144 were of 
particularly high quality. 
 
While the fluorinated analogues (R,R)- and (S,S)-144 provided suitable crystals for 
X-ray diffraction, the hydroxy compounds (R,R)- and (S,S)-145 failed to crystallise 
under the same conditions Altering the conditions for crystallisation failed to produce 
any suitable crystals for diffraction (Nancy Campbell, UCL). These compounds would 
have enabled a useful comparison as an intermediate between hydrogen and fluorine in 
the pyrrolidine ring, however suitable co-crystals were not forthcoming. 
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3.5.2 - General observations in the co-crystals with (S,S)- and (R,R)-144 
 
The topology observed within the unit cell for both enantiomers of 144 is the same. This 
corresponds to the quadruplex DNA assembling with the thymine bases forming a loop 
at either end of the quadruplex in an identical manner to the co-crystals BSU6039 141a 
discussed in Chapter 2.11 (Figure 3.12). The DNA and ligand are bound in a one to one 
ratio with the acridine ligand occupying the cavity between an upper guanine tetrad and 
the thymine base loop (Figure 3.13). Although the two structures are formally 
diastereomers this does not significantly change the G-quadruplex conformation. 
 
[S, S] [R, R]
 
Figure 3.12. Co-crystal structures for fluorinated pyrrolidine analogues. A - (S,S)-144 and B - (R,R)-144 
both with quadruplex DNA (G4T4G4). The blue arrows highlight the ligand binding to the top face of the 
quadruplex. Representation created with PyMol.129  
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Figure 3.13. Surface representation in cyan with 50% transparency. The binding cleft of the fluorinated 
BSU6039 ligands can be clearly seen at the top of both structures. A - (S,S)-144 & B - (R,R)-144. 
Generated with PyMOL. 129 
 
The unity of the electron density maps in structures (R,R)- and (S,S)-144 correlates well 
with the resolution of the data, and enables a high degree of certainty in assigning atom 
coordinates (Figure 3.14 & 3.15). Where the electron density is poorly resolved, the 
crystallographer must use chemical intuition in fitting the structure. In Figures 3.14 & 
3.15, the structures are represented according to the preset b-factor colours (COOT 
package), with cool (blue/green) and hot (yellow/red) representing low and high 
disorder of the atoms relative to one another. The b-factor is an important parameter of 
the solved data providing an appropriate measurement of the static/dynamic nature of 
the atoms within the crystal structure. It is intrinsically linked to the occupancy factor 
for each atom. The occupancy factor (0.10–1.00) is used in conjunction with the 
b-factor data to provide information about the precise geometry of substituents within 
the structure.  
 
A B 
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Figure 3.14. Electron density maps for (S,S)-144 Oxytricha nova quadruplex DNA. Represented at the 
σ = 1 level using the COOT package.187 Distances are in Å. 
 
  
 
Figure 3.15. Electron density maps for (R,R)-144 with Oxytricha nova quadruplex DNA. Represented at 
the σ = 1 level generated with the COOT package.187 Distances are in Å. 
 
The occupancy and b-factors (Table 3.01 and Figure 3.14/3.15) for each atom correlate 
well with the hydrogen bonding and electrostatic interactions, suggesting their 
contribution to structural stability.  
 
 
 
 
 
 
b-factorlow high
Monday, 5 March 2012
b-factorlow high
Monday, 5 March 2012
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Acridine 
nitrogen 
Pyrrolidine-N  
(LHS/RHS) 
C–F  
(LHS/RHS) 
C–F 
 (LHS/RHS) 
BSU6039 (2.4 Å) 9.04 33.96 / 25.65 N/A N/A 
(S,S)-144 (1.10 Å) 6.73 11.03 / 18.65 17.21 / 37.35 11.03 / 18.65 
(R,R)-144 (1.18 Å) 8.05 17.54 / 25.77 23.56 / 56.09 17.54 / 25.77 
 
Table 3.01. b-Factors for the crystal structures with BSU6039 141a, (S,S)-144 and (S,S)-144 
 
3.5.3 - Detailed assessment of the DNA co-crystal with (S,S)-144 
 
The structure of BSU6039 141a, discussed in Chapter 2.16 is reproduced for 
comparison (Figure 3.16). The (S,S)-144 bound ligand is considered in Figure 3.17.  
 
 
Figure 3.16. Hydrogen bonding and electrostatic interaction distances found in the BSU6039 141a crystal 
structure. Distances are in Å. 
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Figure 3.17. A - Expanded section of the mode of binding for ligand (S,S)-144 with quadruplex DNA &        
B - graphical summary of angles and bond lengths. Distances are in Å. 
 
 
The most notable difference in the binding of fluorinated (S,S)-144 (Figure 3.17) over 
non-fluorinated BSU6039 141a (Figure 3.16) is that the fluoropyrrolidine rings have 
rotated by 180º and are forming new contacts within the crystal structure. Interestingly, 
in the left hand side (LHS) of the binding pocket (Figure 3.17), the N–H of the 
pyrrolidine is no longer forming a hydrogen bond with a crystallographically resolved 
water molecule. This water molecule is observed in all structures of this series and 
presumably plays an important role in the stabilisation of the guanine tetrad through a 
hydrogen-bonding network between the pyrrolidine and the guanine base (Figure 3.17). 
In fact, the pyrrolidine N–H of the structure with (S,S)-144 now forms a hydrogen bond 
with a phosphate on a neighbouring quadruplex within the unit cell. It may be the 
change in the pKa of the pyrrolidine substituent, due to fluorine incorporation, is 
responsible for the change in hydrogen bonding partner. The trajectory of the                 
N+–H⋯-O–P hydrogen bond is close to 180º and the H⋯O distance is short at <1.7 Å 
(Figure 3.17, B), correlating well with the more acidic hydrogen bonding to the basic 
A 
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phosphate to result in a ‘strong’ hydrogen bond. The observed occupancy factors 
(F = 1.00 and N = 1.00) and a good fit with the electron density map (Figure 3.14), 
suggest high order and a stable hydrogen bonding interaction. The pyrrolidine ring is 
clearly puckered as a result of the C–F⋯N–H+ dipole-charge interaction, with a              
F–C–C–N angle of approximately 90º.  
 
A similar situation occurs at the RHS of the crystal structure (Figure 3.17) where again 
the pyrrolidine N–H directionality has rotated through 180º relative to BSU6039 141a 
(Figure 3.15) and a hydrogen bond forms now with the phosphate backbone, albeit with 
a longer N–H⋯O–P contact (Figure 3.17) of 1.98 Å. The b-factors for the atoms in this 
ring are lower (Table 3.01) perhaps suggesting a weaker hydrogen bond between this 
pyrrolidine ring and the phosphate. As with the LHS, the RHS pyrrolidine ring is also 
puckered, with the C–F bond occupying a dramatic axial orientation (fluorine 
occupancy = 1.00). The distance between the N–H and C–F bond (~3.0 Å) and the 
narrow angle (< 100º) in both of the rings in (S,S)-144 preclude a reasonable hydrogen 
bond but are consistent with a charge-dipole interaction as discussed in Chapter 1. 
 
3.5.4 - Detailed assessment of the DNA co-crystal with (R,R)-144 
 
Examination of the binding mode of (R,R)-144 (Figure 3.18) with the quadruplex, 
reveals a similar change in pyrrolidine ring orientation relative to BSU6039 141a 
(Figure 3.16). On the LHS of the structure (Figure 3.18, A) again the N–H of the 
pyrrolidine forms a hydrogen bond (Figure 3.18, B) with a phosphate group of a 
neighbouring quadruplex within the unit cell. The C–F bond is also axial (fluorine 
occupancy = 0.90), exhibiting a similar conformational bias to that observed for 
(S,S)-144 (Figure 3.17).  
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Figure 3.18. Expanded section of the mode of binding for ligand (R,R)-144 with quadruplex DNA & 
B - graphical summary of angles and bond lengths. Distances are in Å.  
 
The b-factors for the LHS of the X-ray structure of the co-crystalline (R,R)-144 with 
DNA (Table 3.01) although slightly higher than for (S,S)-144, remain low compared to 
141a and indicate high resolution data. In the RHS binding pocket, it is clear that the 
co-crystalline DNA-(R,R)-144 structure the interaction between the pyrrolidine ring and 
the phosphate group is more electrostatic in nature. This is deduced from the longer  
N+–H⋯-O–P contact distance and non-linear contact angle (Figure 3.18, B), which are 
out-with the topological parameters for a strong hydrogen bond. Based on this 
observation, it is anticipated that the tolerance of the RHS binding interaction is less 
favourable to accommodating the fluorine in the pyrrolidine ring. The orientation of the 
C–F bond, in the case of (R,R)-144, possibly positions the C–F bond closer to the 
phosphate resulting in a charge-dipole repulsion. The stereospecific incorporation of a 
C–F bond in this manner can lead to a diastereotopic difference in the topology of 
binding between the two enantiomers (S,S)- and (R,R)-144, altering their relative modes 
of binding.  
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3.6 - FRET studies with quadruplex DNA 
 
The melting temperatures of co-complexes between the 144 and 145 series with 
quadruplex DNA were measured. This enabled the assessment of the relative stability of 
quadruplex DNA following addition of (S,S)- or (R,R)-144 and 145. For this 
application, the monomeric human quadruplex DNA sequence G3(T2AG3)3 with the 
donor and acceptor appendages TAMRA and FAM, as described in Chapter 2, were 
employed. These experiments were carried out in triplicate with 1 µM of (S,S)- or 
(R,R)-144 and 145 (Table 3.02. By Tony Respka, UCL). 
 
Sample Concentration Run1 (ºC) Run 2 (ºC) Run 3 (ºC) Average Tm (ºC) dTm (ºC) 
DNA control N/A 58.6 58.7 58.7 58.7  N/A 
(R,R)-144  1 μM 62.8 63.4 63.3 63.2  4.5 ± 0.4 
(S,S)-144  1 μM 64.9 64.7 64.7 64.8  6.1 ± 0.2 
(R,R)-145  1 μM 71.0 71.1 71.2 71.1  12.4 ± 0.2 
(S,S)-145 1 μM 71.1 71.3 71.3 71.2  12.6 ± 0.2 
BSU6039 1 μM - - - - 13.3 
 
Table 3.02. Results from the FRET based assessment of (R,R)- and (S,S)-144 and 145. Errors by 
standard deviation of the mean and are reported to 1 DP. 
 
Both types of ligands stabilised the quadruplex, however the fluorinated ligands 
(S,S)-and (R,R)-144 resulted in a lower overall stabilisation of the fold relative to 
BSU6039 141a. This difference is difficult to quantify empirically, however it is likely 
that change in orientation of hydrogen bonding observed for the C–F ligands relative to 
BSU6039 141a weakens the structures. By contrast the hydroxyl compounds (S,S)- and 
(R,R)-145 demonstrated a much better stabilisation compared to BSU6039 142a. These 
results show that the C–F bond in the peripheral pyrrolidines perturbs the mode of 
binding more than that of the C–OH bond.  
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3.7 - Conclusion  
 
This chapter reports the synthesis of the (S,S)-/(R,R)-fluoro 144 and 
(S,S)-/(R,R)-hydroxy 145 analogues of BSU6039 141a. The fluoro analogues were 
successfully co-crystallised with the bimolecular O. nova quadruplex DNA and the 
X-ray structures were solved to high resolution. This data enabled a detailed assessment 
of the mode of binding between the two enantiomers of 144 and relative to 
BSU6039 141a. This analysis demonstrated that the C–F bond orientated in an axial 
position, consistent with the anticipated literature and that the hydrogen bonding 
network between the quadruplex DNA and ligand changed. In these structures with 
(S,S)- and (R,R)-144 the pyrrolidine N–H had rotated by 180º and paired with the 
phosphate backbone to form new hydrogen bonding interactions. Further to this, FRET 
analysis indicates that the fluorinated derivatives increased the stability of the 
quadruplex fold, however to a lesser extent when compared to BSU6039 141a. This 
may be explained by the hydrogen-bond differences observed in the co-crystal 
structures. Overall, the incorporation of a C–F bond in the peripheral pyrrolidines leads 
to a ring pucker and perturbed the mode of binding to quadruplex DNA.  
  
Chapter 4 
 
Synthesis of C–F bond incorporated BRACO-19 
analogues 
 
 
 
 
4.1 - Introduction 
 
This chapter describes the synthesis of an enantiomeric pair of 3- and 6- substituted 
di-fluorinated analogues (152) of BRACO-19 (142a) (Figure 4.01), to investigate if the 
C–F bonds can induce an improved binding conformation over BRACO-19 142a to 
quadruplex DNA.  
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Figure 4.01. BRACO-19 142a & 3,6-C–F bond substituted BRACO-19 152 analogues.  
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In BRACO-19 142a, the amino groups of the pyrrolidine substituents are protonated at 
physiological pH, thus stereospecific C–F bond incorporation in the α-amide positions 
will exert a stereoelectronic influence to provide enantiomeric conformations of 
(R,R)- and (S,S)-152. This conformational bias is anticipated to arise for two reasons, 
charge-dipole compensation between C–F and N+–H bonds and the α-fluoroamide 
effect (Figure 4.01).  
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Scheme 4.01. The charge-dipole effect (A) and α-fluoroamide effect (B). R/R' = H, CH3. 
 
 
Therefore, for each stereoisomer, the C–F bond will orientate anti to the carbonyl, 
extending the planarity of the amide bond (Figure 4.01). Also, the protonated ring 
amine will align g+ or g- relative to the C–F bond through the charge-dipole effect 
(Chapter 1). Thus, the (R,R)-stereoisomer of 152 should have an enantiomeric twist 
relative to the (S,S)-stereoisomer (Figure 4.02).19 
 
The conformational bias induced in 152 will force the charged pyrrolidine substituents 
to orientate towards the phosphate grooves of a quadruplex DNA fold. Thus, this 
conformation will be in contrast to the planar binding mode of BRACO-19 142a with 
quadruplex DNA (Figure 2.18). This conformational bias coupled with the change in 
pKaH of the pyrrolidine nitrogen, as a result of C–F bond incorporation, will generate the 
potential for new hydrogen bonds between 152 and the phosphate backbone of 
quadruplex DNA structure. This altered binding conformation is hypothesised to result 
in a stronger complementary binding between 152 and quadruplex DNA and thus 
stabilise the DNA fold more than that of BRACO-19 142a.   
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Figure 4.02. Conformational representations of the influence of the C–F bond in fluorinated BRACO-19 
analogues 152.  
 
4.2 - Aims 
 
It therefore became a research objective to prepare the (R,R)- and (S,S)- enantiomers of 
152. A retrosynthesis is shown in Scheme 4.02.  
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Scheme 4.02. Retrosynthetic approach to the synthesis of α-fluorinated BRACO-19 152 analogues.  
 
A key step in the synthesis involved the preparation of each enantiomer of the 
fluorinated amino ester 153.  
(R,R)-152 
(R,R)-152 
 (R)-153 
155 154 
(S,S)-152 
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4.3 - Synthesis of an α-fluoro-β-amino acid 
 
As highlighted in Chapter 1, Deniau et al., employed a DAST 32 mediated approach for 
the synthesis GABA analogues 110.87 Treating β-amino alcohol (R)-157 with DAST 32 
resulted in fluorination to furnish (S)-158 in a stereospecific manner. The benzyl 
protected amine 158 could be further manipulated to 3-fluoro GABA (S)-110 after 
oxidation of the aromatic ring and subsequent deprotection of the amine (Scheme 4.03). 
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Scheme 4.03. Synthesis of 3-fluoro GABA (S)-110. 
 
The rearrangement and fluorination arise from the aziridinium intermediate 160 formed 
from SNi attack of the nitrogen lone pair at the β-carbon following activation of the 
alcohol by DAST 159 (Scheme 4.04).188 The transient intermediate 160 can either be 
fluorinated in the α- or β-positions respectively by SN2 attack of fluoride (Scheme 4.04).  
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Scheme 4.04. Mechanism of DAST 32 mediated fluorination of β-amino alcohols  
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Nucleophilic attack of fluoride to the α-position leads to the substitution product 
(R)-161, whereas attack at the β-position results in the rearranged product (S)-158 and 
with an inversion of stereochemistry (Scheme 4.04). In this particular example the 
fluorination proceeds with a 4:1 selectivity in favour of the β-fluorinated product. 
 
The fluorination of esters of the natural amino acid L-serine, with DAST 32, also 
undergoes this rearrangement to furnish esters, (R)-120 and (S)-163 respectively 
(Scheme 4.05). This transformation typically proceeds with high α-fluorination 
selectivity and with excellent enantiocontrol.95 
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Scheme 4.05. Putative aziridinium intermediate formed during fluorination of benzyl protected (S)-serine 
methyl ester (S)-119.  
 
The approach seemed appropriate for the synthesis of (R)- and (S)-153. The only 
concern was the tolerance of the functional groups on the nitrogen. Only benzyl 
protecting groups are reported in the literature for this transformation.95 
 
The dialkyl amino acid 119 was first prepared from methyl ester 165. Starting with 
racemic serine 164, the methyl ester 165 could be synthesised on a gram scale by 
treatment with thionyl chloride in methanol (Scheme 4.06). Treatment of 165 with 
benzyl bromide and potassium carbonate enabled a straightforward preparation of 119 
in good yield (94%) (Scheme 4.06), ready for fluorination with DAST 32 
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Scheme 4.06. Reagents and conditions: a) SOCl2, MeOH, rt, 24 h and b) Benzyl bromide (2.2 eq), K2CO3 
(4 eq), MeCN, rt, 24 h, 94%. 
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The reaction between alcohol 119 and DAST 32 in THF (Scheme 4.07) was monitored 
by 19F NMR spectroscopy, which revealed the presence of the α- and β-products, with 
signals at -190 ppm and -220 ppm. 
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Scheme 4.07. Reagents and conditions: DAST 32 (1.1 eq), THF, 0 ºC, 1 h, 90%.  
 
The major product was the α-isomer 120, which was formed with 95:5 selectivity over 
the β-isomer 163. This reaction scaled well and the α-isomer 120 was isolated in 
excellent yield (90%). This procedure was repeated with enantiopure D- and L-serine 
164 and furnished the individual enantiomers (S)- and (R)-120 in gram quantities with 
excellent enantiocontrol (>90% ee) as analysed by chiral HPLC (ChiralCel OD-H).  
 
Debenzylation of methyl ester 120 was not straightforward. Classical hydrogenation 
conditions using 10% Pd/C in methanol or ethyl acetate under a hydrogen atmosphere 
was unsuccessful (Scheme 4.08).  
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Scheme 4.08. Hydrogenation of benzyl protected ester 120 gave multiple products. 
 
In these reactions, analysis of the reaction product by 19F NMR showed various 
fluorinated products, which could not be separated by standard reverse phase 
chromatography. These products could not be identified other than containing desired 
amine 166. The addition of acid during the reaction resulted in elimination forming 
acrylate type products as confirmed by 19F NMR. Successful debenzylation of 120 was 
achieved with Pd(OH)2/C in methanol, with ester 166 isolated in quantitative yield 
(Scheme 4.09). However, this reaction was unreliable and readily gave multiple 
products despite successful literature reports.189,94,190 
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Scheme 4.09. Reagents and conditions: a) Pd(OH)2/C, H2, MeOH, 24 h followed by HCl (1 M), 99%. 
 
When the debenzylation was followed by 19F{1H} NMR, only one product at -200 ppm 
was observed, presumably the debenzylated material 166. However, purification 
through Celite led to degradation. Thus, in an attempt to isolate amine 166 it was 
protected as its carbamate ester in situ following removal of the palladium catalyst by 
filtration, without addition of HCl to the mixture (Scheme 4.10). 
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Scheme 4.10. Reagents and conditions: a) Boc2O, Et3N, aqueous dioxane (25% v/v), rt, 24 h. 
 
The 19F{1H} NMR spectrum of this mixture again indicated a complex mixture from 
which both 167 and 168 could not be isolated cleanly as they co-eluted with multiple 
unidentifiable products, although the 1H NMR spectrum had no evidence for aromatic 
residues. Due to the nature of this complex product mixture this approach proved 
unsuccessful and was discontinued. 
4.3.1 - Pyrrolidine functionalisation of 166 
 
The double alkylation of 166.HCl to form a pyrrolidine ring was next investigated. This 
involved treating the amine with 1,4-dibromobutane and a catalytic amount of TBAI 
(Scheme 4.11). 
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Scheme 4.11. Reagents and conditions: 1,4-Dibromobutane (1.1 eq), TBAI (0.2 eq), Na2CO3 (4.0 eq), 
MeCN, reflux, 4 h, 77%.  
166.HCl 120 
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Pyrrolidine 153 was isolated in good yield (77%) following purification by 
chromatography. However, this route was not practical for the synthesis of 153, with the 
inefficient debenzylation step limiting the quantity of amine 166 available. Therefore an 
alternative approach was sought, which involved debenzylation after amide coupling to 
the acridone core (Scheme 4.12).  
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Scheme 4.12. Proposed amide coupling route to functionalise acridone 169. 
 
In order to investigate amide coupling to acridone 155, the methyl ester 120 required 
hydrolysis to carboxylic acid 170. This was achieved with KOH in methanol and 
generated (R)-170 in 97% yield (Scheme 4.13). 
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Scheme 4.13. Reagents and conditions: KOH, MeOH, rt, 36 h, 97%. 
 
The reaction was repeated also for the (S)-170 enantiomer. Thus with the carboxylic 
acids (R)- and (S)-170 available, it was next required to synthesise acridone 155. 
 
4.4 - Acridone 155 synthesis  
 
The synthesis of acridone 155, the structural core of BRACO-19 142a, was carried out 
according to a literature method.191,192 The tetranitro diphenylmethane 172 was prepared 
from diphenyl methane 171 in refluxing sulfuric acid with potassium nitrate 
(Scheme 4.14). The reaction product was recrystallised from acetic acid and furnished 
172 in good yield (74%). Oxidation to benzophenone 173 was high yielding (95%) and 
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was achieved by refluxing 172 with chromium trioxide in acetic acid (Scheme 4.14).  
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Scheme 4.14. Reagents and conditions: a) KNO3, H2SO4 (conc), 70 °C, 2 h, 74%; b) CrO3, acetic acid, 
118 °C, 16 h, 95%.  
 
The nitro-groups of the benzophenone derivative 173 were reduced by refluxing with a 
large excess of tin(II) chloride in hydrochloric acid. This also facilitated ring closure to 
form acridone 155 with the 3,6-diamino regiochemistry (Scheme 4.15). 
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Scheme 4.15. Reagents and conditions: a) SnCl2, HCl (conc.), EtOH, reflux, 3 h, 63%.  
 
Acridone 155 is a clay-like solid that was difficult to manipulate and had poor solubility 
in DMSO, DMF or DMAc. Despite this, it was possible to obtain an 1H NMR spectrum 
in d6-DMSO where both NH2 and NH resonances could be assigned in-line with the 
literature.191 
4.5 - Coupling reactions with diaminoacridine 155 
 
With suitable quantities of acridone 155 in hand, it was now possible to investigate 
coupling conditions with the fluorinated amino acid 170. There is limited literature on 
the chemistry of acridone 155. In the synthesis of BRACO-19 142a, 3-chloropropionyl 
chloride 148 is used as the reaction solvent under forcing conditions to prepare amide 
174 (Scheme 4.16),191 with a microwave irradiation approach also requiring a 
significant excess of the acid chloride 148.184 Another approach to form amides on 
acridone 155, employed 1:1 mixtures of acid anhydrides under forcing conditions, to 
prepare acetamides such as 175 (Scheme 4.16).193 
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Scheme 4.16. Synthesis of bis-chloro and acetamide acridones.  
 
From these examples it is clear that forcing conditions are required but in our case a 
large excess of fluorinated amino acid is not practical. Alternative efforts with practical 
equivalents of acid chloride 176 were investigated. Initially, 2.5 equivalents of the acid 
chloride 176, which was formed in situ from with thionyl chloride and directly added to 
acridone 155 in DMAc, was explored (Scheme 4.17).  
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Scheme 4.17. Attempted coupling of acid chloride 176 to acridone 155. Conditions are summarised in 
Table 4.01. 
 
The use of 19F{1H} NMR with unquenched reaction aliquots was useful in following 
this reaction as both acid 170 and acid chloride 176 have characteristic chemical shifts. 
However, these reactions, which were heated over extended time periods, failed to give 
product as judged by TLC and 19F{1H} NMR. Alternative conditions with different 
equivalents of acid or with different reagents were attempted (Table 4.01), but in each 
case no product could be observed. 
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Entry Acid equiv. Reagent Base Solvent 
Temp 
(ºC) 
Time 
(h) 
1 2.5 SOCl2 Na2CO3 DMAc 100 24-48 
2 2.5 SOCl2 Na2CO3 DMAc 160 24 
3 20 SOCl2 - DMAc 160 24 
4 20 SOCl2 Na2CO3 DMAc 100 48 
5 20 SOCl2 pyridine DMAc 100 24 
6 20 SOCl2 DMAP DMAc 100 24 
7 2.5 cyanuric fluoride pyridine DMAc 100 16 
8 4 Ethyl chloroformate NMM DMAc rt >24 
9 4 Benzyl chloroformate NMM DMAc rt >24 
10 2.5 EDC + HOBt NMM DMF rt >24 
11 2.5 EDC + HOBt DiPEA DMF rt 24 
12 2.5 EDC + HOBt DiPEA + DMAP (cat.) DMF rt 24 
13 2.5 EDC + HOBt DiPEA DMF 60 24 
14 2.5 HBTU DiPEA DMF rt 24 
15 2.5 HATU DiPEA DMF rt 24 
 
Table 4.01. Attempted conditions for the coupling of acid 170 with acridone 155. In all cases there was no 
evidence for the formation of product 166.  
 
It was clear that the nucleophilicity of the amine in acridone 155 is insufficient for 
amide bond formation by classical means. An alternative literature approach employing 
metal amides, such as 178, for the synthesis of aromatic amides such as 180 was 
subsequently explored (Scheme 4.18).194,195 
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Scheme 4.18. Generation of the bis-lithium amide for the aminolysis reaction. 
 
This was an attractive alternative for the construction of the desired acridone 169 
(Scheme 4.19).  
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Scheme 4.19. Reagents and conditions: BuLi (4 eq), THF, -78 ºC, 1 h, followed by 120, -78 ºC, 3 h, <10%.  
 
The solubility of acridone 155 in THF was problematic, however the addition of BuLi 
brought the acridone into solution, resulting in a homogenous yellow solution. The 
addition of fluorinated ester 120 maintained this colour. Monitoring of the reaction by 
TLC and 19F{1H} NMR indicated multiple products. Separation of these products by 
column chromatography enabled the isolation of the coupled acridone 169, although in 
low yield (<10%). The remaining products from the reaction, which were both 
non-fluorinated and fluorinated, could not be identified. Subsequent optimisation of the 
reaction conditions showed that treatment of acridone 155 with KHMDS followed by 
the addition of ester 120 in THF at -78 ºC via cannula, resulted in a modest 
improvement in the reaction yield (19%).  
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Treating acridone 169 with neat phosphorus oxychloride gave the 9-chloro intermediate 
181, which was reacted directly with N,N-dimethylaminoaniline 154 in chloroform 
(Scheme 4.20).  
 
N
H
O
N
H
N
H
O
F
NBn2
O
F
Bn2N
N N
H
N
H
O
F
NBn2
O
F
Bn2N
HN
N
a), b)
N
Cl
via
 
 
Scheme 4.20. Reagents and conditions: POCl3 (neat), 105 ºC, 3 h and b) N,N-dimethylaminoaniline 154 
(10 eq), CHCl3, reflux, 2 h, 23% over two steps.  
 
Decomposition of aniline 154 complicated both TLC analysis of the reaction and also 
the subsequent purification of racemic acridine 182. Multiple columns were required to 
obtain a pure sample of the trisubstituted product 182. The HCl salt of 182 was 
particularly insoluble and was not suitable for DNA quadruplex binding studies.  
 
4.5.1 - Debenzylation of acridone 169 
 
It was evident that the benzyl groups of 182 gave an unsuitable non-drug like 
compound, thus removal of the benzyl groups of acridone 169 was explored. Various 
conditions (Table 4.02) were attempted (Scheme 4.21), however, multiple products 
were observed (19F{1H} NMR analysis), similar to that obtained with ester 120. 
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Scheme 4.21. Debenzylation of acridone 169.  
 
Entry Catalyst Solvent Temp. Pressure 
1 10% Pd/C CH3OH rt atm 
2 20% Pd(OH)2/C CH3OH rt atm 
3 20% Pd(OH)2/C CH3OH + Acetic acid rt atm 
4 20% Pd(OH)2/C Ethyl Acetate rt atm 
5 Pd black CH3OH rt atm 
6 (H-Cube®) Pd/C MeOH  rt 1 bar 
7 (H-Cube®) 20% Pd(OH)2/C MeOH  rt 1 bar 
8 (H-Cube®) 20% Pd(OH)2/C MeOH 40 ºC 1 bar 
9 (H-Cube®) 20% Pd(OH)2/C MeOH rt 50 bar 
 
Table 4.02. Attempted hydrogenation conditions on tetra-benzylated 169. All flow reactions were 
conducted on a 1 mmol scale with a flow rate of 1 mL/min. In all cases multiple products were observed. 
 
4.6 - Alternative protecting groups 
 
Alternative dialkyl protecting groups for serine were next explored. Cossy reported in 
2010 that treating allyl protected 184 with DAST 32 resulted in fluorination and 
rearrangement, consistent with other amino alcohols, to furnish 185 with high 
selectivity and excellent enantiocontrol (99% ee). Deprotection of amine 185 was 
achieved to furnish 186 with a palladium based catalyst (Scheme 4.22).196 
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Scheme 4.22. Fluorination of quaternary-β-amino alcohols. 
 
Thus, the route was investigated, with the potential for this motif to undergo RCM to 
form the 5-membered pyrrolidine ring. Starting from the respective serine methyl ester, 
both (R)- and (S)-187 were prepared in good yields (62% and 57%) (Scheme 4.23). 
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Scheme 4.23. Reagents and conditions: a) Allyl bromide (4 eq), K2CO3, MeCN, reflux, 16 h, 57%.  
 
Fluorination of alcohols (R)- and (S)-187 was achieved by treatment with DAST 32 and 
this gave their respective α-fluorinated isomers (S)- and (R)-188 in good yield (69% and 
61% respectively, >95% ee) (Scheme 4.24). Analysis of the reaction mixture with 
19F{1H} NMR showed that fluorination to the α-product 188 proceeded with 95:5 
regioselectivity over the β-product 189, consistent with that found with the benzyl 
moiety. 
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Scheme 4.24. Reagents and conditions: DAST 32 (1.1 eq), THF, 0 ºC, 1 h. 
 
The removal of the allyl groups was next explored. Treatment of allyl protected 188 
using various literature procedures (Table 4.03), failed to furnish free amine 166.197  
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Scheme 4.25. Attempted de-allylation reaction with conditions summarised in Table 4.03 
Entry Catalyst Solvent Temperature 
1 RhCl(PPh3)3 THF reflux 
2 PdCl2 THF reflux 
3 Pd(dppb) THF reflux 
4 PdCl2 THF rt 
 
Table 4.03. Summary of the conditions attempted for the cleavage of the allyl groups in 188. In all cases 
multiple products were observed by TLC and NMR. 
 
It was found that diallyl amine 188 exhibited a similar side-reactivity to hydrogenation 
of benzyl protected 120, with multiple products observed in the 19F{1H} NMR spectrum. 
Thus an alternative approach was sought.  
 
4.6.1 - Ring closing metathesis approach with 188 
 
The allyl groups in 188 offered the opportunity for ring-closing metathesis through to 
dehydropyrrolidine 190 (Scheme 4.26). Initial attempts of the RCM reaction of ester 
188, with 10 mol% of Grubbs 1st generation catalyst 191 failed to provide the desired 
cyclised product 190, as judged by NMR and MS analyses. 
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Scheme 4.26. Ring closing metathesis strategy to dehydropyrrolidine  190.  
 
The addition of Ti(OiPr)4 or acetic acid with the Grubbs I catalyst 191, in CH2Cl2 or 
toluene at room temperature or reflux also failed to provide dehydropyrrolidine 
190.198,199 Alternative catalysts such as Hoveyda-Grubbs 193 or the temperature stable 
(R)-188 (R)-166 
(R)-188 (R)-190 
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indenylidene based 194 at 1.0 mol% to 10 mol% catalytic loadings were also 
unsuccessful (Figure 4.03).200 In each case multiple products were observed by 19F{1H} 
NMR analysis.  
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Figure 4.03. Catalysts employed in the investigations of the RCM reaction of (R)-188. 
 
4.7 - Acridone coupling with ester 188 
 
As an alternative strategy, the diallyl ester 188 was coupled to acridone 155 and then 
chemistry on the side chains was subsequently explored. Thus (S)-188 was treated with 
the optimised base mediated coupling procedure (Scheme 4.27) and diamide acridone 
(S,S)-195 was isolated in a modest yield (23%). 
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Scheme 4.27. Reagents and conditions: KHMDS, THF, -78 ºC 1 h, followed by (S)-188, 78 ºC to rt, 12 h, 
23%. 
 
The 1H and 13C NMR spectra of (S,S)-195 were readily assigned with the overlapping 
terminal allyl resonance and CHF resonance confirmed by 1H-19F HMQC analysis 
(Figure 4.04) 
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Figure 4.04. 1H-19F HMQC (300/282 MHz, CD3OD) spectrum of acridone (S,S)-195.  
 
Repeating the procedure starting from (R)-188 enabled isolation of the enantiomeric 
(R,R)-195, which had identical spectroscopic characteristics. 
 
4.7.1 - Allyl deprotection of acridone 195 
 
With suitable quantities of both stereoisomers of (R,R)- and (S,S)-195 in hand, RCM 
and de-allylation of the allyl groups was explored. Ring closing metathesis failed again 
with the conditions previously attempted for ester 188. This was presumably due to the 
lone pair of the secondary amine, but also to the insolubility of 195 in toluene or 
CH2Cl2. However, the de-allylation of acridone 195 to diamine 196 was achieved 
following a modification of a literature procedure. This used thiosalicylic acid 197 and a 
palladium phosphine based catalyst 198 (Scheme 4.28). 
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Scheme 4.28. Reagents and conditions: Pd2(dba)3 (10 mol%/allyl group), DPPB, thiosalicylic acid 197, 
THF, reflux followed by HCl, 89%. 
 
This reaction proceeds via the Pd-allyl cation 199 facilitating nucleophilic attack of 
thiosalicylic acid 197, which acts as an allyl scavenger (Scheme 4.29).  
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Scheme 4.29. Mechanism for Pd catalysed de-allylation with stoichiometric thiosalicylic acid. R/R' = alkyl, 
aryl. 
 
This reaction proceeded smoothly, with an acidic work up enabling the isolation of 
amine (S,S)-196.HCl by aqueous extraction. Purification by reverse phase 
chromatography followed by freeze-drying provided amine (S,S)-196.HCl in an almost 
quantitative yield (95%). By contrast, when ester 188 had been treated under these 
conditions multiple products were observed. However, this post coupling strategy 
proved much more successful with acridone 195. 1H NMR analysis confirmed that the 
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acridone core had remained intact and that the allyl groups were cleanly removed 
(Figure 4.05).  
 
5.0 3.04.06.07.08.0  
Figure 4.05. 1H NMR (300 MHz, D2O) spectrum of acridone (S,S)-196 after allyl deprotection. 
 
Repeating the procedure with (R,R)-195 enabled the isolation of the complementary 
diamine (R,R)-196 (Figure 4.06). With both diamines available in suitable quantities, an 
investigation into the functionalisation of the terminal amines was now explored.  
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Figure 4.06. Both enantiomers of the deallylated acridone.  
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4.7.2 - Functionalisation of acridone 196 
 
Pyrrolidine formation of the terminal amines of 196 with 1,4-dibromobutane was 
explored (Scheme 4.30), however these reactions were unsuccessful despite trying a 
range of conditions (Table 4.04).  
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Scheme 4.30. Attempted functionalisation of the amino group in acridone 196. Conditions tested are 
summarised in Table 4.04.  
 
1,4-dihalobutane Base Solvent Conditions Time (h) Outcome 
Bromo- DiPEA MeCN reflux 48 No Rx 
Bromo- + TBAI (cat) DiPEA MeCN reflux 48 Inconclusive 
Bromo- K2CO3 THF reflux 48 Inconclusive 
Iodo- K2CO3 THF reflux 48 No Rx 
Iodo- K2CO3 DMF 100 ºC 24 Cleavage of amide 
Iodo- K2CO3 THF/MeCN (1:1) 
Microwave, 
120W 0.5 No Rx 
Iodo- K2CO3 DMF Microwave, 120W 0.5 
Cleavage of 
amide  
Iodo- 
K2CO3 
Et3N (2 
eq) 
THF/DMF 
(9:1) rt 48 No Rx 
Iodo- Et3N (6 eq) DMF rt 48 No Rx 
cis-1,4-dichloro-2-butene Et3N (6 eq) DMF rt 48 No Rx 
 
Table 4.04. Attempted conditions for the reaction detailed in Scheme 4.30. 
 
 
 
 
202 
196 
Table 4.04 
Chapter 4 
 98 
An alternative approach involved the double reductive amination of acridone 196 with 
1,4-butanedial 204 (Scheme 4.32). The required succinate dialdehyde 204 was accessed 
by hydrolysis of 2,5-dimethoxytetrahydrofuran 203 (Scheme 4.31). 
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Scheme 4.31. Reagents and conditions: HCl (1 M), rt, 20 min, basified and distilled.201 
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Scheme 4.32. Attempted route towards pyrrolidine functionalised acridone 202. 
  
Again, the solubility of acridone 196 was a limiting factor in this reaction 
(Scheme 4.32). Various borohydride reagents such as NMe4BH(OAc)3 and 
NaBH(OMe)3 in THF were used with and without acetic acid.202 However, the desired 
product was not identified.  
 
4.8 - Trisubstituted acridine 206 synthesis  
 
An alternative strategy where the acridone moiety in 195 was converted to the 
appropriately trisubstituted acridine was taken. This would enable the synthesis of 
analogues for DNA binding and telomerase assays. To achieve this, acridone 195 was 
treated with neat phosphorus oxychloride to access the 9-chloro intermediate 205 
(Scheme 4.33). The use of elevated temperatures resulted in the elimination of diallyl 
amine as indicated by a resonance at -120 ppm in the 19F NMR spectrum.  
203 204 
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Scheme 4.33. Reagents and conditions: a) POCl3 (neat), rt, 24 h & b) N,N-dimethylaminoaniline 154 
(20 eq), CHCl3, reflux, 5 h, 59%.  
 
The intermediate was used straight away in a SNAr reaction with aniline 154, using the 
stable monohydrochloride 207, which was neutralised and used immediately to avoid 
decomposition (Scheme 4.34). 
 
ClH3N
N a)
H2N
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Scheme 4.34. Reagents and conditions: Na2CO3 (sat. aq. soln.), Et2O, rt, quantitative.  
 
Exclusion of light and air minimised the decomposition of the extracted aniline prior to 
the reaction. Refluxing aniline 154 with (S,S)-195 in chloroform for 5 h enabled the 
formation of the desired acridine product in good yield over two steps (59%). The 
1H NMR spectrum of (S,S)-195 was readily assigned with the aniline substituent clearly 
defined (Figure 4.07). Starting from (R,R)-195, it was also possible to access the 
complementary (R,R)-195 enantiomer, in a yield of 61%.  
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5.0 3.03.54.04.55.56.06.57.07.58.08.5
9.810.04.02.02.01.91.82.0
 
Figure 4.07. 1H NMR (400 MHz, CD3OD) spectrum of trisubstituted acridine (S,S)-206. 
 
The UV-vis absorption spectrum of acridine 206 (maxima at 268, 294, 365 and 425 nm) 
has a broad absorption extending up to 700 nm. This made it difficult to record an 
optical rotation value. 
 
4.8.1 - Allyl deprotection of acridine 206 
 
With practical quantities of acridine (R,R)- and (S,S)-206 in hand, allyl group 
deprotection was next investigated. This was successfully achieved following the 
protocol developed for the deallylation of acridone 195 (Scheme 4.35). 
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Scheme 4.35. Reagents and conditions: Pd2(dba)3 (10 mol%/allyl group), dppb, thiosalicylic acid, THF, 
reflux followed by HCl, 61%. 
 
Analysis of the crude reaction product by NMR indicated that the acridine heterocyclic 
core was unaffected by the conditions and that the allyl groups were cleaved to furnish 
(S,S)-208 as its HCl salt. This required careful purification by C-18 reverse phase 
chromatography. The 1H NMR confirmed cleavage of the allyl groups and the 
CH2CHF, CHF and aromatic resonances were clearly resolved (Figure 4.08). The 
procedure was repeated for the other (R,R)-206 enantiomer, to yield amine (R,R)-208 in 
51% yield.  
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Figure 4.08. 1H NMR (500 MHz, D2O) spectrum of acridine (S,S)-208.HCl after reverse phase 
chromatography.  
 
The two stereoisomers (R,R)- and (S,S)-208.HCl are undergoing binding assays with 
human quadruplex DNA at the UCL School of Pharmacy (Figure 4.09). 
Co-crystallisation trials with the G3(T2AG3)3 telomeric sequence are also underway to 
enable a structural assessment of the influence of the C–F bond on ligand binding to 
quadruplex DNA. 
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Figure 4.09. Selectively fluorinated acridines for studies with quadruplex DNA. 
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4.9 - Alternative side chain functionalisation  
 
A hydrogenation reaction of the allyl groups of ester (S)-188 was explored 
(Scheme 4.36). This proceeded smoothly with 10% Pd/C as a catalyst, and gave the 
N,N-dipropyl product (S)-209 in good yield (61%) 
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Scheme 4.36. Reagents and conditions: a) 10% Pd/C (20 mol%), H2, EtOAc, 24 h, rt, 61%.  
 
Repeating this reaction for (R)-209 enabled the isolation of the other enantiomer in a 
yield of 51%.  
 
4.9.1 - Acridone coupling with ester 209  
 
The N,N-dipropyl ester (S)-209 was thus subject to the general coupling procedure 
described above, to generate acridone (S,S)-210 (Scheme 4.37). This reaction went 
smoothly and purification of acridone (S,S)-210 was relatively straightforward. 
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Scheme 4.37. Reagents and conditions: KHMDS, THF, -78 ºC, 1 h, followed by (S)-209, 78 ºC to rt, 12 h, 
26%. 
 
The propyl groups in (S,S)-210 simplified the analysis of the 1H (Figure 4.10) and 
13C NMR assignment, relative to the diallyl product 195.  
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4.0 1.02.03.05.06.07.08.0  
Figure 4.10. 1H NMR (300 MHz, CD3OD) spectrum of acridone (S,S)-210. 
 
This acridone coupling procedure was then carried out with the opposite enantiomer of 
ester (R)-188 to furnish (R,R)-210 acridone in 30% yield.  
 
The N,N-dipropyl derivatised acridones (S,S)- and (R,R)-210 were again treated with 
phosphorus oxychloride followed by the addition of aniline 154. These reactions went 
smoothly to give the (S,S)- and (R,R)- enantiomers of acridine 212 (Scheme 4.38). 
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Scheme 4.38. Reagents and conditions a) POCl3 (neat), rt, 24 h & b) N,N-dimethylaminoaniline 154 
(20 eq), CHCl3, reflux, 5 h, 21%.  
 
In each case purification was achieved by silica gel chromatography, furnishing the 
(S,S)- and (R,R)-212 enantiomers in reasonable yields (21% and 25% respectively) over 
two steps. The 1H NMR spectrum of (R,R)-212 is shown in Figure 4.11 by way of 
example, with each resonance clearly resolved.  
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Figure 4.11. 1H NMR (400 MHz, CD3OD) spectrum of trisubstituted acridine (R,R)-212. 
 
The two enantiomers of the propyl functionalised acridines 212 (Figure 4.12) have also 
been submitted for binding assays to human telomeric DNA.  
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Figure 4.12. Selectively fluorinated enantiomers of BRACO-19 analogues. 
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4.9.2 - 1H-19F HOESY analysis of (S,S)-212 
 
To investigate the solution conformation of the α-fluoroamide moiety in 212 a 1D 
1H-19F HOESY NMR of (S,S)-212 was recorded. In this experiment, irradiation of the 
fluorine resonance strongly enhances the NH and the CHF resonances in the 1H NMR 
spectrum (Figure 4.13). This is consistent with the C–F and N–H bonds orientated close 
in space, as expected for the anticipated α-fluoroamide conformation (Figure 4.14). 
 
4.05.08.09.010.0 7.011.0 6.0 !  
Figure 4.13. HOESY analysis of (S,S)-212. Lower NMR– 1H NMR (500 MHz, CDCl3) of acridine 212 with 
broad peaks as a result of CDCl3 and Top NMR – 1H NMR (500 MHz, CDCl3) recorded during selective 
irradiation of the 19F signal at -191.1 ppm. 
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Figure 4.14. Simplified representation of acridine 212 with arrows detailing the main NOE enhancements 
in the HOESY spectrum in Figure 4.14. R = propyl, R' = N,N-dimethylaminoaniline. 
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4.10 - Non-fluorinated BRACO-19 142a analogues 
 
The non-fluorinated compounds 213.HCl and 214 have not been previously synthesised 
and were required as reference compounds to compare the effects of selective 
fluorination on the stabilisation of quadruplex DNA (Figure 4.16).  
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Figure 4.15. Non-fluorinated BRACO-19 analogues for comparative studies. 
 
 
Initially, bis-chloro amide 174 was prepared by refluxing acridone 154 in neat 
3-chloropropionyl chloride 148 (Scheme 4.39). 
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Scheme 4.39. Reagents and conditions: 3-Chloropropionyl chloride (neat), 145 ºC, 3 h, 27% 
 
Acridone 174 proved difficult to isolate and purify, however gram scale reactions 
enabled the isolation of sufficient quantities for subsequent reactions. The resultant 
acridone 174 was then treated with either diallylamine (215) or dipropyl amine (216), 
and sodium iodide to furnish 140i and 140j respectively (Scheme 4.40).  
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Scheme 4.40. Reagents and conditions: for 140i a) Diallylamine, EtOH, 80 ºC, 3 h, 46% and for 140j 
a) dipropylamine, EtOH, 80 ºC, 3 h, 26%. 
 
The literature purification of similar acridone compounds calls for the recrystallisation 
from DMF and ethanol, however acridones 140i/j were much more reasonably purified 
by column chromatography, albeit with the need to pre-basify the column with 
triethylamine.191 In the event both 140i/j were isolated in acceptable yields (46% & 
26% respectively).  
 
Treatment of acridones 140i/j with neat phosphorus oxychloride at reflux afforded the 
corresponding 9-chloro intermediates 216 and 217 respectively. Again the chlorides 
were not purified but were reacted immediately, following a brief work-up, with aniline 
154 (Scheme 4.41). Both of the trisubstituted acridines 219 and 214 were isolated in 
acceptable yields (37% & 29% respectively) following purification by column 
chromatography.  
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Scheme 4.41. Reagents and conditions: For both a) POCl3 (neat), 140 ºC, 3 h, 37% & 
b) N,N-dimethylaminoaniline, CHCl3, 80 ºC, 4 h, 29%.  
 
The purification of 219 and 214 by column chromatography proved to be less 
straightforward than with the fluorinated analogues 206 and 212. Acridines 219 and 214 
were loaded on the column as their HCl salts and the column was flushed with 
chloroform and methanol (95:5) to remove any impurities. Addition of triethylamine to 
the eluant neutralised the salts, enabling the isolation of analytically pure tetra-allyl 
protected 219. Repeated chromatography was required to provide a pure sample of the 
propyl functionalised acridine 214.  
 
 
 
 
 
 
 
 
 
 
 
219 R - allyl, 37% 
214 R - propyl, 29% 
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Finally, removal of the allyl groups in 219 to furnish diamine 213 was achieved 
following the standard procedure using Pd2(dba)3 and thiosalicylic acid (Scheme 4.42). 
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Scheme 4.42. Reagents and conditions: Pd2(dba)3 (10 mol%/allyl group), dppb, thiosalicylic acid, THF, 
reflux followed by HCl, 17%. 
 
Purification of acridine 213 by reverse phase chromatography was particularly 
problematic and amine 213 could only be isolated in milligram quantities following the 
addition of formic acid to the eluant. Thus 213 was isolated as its formic acid salt and in 
a poor yield (17%). However, sufficient material was prepared for comparative 
biological assessment with the fluorinated analogues (S,S)- and (R,R)-208.  
 
4.11 - Crystallographic assessment  
 
To date, no suitable co-crystals of the fluorinated trisubstituted acridines have been 
achieved for X-ray diffraction despite repeated attempts to identify good crystallisation 
conditions. Crystals of (R,R)- and (S,S)-212 with the human telomeric sequence have 
formed, however with poor morphology. Diffraction of these crystals has so far only 
provided low-resolution data (>6 Å). However this preliminary data demonstrated that 
the propyl functionalised acridine (S,S)-212 does form a quadruplex fold with the DNA 
as highlighted by the characteristic π-π stacking observed in the diffraction pattern. 
Studies have now focused on investigating conditions with the O. nova quadruplex 
 219 
  213 
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DNA sequence, which generally accommodates a wider variety of ligand 
substituents.182 
 
Whole cell based assays and in vitro analysis by FRET are currently underway with our 
collaborators at the UCL School of Pharmacy in London.  
 
4.12 - Conclusions  
 
The chapter has demonstrated the successful synthesis of (S,S)- and (R,R)- stereoisomers 
of fluorinated 208 and 212. In addition, the complementary non-fluorinated ligands 213 
and 214 were also prepared for assessment by X-ray crystallography and in vitro based 
assays.  
 
  
Chapter 5 
 
Studies on the selective fluorination of 
dipeptides 
 
 
 
5.1 - Introduction 
 
In this chapter an alternative approach for the synthesis of α-fluoroamides is explored. 
The fluorination of β-alcohol amino esters, as discussed in Chapters 1 and 4, with sulfur 
trifluoride reagents provides an efficient method for the generation of an array of 
fluorinated building blocks. The reaction of DAST 32 with peptides bearing the 
β-hydroxy functionality, such as in 220, is commonly employed for the synthesis of 
oxazoles (222) and oxazolines (223) (Scheme 5.01) without incorporation of fluorine. 
The approach allows the synthesis of these heterocycles with various degrees of 
functionalisation and structural diversity.203 Such activation with DAST 32 has even 
been employed in the synthesis of the telomerase inhibitor telomestatin 134 
(Chapter 2.9.1), which contains repeating oxazole units.162 
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Scheme 5.01. Synthesis of oxazoles and oxazolines with sulfur trifluoride reagents. R,R', R'' = H, alkyl, 
aryl. 
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However, the use of dehydroxyfluorination reagents on α-amino-β-hydroxyamides such 
as 224 has not been reported. At the outset the aim was to explore the scope and 
potential of the fluorination of dipeptides 224 with a terminal serine residue 
(Scheme 5.02).  
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Scheme 5.02. Fluorination pathway for β-hydroxy amines bearing the amide functionality. The double 
bond character could support the intermediate or facilitate in the formation of an α-carbocation leading to 
racemisation. R = allyl/benzyl & R' = H, alkyl, aryl.  
 
The influence of the amide bond on the opening of the aziridinium ring in intermediate 
225 and its effect on the distribution of α- and β-fluorinated regioisomers 227 and 228 
was a key consideration (Scheme 5.02). The amide resonance in 226 may also stabilise 
a carbocation at the α-position and promote racemisation in the α-fluorinated product 
227.  
 
5.2 - Carboxylic acid synthesis for peptide couplings 
 
The serine derivative (S)-229 was first prepared (Scheme 5.03). N,N-Diallylation of 
L-serine methyl ester 165 was achieved by reaction with allyl bromide as summarised in 
Scheme 5.03. This proceeded straightforwardly generating gram quantities of alcohol 
(S)-187. The terminal hydroxyl group was then protected as its TBDMS ether (S)-229 in 
preparation for peptide coupling (Scheme 5.03).  
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Scheme 5.03. Reagents and conditions: a) Allyl bromide (2.5 eq), K2CO3 (4.0 eq), CH3CN, 60 ºC, 16 h, 
57%; b) TBDMSOTf (1.1 eq), Et3N (5.0 eq), CH2Cl2, rt, 16 h, 83%.  
 
Methyl ester (S)-229 was hydrolysed using lithium hydroxide in methanol to give 
carboxylic acid (S)-230 (Scheme 5.04). The purity of the extracted product was 
sufficient to be used directly in peptide coupling reactions.  
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Scheme 5.04. Reagents and conditions: a) LiOH (4.0 eq), CH3OH:THF:H2O (3:1:1), 24 h, 90%. 
 
5.3 - Peptide couplings  
 
Peptides 323a-c were prepared by coupling to a variety of commercially available 
amino acid methyl esters 231a-c (Scheme 5.05).  
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Scheme 5.05. Reagents and conditions: a) T3P® (1.5 eq), amine 231a/b/c (2.0 eq), diisopropylethylamine 
(4.0 eq), CH2Cl2, 0 ºC to rt, 1-12 h, 79-85%. 
 
Both HBTU and T3P® were effective for the coupling reactions, although from a 
practical point of view, T3P® offered an advantage over HBTU. This was because the 
hydrolysis product is water-soluble and could be removed along with excess unreacted 
(S)-165 (S)-187 (S)-229 
231a-c 
(S)-229 
 
(S)-230 
 
(S)-230 
 
232a - 81%, R = CH2Ph  
232b - 85%, R = CH3  
232c - 79%, R = CH(CH3)2 
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amine by an acidic wash upon work-up (Scheme 5.05). More generally, T3P® mediated 
peptide couplings proceed in high yields with low levels of epimerisation.204 
 
The synthesis of the L-phenylalanine dipeptide 232a proved amenable to scale-up and 
was isolated in 81% yield. Dipeptides 232b/c derived from L-alanine and L-valine, were 
synthesised in 85% and 79% yields respectively. All three dipeptides 232a-c, were 
isolated with good diastereoselectivity, with only a very low level of epimerization at 
the α-carbon (95:5 dr).  
 
Fluorination of 232a-c required that the silyl protecting group be removed to release 
alcohols 224a-c. Initial silyl ether deprotection of 232a with TBAF in THF cleaved the 
silyl ether to yield 224a but also resulted in the hydrolysis of the methyl ester to give 
233. This gave rise to an unexpected cyclisation to the cyclic dimer 234 (Scheme 5.06). 
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Scheme 5.06. Reagents and conditions: a) TBAF (2 eq), THF, 0 ºC to rt, 2 h. 
 
Both carboxylic acid 233 and cyclic dimer 234 co-eluted during purification with the 
structure of the cyclic depsipeptide confirmed by single crystal X-ray crystallographic 
analysis (Figure 5.01). The formation of 234 is clearly a dimeric condensation, although 
the detailed sequence of events is not clear.  
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Figure 5.01. Crystal structure of the 14-membered cyclic (R,R) 234. Structure A shows two cyclic dimers 
in the unit cell. The nature of the allyl groups results in some disorder. Structure B represents one ring with 
the peripheral benzyl and allyl groups removed so that both amide and ester bonds are clearly observed. 
 
In order to circumvent the problematic methyl ester hydrolysis and cyclisation, the silyl 
ether was removed with an acetic acid buffered TBAF solution in dry THF, at rt 
(Scheme 5.07).  
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Scheme 5.07. Reagents and conditions: a) TBAF (4.0 eq, 1 M THF soln.), AcOH (5.0 eq), THF, rt, 12-24 h, 
73-88%. 
 
This gave an excellent conversion to the free alcohols 224a-c (73-88%), which could 
then be purified by chromatography in a straightforward manner. Importantly, no 
further epimerisation was observed in the products.  
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5.3.1 - Fluorination reactions of dipeptides with DAST 32 
 
The fluorination of L-phenylalanine derived dipeptide 224a with DAST 32 was initially 
explored (Scheme 5.08). 
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Scheme 5.08. Reagents and conditions: a) DAST 32, THF, 0 ºC, 1 h, 81% (total fluorinated yield).  
 
TLC analysis indicated that the starting material was consumed after 1 h stirring at 0 ºC 
showing a similar reactivity to the ester substrates 119/187 in Chapter 4. Analysis of the 
product mixture by 19F and 1H NMR indicated a ratio of 60:40 for the α- and 
β-fluorinated products (227a:228a). The α- and β- regioisomers could be distinguished 
by their distinctive coupling patterns in both the 19F and 1H NMR spectra and chemical 
shift in the 19F NMR spectrum. This is a significant change in selectivity relative to the 
fluorination of esters 119/187 (Chapter 4). In those cases the α-products were favoured 
in a 95:5 (α:β) ratio (Table 5.1). However, despite the poorer selectivity in 224a, the 
reaction proceeds cleanly, with the 1H NMR and 19F NMR spectra correlating 
accordingly.  
 
O
O
NR2
HO
O
NR2
FO
O
F
R2N +
DAST
O
 
Entry R  α-NMR ratio β-NMR ratio 
1 Benzyl (119) 95 (120) 5 (160) 
2 Allyl (187) 95 (188) 5 (189) 
 
Table 5.1. Fluorination selectivity ratio for esters, 119 and 187 (Chapter 4.3/4.7).  
 
The two fluorinated regioisomers 227a and 228a were readily separated by column 
chromatography. This is in contrast to the fluorinated esters 119/187, which could not 
be easily separated. Both 227a and 228a were isolated in 43% and 38% representing an 
228a - 38% 224a 227a - 43% 
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efficient overall transformation. The diastereomeric ratio of the α-fluorinated product 
227a was determined to be 95:5 from the 1H and 19F NMR spectra. This suggests that 
the reaction has good stereocontrol and does not proceed via substantial carbocation 
character at the α-position. 
 
The significant shift from high α-selectivity in esters 119/187 to a poorer α-selectivity 
for amide 224a was unexpected. Accordingly, dipeptides 224b/c were explored to 
assess the influence of less bulky amino acid side chain substituents on the outcome of 
the fluorination.  
 
N
H
O R'
NR2
HO N
H
O R'
NR2
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H
O R'
F
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a)
O
O
O
O
O
O +
 
 
 
Scheme 5.09. Reagents and conditions: a) DAST 32, THF, 0 ºC, 1 h, 47-54% (total fluorination). R = allyl 
 
The reactions of 224b/c with methyl and isopropyl side chains respectively, with 
DAST 32 demonstrated a shift towards the β-fluorinated product (Table 5.2, Entries 
2/3) with an α:β ratio of 35:65 and 25:75 for 227b/228b and 227c/228c respectively. 
The fluorination ratios for 224a-c are summarised in Table 5.2 along with their 
respective diastereomeric ratios.  
 
Entry Substitution α:β ratio dr 
1 Phe, 224a 60:40 95:5  
2 Ala, 224b 35:65 85:15  
3 Val, 224c 25:75 92:8  
 
Table 5.2. Fluorination ratios and diastereomeric ratios of products 224a-c.  
 
An overlay and progressive offset display of the 19F{1H} NMR spectra of the crude 
reaction mixtures illustrates the α:β fluorination ratio of the three dipeptides 227/228a-c 
products (Figure 5.02).  
 
224b  
224c 
227b - 18%, R' = CH3  
227c - 12%, R' = CH(CH3)2 
 
228b - 36%, R' = CH3 
228c - 35%, R' = CH(CH3)2 
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Figure 5.02. Overlay of the 19F{1H} NMR (376 MHz, CDCl3) spectra of the crude products from the 
fluorination of amides 224a-c. 
 
These fluorination reactions proceed via an aziridinium intermediate with subsequent 
fluorination at either the α- or β-positions of 236a-c (Scheme 5.10).95 It is assumed that 
the β-product results from nucleophilic fluoride attack at the β-position of aziridinium 
236a-c, rather than by direct SN2 attack of fluoride at the activated alcohol 235a-c. It is 
not obvious that the β carbon will be significantly more electropositive in the 
aziridinium intermediate for the amides 224a-c over that of the esters 119/187. However, 
the product ratios observed for the fluorinations from 224a-c suggest an increased 
β-reactivity (Scheme 5.10).  
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Scheme 5.10. Two proposed reaction pathways that could be occurring to explain the product distribution. 
R = allyl, R'= Phe (a), Ala (b), Val (c). 
 
For the aziridinium intermediate 236a-c to form, terminal alcohol 224a-c requires to be 
activated (235a-c) such that the lone pair of the α-amine nitrogen can undergo SNi 
attack at the β-carbon. The rate at which this intramolecular SNi reaction (k4) occurs is 
governed by the availability of the nitrogen lone pairs of 235a-c (Scheme 5.10). This 
will be compromised if the lone pairs form a hydrogen bond to the N–H of the amide. 
Such 5-membered hydrogen bonded rings are observed in the solid state within this 
structural class.205 Therefore, the rate of aziridinium formation (k3) over direct SN2 
substitution (k2) at the β-carbon will be affected by this hydrogen bond (Scheme 5.10). 
On the other hand, if the nitrogen lone pair is free to form an aziridinium intermediate 
236a-c - as in the case of esters 119/187 - then the rate of this intramolecular reaction 
(k4) will be significantly faster than the intermolecular fluoride ion attack (k2) (Scheme 
5.10). If k2>>k3 then β-fluorination dominates, if k2 ≥ k3 then this results in a mixture of 
α- and β-products and if k3>>k2 then α-fluorination dominates. Fluoride attack of 
aziridinium intermediate 236 (Scheme 5.10) can either be at the α- or β-position (k5 or 
k5′). Based on the observation with esters 119/187, k5′ is significantly faster than k5 and 
so α-fluorination will dominate as a result of the more electropositive α-carbon. 
 
224a-c 
227a-c 228a-c 
235a-c 235'a-c 
-c 
236a-c 
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Therefore, in the case of the L-phenylalanine dipeptide 224a this analysis suggests that 
the benzyl group dictates a less favourable hydrogen bonding interaction than the 
methyl and isopropyl groups in 224b/c. By comparing the chemical shift difference 
between the amide NH 1H NMR resonance of 224a-c, a correlation between the 
fluorination ratios and the relative chemical shifts is apparent (Figure 5.03). A higher 
NH chemical shift and therefore a relatively stronger hydrogen bond, appears to 
correlate with a higher proportion of the β-product in the L-alanine and L-valine 
dipeptides.  
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Hydrogen bond
no 5-membered
Hydrogen bond
 
 
Figure 5.03. Analysis of the NH 1H NMR resonance between non-fluoro, α and β fluorinated products 
detailing the chemical shift disparities. Chemical shifts are reported in ppm and are quoted relative to 
CDCl3. 
 
The analysis of the amide NH chemical shifts in the 1H NMR spectrum in both the 
dipeptide starting materials 224a-c and α/β fluorinated products 227/228a-c provides 
further evidence of hydrogen bonding. In the α-fluorinated products 227a-c, the NH 
resonance is approximately 0.9 ppm upfield relative to the respective starting materials 
224a-c and β-fluorinated products 228a-c. Without the hydrogen bonding in these 
compounds, the direction of the chemical shift change of the α-fluorinated products may 
appear counter intuitive based on the electronegativity of the α-C–F bond. Thus these 
observations further support the evidence for a hydrogen bond in the alcohols 224a-c 
resulting in a 5-membered ring.  
 
224a-c 
228a-c 
227a-c 
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To test this hypothesis further, the effect of temperature on the regioselectivity of the 
reaction was explored. It was anticipated at lower temperatures, that the selectivity for 
the β-fluorination in 224a would increase relative to the α-fluorinated. Carrying out the 
reaction at -78 ºC gave rise to low levels of fluorination, however, the 19F NMR 
spectrum of the reaction mixture after 5 h showed only the β-fluorinated product. The 
reaction was then conducted at -20 ºC. After 2 h the 19F NMR spectrum showed a 
greater level of the α-fluorinated product, with an α:β ratio of 75:25. At ambient 
temperature, a black solution is immediately formed upon the addition of DAST 32. 
After 20 minutes the 19F NMR spectrum of the crude mixture revealed an unexpected 
shift towards β-fluorinated product in a ratio of 50:50. The temperature profile was 
more complex than expected, but indicated a tendency to β-product at low temperature 
(-78 ºC).  
 
5.3.2 - Dipeptide conformation in 227a 
 
19F NMR analysis of α-fluorinated products 227a-c, shows a through space 4JFH 
coupling constant, between the fluorine and the amide proton (Figure 5.04). These 
coupling constants are: 4.0, 3.7 and 4.3 Hz, corresponding to compounds 227a, 227b 
and 227c respectively. This is indicative of an NMR solution structure with the 
expected ~180º relationship between the C–F bond and the amide (Chapter 1.11.2).77  
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Figure 5.04. 19F NMR (470 MHz, CDCl3) of 227a detailing the coupling pattern of the CHF resonance.  
 
5.4 - Preparation of α-amino acid N–H and N–CH3 amide derivatives 
 
In order to study the effect of hydrogen bonding on the α/β fluorination ratio, 
incorporation of an N-methyl group on the amide nitrogen was explored. This removes 
any possibility of a hydrogen bond and may show an increase in α-fluorination 
selectivity. An initial effort to synthesise N-methylated 238 proved unsuccessful, even 
though a number of reported literature conditions were attempted (Scheme 5.11).206,207      
In our hands, the treatment of Boc protected L-phenylalanine with various bases and 
methyl iodide failed to furnish the desired N-methylated product 238 in suitable 
quantities and only complex mixtures resulted.  
NBoc
O
O
Ph
Various 
conditions
NHBoc
O
O
Ph
 
 
Scheme 5.11. Attempted synthesis of N-methyl phenylalanine. 
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An alternative strategy was taken for the syntheses of appropriate N-methyl analogues 
and was achieved with secondary benzylamines 239a/b. Starting from amine 239a and 
following the same coupling procedure with T3P®, amide 240a was synthesised in good 
yield (Scheme 5.12). 
  
a)
O
N
TBDMSO OH
+
O
N
TBDMSO N
R
Ph
HN
R
Ph
 
 
 
Scheme 5.12. Reagents and conditions: a) T3P® (1.5 eq), amine 239a/b (2.0 eq), diisopropylethylamine 
(4.0 eq), CH2Cl2, 0 ºC to rt, 1-12 h. 
 
Amide 240a showed a significant cis-trans isomer ratio in the 1H NMR spectrum with a 
75:25 preference for the trans isomer (Scheme 5.13). Isomerisation in this class of 
compound arises from the higher steric demand of the amide N′–CH3 over that of an      
N–H in 232a-c. The identification of the resonances attributed to both the cis and trans 
conformers in 240a was possible by analysis of the 1H-1H COSY spectrum. The 
resonance of the N′-CH3 corresponding to the trans isomer was 0.2 ppm downfield of 
the cis resonance, with a ratio of 25:75 (cis:trans). This ratio was also observed for the 
α-CH3 resonance with the trans isomer 0.07 ppm upfield from that of the corresponding 
cis isomer. In 1D and 2D nOe experiments, irradiation of the α-CH3 (1.47 ppm) of the 
trans isomer resulted in a transfer of magnetization to both cis and trans conformers. 
This highlights that the two conformations are interconverting on the NMR timescale, 
complicating the unambiguous assignment of the cis and trans isomers. 
 
 
 
N
O
Me
Ph
NR2
TBDMSO N
O
NR2
TBDMSO
Ph
Me
 
 
 
Scheme 5.13. Cis-trans isomerisation of the tertiary amide 240a. The trans conformation is preferred by 
3:1 as indicated from integration of the 1H NMR signals. R = allyl. 
 
 
230 240a, 82%, R = CH3  
240b, 78%, R = H 
239a, R = CH3 
239b, R = H 
cis - 240a  
 
trans - 240a  
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For a direct comparison of the fluorination ratio between N′-Me and N-H amides, amide 
240b was synthesized from α-methylbenzylamine 239b (Scheme 5.12). The amide 240b, 
like the dipeptides 232a-c, did not show any obvious cis-trans isomerisation by 
1H NMR.  
 
The silyl protecting groups of amides 240a/b were removed using acetic acid buffered 
TBAF (Scheme 5.14), enabling the isolation of alcohols 241a/b in good yields. The 
cis-trans isomer ratio in amide 241a was also 25:75.  
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Scheme 5.14. Reagents and conditions: b) TBAF (4.0 eq, 1 M THF soln.), AcOH (5.0 eq), THF, rt, 12-24 h. 
 
5.4.1 - Fluorination Reactions of amides 241a/b 
 
With the N′-alkylated substrates in hand, alcohols 241a/b were treated with DAST 32 
under the same conditions to that used previously, such that the α:β ratios could be 
directly compared (Scheme 5.15 & 5.16).  
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Scheme 5.15. Reagents and conditions: a) DAST 32 (1.1 eq), THF, 0 ºC, 1 h.  
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Scheme 5.16. Reagents and conditions: a) DAST 32 (1.1 eq), THF, 0 ºC, 1 h.  
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Direct analysis of the reaction mixture of N–H amide 241b, which was still capable of 
forming a 5-membered intramolecular hydrogen bond, showed a 70:30 (α:β) bias for 
fluoride attack at the α–carbon (Figure 5.05, lower NMR). This reaction proceeded with 
a diastereomeric ratio of 92:8. Although the bias has shifted, it represents a significantly 
lower selectivity compared to esters 119 and 187. This shift back to an α-fluorination 
preference suggests that the mechanism for selectivity may be more complex than 
anticipated. By contrast, analysis of the α:β ratio from N′-methylated amide 241a was 
99:1 in favour of α-fluorination (Figure 5.05, top NMR). However, analysis of the crude 
1H NMR indicated a diastereomeric ratio of 89:11. This represents a drop in 
diastereoselectivity for the fluorination of the N-substituted substrate 241b compared to 
224a-c, suggesting that the reaction may have some SN1 character. The 19F NMR of 
α-fluorinated 242a, shows cis and trans products with resonances 
of -184.6 and -186.8 ppm respectively. 
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Figure 5.05. Overlay of the crude 19F{1H} NMR (376 MHz, CDCl3) from the fluorination of 241a/b with 
DAST 32.  
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The high fluorination selectivity for the N′-Me substrate for the α-product 242a is 
greater than that observed for the fluorination of the amino esters 119 and 187 
(Table 5.1). This is the first example of selective α-fluorination of an N'-substituted 
amide by deoxyfluorination. The difference in fluorination ratio between the 
N′-substituted amide 241a and amide 241b is consistent with the involvement of 
hydrogen bonding influencing the product profile.  
 
It was possible to observe spin polarization in the 1D HOESY (19F-1H nOe) following 
selective irradiation of the fluorine signal in the two isomers of 242a.59 Selective 
irradiation of the cis isomer at -184.6 ppm in the 19F NMR (Figure 5.06, A) showed an 
enhancement of the trans Cα+1–H proton.  
 
 
 
 
 
 
 
7ppm 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 2.57.5
non selective 
selective major
selective minor
Friday, 27 January 2012
 
Figure 5.06. 1D HOESY (500 MHz, d6-DMSO) of 242a. A - Selective cis C–F irradiation at -184.6 ppm in 
242a; B - Selective trans C–F irradiation at -186.8 ppm in 242a; C - Non-selective dual irradiation of cis 
and trans 242a; D - standard 1H NMR.  
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This appears counterintuitive, however, this enhancement is observed as the amide is 
equilibrating on the NMR timescale, where during !m the spin polarization and 
enhancement is ‘carried’ over to the trans isomer. These is a strong enhancement of the 
allyl resonances, which overwhelms the cis Cα+1–H resonance. Such an enhancement of 
the trans Cα+1–H is not observed when selective irradiation of the signal at -186.8 ppm 
is carried out (Figure 5.06, B). An averaging of the enhancement is observed when a 
non-selective irradiation of the fluorine is conducted. The dynamic nature of the 
cis-trans isomerisation in 242a clearly complicates the assignment.  
 
5.5 - Extending the applicability to useful N-substituted amides 
 
In order to extend the potential of this methodology, the N-allylamide 244 was prepared 
carrying non-orthogonal protecting groups. This protection strategy was designed to 
enable a one-pot deprotection to furnish a synthetically useful dipeptide for further 
peptide coupling through the free β-amine in 246 (Scheme 5.17).  
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Scheme 5.17. Synthesis and deprotection strategy to peptide 246.  
 
The synthesis of N-allyl amine 247 was achieved by treating methyl ester 231a with 
allyl bromide in DMF and diisopropylethylamine (Scheme 5.18). The addition of the 
reagents at 0 ºC and slow warming to room temperature enabled isolation of 
mono-allylated 247, with no dialkylation observed. This method was efficient and gave 
244 
245 
 
246 
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rise to sufficient quantities of allyl amine 247 for peptide coupling experiments to be 
conducted.  
H2N
O
O
Ph
N
H
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O
Ph
a)
.HCl  
 
Scheme 5.18. Reagents and conditions: a) Allyl bromide (5.0 eq), diisopropylethylamine (4.0 eq), DMF, 
0 ºC to rt, 24 h, 38%.  
 
Initial efforts to prepare the allyl protected tertiary amide 248 utilising the conditions 
employed so far with T3P®, only provided a trace of the desired tertiary amide 248 
(Table 5.3, Entry 1 & 2). Other peptide coupling reagents such as CDI, EDCI and 
HATU in either DMF or CH2Cl2 at room or elevated temperatures were also 
unsuccessful (Table 5.3, Entries 3-7 It is clear from these unsuccessful conditions that 
the N-allylated nitrogen is poorly nucleophilic as a result of the high steric hindrance 
from both the allyl and benzyl moieties in 230. 
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Entry Reagent Solvent Temp (ºC) Product 
1 T3P® CH2Cl2 20 <5% (48 h) 
2 T3P® DMF 20 Trace 
3 HATU CH2Cl2 20 No 
4 HATU DMF 20 No 
5 HATU DMF 60 No 
6 CDI CH2Cl2 20 No 
7 EDCI CH2Cl2 20 No 
8 PyBrop CH2Cl2 20 No 
9 PyBrop DMF 20 No 
10 PyBrop DMF 60 No 
11 SOCl2 CH2Cl2 20 Multiple 
 
Table 5.3. Attempted peptide coupling conditions between 230 and 247.  
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231a 247 
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     Conditions: 
    see below 
 Chapter 5  
  
 131 
Entries 1 - 7 (Table 5.3) were also explored adding a catalytic amount of DMAP, 
however, this failed to generate the desired amide 248. Alternative and more tailored 
peptide coupling reagents were explored. Attempts with the phosphonium salt, 
PyBrop208 249 (Figure 5.07) were also unsuccessful in the preparation of the coupled 
amide (Table 5.3, Entries 8-10). In each case starting materials were recovered from the 
reaction.  
 
 
P+
BrN N
N PF6-
PyBroP  
Figure 5.07. Tailored phosphonium salt for peptide coupling with sterically hindered substrates.  
 
A final approach to prepare 248 was attempted using the acid chloride of 250 (Table 5.3, 
Entry 11) (Scheme 5.19). 
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Scheme 5.19. Reagents and conditions: a) SOCl2, CH2Cl2, DMF (cat.), rt, 1 h followed by the addition of 
247; b) CH3OH quench. 
 
Acid chloride 250 was prepared by treatment of the carboxylic acid 230 with thionyl 
chloride in CH2Cl2, and a catalytic amount of DMF. Its formation was confirmed by a 
methanol quench to furnish the corresponding methyl ester 229 (Scheme 5.19). Once 
the acid chloride was formed, secondary amine 247 was added. TLC analysis indicated 
249 
250 248 
229 
230 
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that multiple products had formed after 1 h, and a complex mixture was observed by 
1H NMR analysis. In light of these results, this route was not investigated any further.  
 
5.6 - Tertiary allylamide from secondary dipeptides 
 
With the coupling between N-allyl amine 247, and carboxylic acid 230, failing to 
furnish the desired amide, attention turned to direct amide allylation (251 to 252). The 
tri-allylated dipeptide 232a, could clearly be accessed using an appropriate base with an 
allyl halide or by the use of a transition metal catalysed allylation reaction 
(Scheme 5.20).  
 
R
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N R'R
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Scheme 5.20. Base and metal mediated approaches for the allylation of amides. R/R' = allyl/alkyl 
 
Treatment of amide 232a with NaH in THF . (Table 5.4, Entry 1 and 2) in the presence 
of an excess of allylbromide resulted in a complex product mixture, of which, the 
β-alanyl 253 species was one of the major side-products as judged by crude 1H NMR 
(Scheme 5.21).  
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Entry Base Equivalents Solvent Temp ºC Products 
1 NaH 1 THF 20 Multiple 
2 NaH 1 DMF 20 Multiple 
3 KHMDS 1 THF -78 Yes  
4 KHMDS 0.9 THF -78 Yes  
5 KHMDS 1 THF -100 Yes  
6 KHMDS 0.9 THF -100 Yes  
7 LiHMDS 1 THF -78 Yes  
8 KOtBu 1 THF 20 No 
9 Cs2CO3 4 THF 20 Multiple 
10 Cs2CO3 4 THF 60 Multiple 
11 K2CO3 4 THF 20 Multiple 
 
Table 5.4. Reagents and conditions used for the attempted allylation of amide 248. 
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Scheme 5.21. Reagents and conditions: a) NaH (1.0 eq), allyl bromide (4.0 eq), DMF, 20 ºC; b) KHMDS 
(1.0 eq), allyl bromide (4.0 eq), THF, -78 ºC, 1-16 h, 53%. 
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When KHMDS and LiHMDS were used (Table 5.4, entries 3-7) at -78 ºC, the Cα+1 
allylated product 254 was formed (Scheme 5.21). This product could also be observed 
even when a substoichiometric equivalent of KHMDS was employed at -78 ºC 
and -100 ºC (Table 5.5, entry 4 & 6). 
 
The Cα+1 product, an α-allyl phenylalanine dipeptide 254 was isolated as a 
diastereomeric pair, from the reaction with KHMDS and allyl bromide. The 
diastereomers could not be separated by column chromatography but were characterised 
as a mixture by 1D and 2D NMR. In the 1H NMR of 254, the loss of the Cα+1 proton 
resonance, and retention of the amide NH resonance were indicative of the formation of 
254. This was confirmed by DEPT and HMBC analyses of 254, which identified the 
expected quaternary carbon. The fact that this is a 1:1 diastereomeric pair is consistent 
with α-proton abstraction and subsequent enolization. This diastereomer mixture was 
also observed when KtOBu was used as a base (Table 5.4, entry 8). From these 
observations it is clear that the pKa of the Cα+1 proton was similar or more acidic than 
that of the amide proton and that the bases were able to deprotonate this hindered proton, 
furnishing the Cα+1 allylated product.  
 
In an effort to circumvent this, the strong, hindered base tert-butyl P4 phosphazene 255 
was explored (Figure 5.08). Developed in the late 90’s by Reinhard Schwesinger, 
tBu P4 255 has a MeCNpKBH+ of 42.7 resulting form the potential large charge 
delocalisation available upon protonation (Figure 5.08). This class of base is well 
documented in the synthesis of N′-benzylated peptides.209,210 
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Figure 5.08. The strong hindered base tBu P4 255.  
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Initial treatment of 232 with of tBu P4 255 at -78 ºC in THF with allyl bromide again 
gave rise to multiple products, of which both the Cα+1 allylated product 254 and the 
desired N′-allyl amide 248 could be isolated (Scheme 5.22).  
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Scheme 5.22. Reagents and conditions: a) tBu P4 255 (0.9 eq), allyl bromide (4.0 eq), THF, -78 ºC, 16 h, 
30-50%.  
 
The N′-allyl amide 248 was only isolated in a 10 % yield, however, interestingly, the 
Cα+1 allylated product 254 was isolated again with a low but significantly improved 
selectivity for one diastereomer (2:1 from 1H NMR). The observation that 254 was still 
formed, even when using a particularly hindered base, highlights the similar pKa of both 
protons. 
 
Using phosphazene base 255 with benzyl bromide in place of allyl bromide, three 
benzylated products could be isolated after chromatography. Analysis identified these as 
the Cα+1 benzyl 256, N′-benzyl 257, and benzyl ester 258 (Scheme 5.23) which were 
isolated in yields of 20%, 18% and 15% respectively. 
232a 
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Scheme 5.23. Reagents and conditions: a) tBu P4 (0.9 eq), benzyl bromide (4.0 eq), THF, -78 ºC, 16 h, 
15-20%.  
 
N′-Benzylated amide 257 was formed in an improved yield (16%) compared to the 
N′-allyl amide 248 (10%). This protecting group is however not so attractive as 
deprotection of N′-benzyl amides involves the use of sodium metal in napthalene, a 
reagent combination incompatible with the functional groups in amide 257.197 The 
apparent hydrolysis of the methyl ester and subsequent carboxylate alkylation to 
generate an ester in 258, was not observed with allyl bromide.  
 
Optimisation of the reaction by increasing the scale and initial treatment of amide with 
tBu P4 at -100 ºC followed by gradual warming through to -78 ºC before the addition of 
allyl bromide, furnished amide 248 in a significantly improved yield of 53% 
(Scheme 5.24). This enabled sufficient quantities of the N′-allyl amide 248 to be 
isolated for subsequent transformations.  
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Scheme 5.24. Reagents and conditions: a) tBu P4 (0.93 eq), allyl bromide (5.0 eq), THF, -100 ºC to -78 ºC 
to rt, 20 h, 53%. 
 
The 1H NMR spectrum of 248 clearly indicates two rotamers, designated here as the cis 
and trans allylic resonances for the N′-allyl group (Figure 5.09). The other resonances 
232a 
256 257 
258 
232a 248 
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were less easy to assign with confidence, however, from Figure 5.09 it would appear 
that the trans rotamer predominates in a ratio of 95:5.  
4.9 4.95.05.05.15.15.25.25.35.35.45.45.55.55.65.65.75.75.85.85.95.96.06.0ppm
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Figure 5.09. 1H NMR (400 MHz, CDCl3) showing the allylic hydrogen spin system of 248 detailing the 
cis/trans resonances of the N′-allyl group. 
 
The cis-trans relationship in 248 is significantly less than that observed in 240a. It is 
likely that the steric demand of the N′-CH3 in 240a and the benzyl moiety are similar. 
Whereas in 248 the CH2 of the N′-allyl group is significantly less demanding compared 
to phenylalanine. Thus, the trans isomer in 248 is likely to be the more stable 
conformation.  
 
Silyl ether cleavage of amide 248 was achieved with acetic acid buffered TBAF to 
furnish alcohol 244 in good yield (Scheme 5.25). The nature of the cis-trans isomerism 
in the 1H NMR was similar to that of allyl amide 248.  
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Scheme 5.25. Reagents and conditions: a) TBAF (4.0 eq), AcOH (5.0 eq), THF, rt, 12 h, 84%. 
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5.6.1 - N-allyl amide dipeptide 244 fluorination with DAST 32 
 
Treatment of 244 with DAST 32 gave the expected α-fluorinated rearranged product 
245 and proved to be high yielding (73%) and also showed a high level of selectivity 
(Scheme 5.26), similar to that observed for fluorination of N′-methyl amide 241a. Direct 
19F NMR analysis of the reaction showed <1% β-fluorinated product 259 (Figure 5.10). 
However, amide 245 was isolated in a diastereomeric ratio of 90:10 suggesting a little 
SN1 character, as observed with the N′-methyl amide 241a. Presumably this arises from 
the steric bulk of the amide and perhaps some stabilisation of a carbocation intermediate 
by the amide bond.  
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Scheme 5.26. Reagents and conditions: a) DAST 32, THF, rt, 1 h, 73%. 
 
Purification of 245 from residual starting material was easily achieved by column 
chromatography. A combination of 1D and 2D NMR techniques were used to assign the 
resonances corresponding to the major trans isomer, which was favoured by 90:10 to 
the cis isomer. 
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Figure 5.10. 19F{1H} NMR (470 MHz, CDCl3) of tertiary amide 244 directly after reaction with DAST 32. 
High selectivity for the α- over the β-fluorinated product. Both cis and trans amide C–F resonances can be 
clearly observed, which were confirmed by VT.  
 
5.7 - N-Allyl amide 245 deprotection 
The next stage in the synthesis required complete N-deallylation of 245 by metal 
catalysis (Scheme 5.27).  
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Scheme 5.27. Proposed one pot de-allylation with a metal catalyst for further functionalisation. 
 
Initially, deprotection of all three allyl protecting groups in one step was attempted 
following the procedure set out in Chapter 4. This involved Pd2(dba)3 as a catalyst and a 
stoichiometric amount of thiosalicylic acid in THF (Scheme 5.28).  
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Scheme 5.28. Reagents and conditions: a) Pd2(dba)3 (25 mol%), dppb (30 mol%), thiosalicylic acid 
(3.3 eq), THF, reflux, 5 h, 93%. 
 
This approach was only partially successful and led to the deprotection of the primary 
allyl groups, furnishing N-allyl amide 260. Increasing the reaction time resulted in 
decomposition of the starting material and there was no evidence that the N′-allylamide 
could be cleaved by this approach. The lack of reactivity of the N′-allyl amide moiety 
can be rationalised as illustrated in Scheme 5.29. Protonation of the allyl amine nitrogen 
by the thiosalicylic acid enables a π-allyl Pd complex to be formed. Without protonation, 
cleavage of the allyl groups is not possible. The partial double bond character of the 
amide bond and subsequent partial positive charge on the amide nitrogen is not 
sufficiently activating for this purpose and does not enable the π-allyl Pd complex to 
form. Thus the N′-allyl amide is less reactive than the N,N-diallylamine towards this 
particular catalytic system. 
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Scheme 5.29. Proposed mechanism for the unsuccesful cleavage of the allylamide protecting group. 
 
The literature contains a wealth of methods for the removal of allyl ethers and amines, 
however there are few examples for the removal of N′-allyl amides.211–213 The 
successful reports all use the same principal involving a metal mediated isomerisation 
of an allyl amide (263) to the enamide 264 (Scheme 5.30), followed by an oxidative 
cleavage, rather than direct cleavage of the N′-allyl amide.214–217  
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Scheme 5.30. Metal mediated isomerisation of an allylamide to cis and trans enamide. R/R′ = various 
alkyl and aryl substituents. M = metal catalyst 
 
For this purpose the free amine of N-allyl amide 245 was protected as the tert-butyl 
carbamate ester 265 in aqueous dioxane with Boc2O and triethylamine (Scheme 5.32). 
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Scheme 5.32. Reagents and conditions: a) Pd2(dba)3 (25 mol%), dppb (30 mol%), thiosalicylic acid 
(2.9 eq), THF, 60 ºC, 3 h, 93%; b) Boc2O (1.3 eq), diisopropylethylamine (3.0 eq), aqueous dioxane 
(25% v/v), rt, 24 h, 71%. 
 
Purification of 265 was easily achieved by chromatography and the carbamate protected 
allyl amide 265 was isolated 71% yield. The 1H NMR was complex due to the NH 
carbamate proton coupling to the diastereotopic CH2 protons and also the CHF group, 
resulting in signal broadening. With the amine protected, it was now possible to screen 
an array of catalysts for allylamide deprotection. Initial efforts with a variety of catalysts 
proved unsuccessful however the reaction with 10 mol% of RuHCO(PPh3)2 in toluene 
did generate the isomerised enamide 266 (Scheme 5.33) as indicated by direct 1H NMR 
analysis of the reaction product. The crude enamide and catalyst were then committed 
directly for oxidative cleavage by RuCl3 and NaIO4 (Scheme 5.33). TLC indicated that 
enamide 266 was consumed and then hydrolysis of the putative N-formyl intermediate 
was attempted by treatment with aqueous NaHCO3 during work-up. However, this work 
263
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up was insufficient to cleave the formyl group with the N-formylamide 267 isolated 
after chromatography. 
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Scheme 5.33. Reagents and conditions: a) RuHCO(PPh3)2 (10 mol%), toluene, reflux, 3 h; b) RuCl3, 
NaIO4, 1,2-dichloroethane, water, rt, 12 h, 59%.  
 
The distinctive chemical shift of the aldehyde proton (~9 ppm) and the carbonyl 
resonances observed in the 13C NMR supported the structure of 267. Subsequent 
hydrolysis of the formyl group in 267, to yield amide 268 was achieved by stirring in 
basic aqueous acetone (Scheme 5.34). 
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Scheme 5.34. Reagents and conditions: a) NaHCO3 (1.0 eq), Na2CO3 (0.1 eq), acetone, water, 10 h, 46%.  
 
Purification was achieved by column chromatography to furnish 268 in a yield of 46%. 
Amide 268, did not show any cis isomer by NMR. The successful deprotection of the 
allyl amide in 265 demonstrates that it is possible to use this methodology to access 
synthetically useful peptides and demonstrates the applicability of selective fluorination 
of amides by DAST 32. 
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5.8 - Conclusions  
 
This chapter reports the scope and limitations of the fluorination of dipeptides and 
amide analogues bearing the hydroxy amine motif. Initial studies with amides 224a-c 
demonstrated poor selectivity for α-fluorination, however for N′-alkylated amides 241a 
and 244 the selectivity for α-fluorination returns. As discussed throughout the Chapter, 
this can be attributed to a hydrogen bond between the dialkylated amine and the amide 
N–H. With this methodology, it was possible to synthesize an α-fluorinated 
N′-allylamide with high fluorination selectivity and satisfactory diastereomeric excess. 
It was also possible to demonstrate that this product could be successfully deprotected 
yielding a synthetically useful fluorinated dipeptide 268.  
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Future work 
 
 
 
6.1 - Future Work for Chapter 3  
 
Solving of the crystal structure with the hydroxy compounds (S,S)- and (R,R)-145 
would supplement the data presented in Chapter 3.5. This would enable a direct 
comparison to be made between the hydroxy-145 and fluoro-144 ligands. To achieve 
this it will be required to reconsider the conditions already attempted and to optimise 
these for suitable crystal growth. This process is timely, however careful optimisation 
should yield crystals that diffract at a suitable resolution. 
 
 
6.2 - Future Work for Chapter 4  
 
The key limitation of the chemistry in Chapter 4 was the amide bond synthesis between 
155 and 120/188/209, which typically returned poor yields of <30% (Chapter 4.5, 4.7 
and 4.9.1). Alternative routes to access the coupled material may be possible through a 
copper or palladium mediated coupling between 3,6-dichloroacridone218 269 and 
fluoropropanamide 270 (Scheme 6.01).219,220 
 
Cl ClN
H
O
NH2
O
F
N+
Cu(I)
Ref 218
Ref 219-220
 
 
Scheme 6.01. Proposed coupling route between 3,6-dichloroacridone 269 and primary amide 270.             
X = halide 
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In addition to this, future work should be focused on the synthesis of a genuine 
BRACO-19 142a analogue. To achieve this, it may be required to re-assess the 
synthesis of the fluorinated amino acid. One promising route would be to treat methyl 
3-chloropropanoate 271 with potassium phthalate 272 (Scheme 6.02) to form the 
protected β-amino acid 273 following simple functional group interconversions. This 
would be followed by a metal mediated asymmetric electrophilic fluorination of the 
acid chloride 273 to yield the α-fluoro product 274  as developed by Lectka (Scheme 
6.02).221 This reaction can be quenched by various nucleophiles to provide esters and 
amides in good yields with high enantiomeric excess. The quenching of the intermediate 
by the dianion of 3,6-diaminoacridone 155 may prove fruitful to explore.  
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Scheme 6.02. Proposed alternative route to the synthesis of true BRACO-19 142a analogues. Nu = -OMe, 
-NHaryl, -NH2 
 
 
In addition to this, the incorporation of two C–F bonds into 208 and 212 may enable a 
useful NMR probe to study the interactions between 208 and 212 with quadruplex 
DNA. The investigation between quadruplex DNA stabilising ligands and DNA is a 
very complicated and multifaceted arena, however, 1D or 2D NMR experiments 
involving 19F NMR may offer further information in addition to standard techniques 
employed.  
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6.3 - Future work for Chapter 5  
 
In order to fully investigate the finer details of the reaction mechanism, the synthesis of 
an aziridine dipeptide such as 276 from 275 would be advantageous (Scheme 6.03). The 
synthesis of similar aziridine containing dipeptides has been previously reported in the 
literature.222  
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Scheme 6.03.  Proposed synthesis of an aziridine containing dipeptide 276 to probe α/β-fluorination 
distribution.  
 
Treatment of 276 with a nucleophilic source of fluorine, such as HF.pyridine, would 
enable the α/β-fluorination selectivity to be probed (Scheme 6.03). Further to this, the 
preparation of 276 as its PF6- salt would allow for X-ray crystallographic evaluation of a 
pseudo-intermediate similar to that of 236 in the DAST pathway mechanism (Scheme 
5.10). This would provide conformational information and thus allow for further 
assessment of the origin of α/β-selectivity in these systems.  
 
In addition to the aforementioned investigations, the synthesis of the structures in 
Figure 6.01 followed by evaluation of the fluorination ratios by treating with DAST 32. 
This would add to the overall quality of this work by providing a comprehensive 
evaluation, scope and limitation survey.  
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Figure 6.01. Target compounds to further understand the scope of the fluorination reaction. 
 
The evaluation of other fluorinating reagents such as Deoxo-Fluor® or MOST would be 
of general interest, however, solvent investigations and work focused on improving the 
overall diastereomeric excess would vastly improve the synthetic use of this 
methodology.  
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Experimental 
 
 
7.1 - General experimental procedures 
 
All glassware was flame dried under high vacuum other than in situations where 
aqueous solutions were employed. Reactions were carried out under an atmosphere of 
argon, unless otherwise noted. Compressed argon was passed through a drying column 
packed with 4 Å molecular sieves, potassium hydroxide and self-indicating desiccant, 
before reaching a double manifold. All reactions involving the use of organometallic 
reagents were conducted by standard air-free techniques in Schlenk tubes or flasks. 
Hydrogenations were conducted in multi-neck flasks and the atmosphere exchanged 
with hydrogen by a pump-purge method. Dry CH2Cl2, Et2O, and THF were obtained 
from an mBRAUN SPS-800 solvent purification machine by passage through a drying 
column packed with 4Å molecular sieves and dispensed under an inert atmosphere 
when required. NOTE: THF from this purification system was unstabilised. Dry 
CH3OH was achieved by reflux over calcium hydride and collected in a still head when 
required. Where appropriate, solvents were degassed by the standard freeze-pump-thaw 
technique at least three times with freshly dispensed dry solvent.223 
 
1H NMR spectra were recorded on 300, 400 or 500 MHz Bruker Avance/Avance II 
spectrometers. All spectra were acquired in deuterated solvents, and calibrated to the 
chemical shift of that residual solvent. Proton assignments are made according to 
chemical shift, multiplicity and 2D NMR experiments. Coupling constants (J) are 
reported to 0.1 Hz and are averaged for coupling nuclei. Complex spectra are numbered 
for ease of interpretation. All other resonances are described based on their chemical 
environment. NMR spectra were interpreted using iNMR or TopSpin.  
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13C NMR spectra were recorded at 75, 101, 126 MHz on Bruker Avance/Avance II 
spectrometers. Resonances were assigned by reference to DEPTQ, HMBC and HSQC 
spectra with coupling constants reported to 0.1 Hz, where appropriate.  
 
19F NMR spectra were recorded at 282, 376, 470 MHz on Bruker Avance/Avance II 
spectrometers. Resonances were assigned according to chemical shift, multiplicity, and 
reference to the literature. Coupling constants are reported to 0.1 Hz and are averaged 
for coupling nuclei. Dr Tomas Lebl recorded all HOESY spectra.  
 
NMR Multiplicities are reported as follows: s - singlet; br s - broad singlet; 
m - multiplet; d - doublet; dd - doublet of doublets; ddd - doublet of doublet of doublets; 
dddd - doublet of doublet of doublet of doublets; dq - doublet of quartets; t - triplet; 
q - quartet; tq - triplet of quartets; qqd - quartet of quartet of doublets  
 
In vacuo refers to the use of a diaphragm vacuum pump to remove solvent under 
reduced pressure on a Büchi Rotavapor at 40 ºC. The bath temperature was reduced to 
0 ºC with ice when removing solvents from volatile compounds. Drying under vacuum 
refers to the use of an Edwards RV-5 rotary-vane oil pump at a pressure of <0.1 mbar.  
 
Lypholisation refers to the removal of water by sublimation on a Christ Alpha 1-2 LD 
Plus freeze dryer equipped with an Edwards RV3 rotary-vane oil pump. 
 
Optical rotations were recorded on a Perkin Elmer optical rotation model 341 machine 
with a cell path length of 1 dm. The vast majority of samples were recorded at 589 nm 
(sodium D-line) at ambient temperature (20 ºC) and are denoted as [α]!!". For acridone 
and acridine compounds the light source was maintained at either 365 nm, 436 nm, 
546 nm or 578 nm in an attempt to achieve satisfactory beam transmission. 
Concentrations (c) are reported in g/dm and specific optical rotations are denoted as [α]!!" in the implied units of 10-1 deg cm3 g-1.  
 
HPLC analysis was conducted on a Varian Prostar HPLC machine equipped with a 
Prostar Auto Sampler model 400 and a Prostar 240 solvent delivery system. Compound 
elution was monitored with a Prostar UV-Vis 325 module at a wavelength of 230 nm or 
250 nm. Column for chiral analysis – Chiralcel OD (25 cm × 4.6mm, 10 µM), Chrialcel 
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OD-H (25 cm × 4.6mm, 5 µM) or Chiralcel AD-H (25 cm × 4.6mm, 5 µM). Reverse 
phase analysis – Nucleosil 100-5 C-18 RP column (25 mm × 3.2 mm, 5 µM). HPLC 
grade solvents were degassed prior to use and the column was preconditioned with the 
solvent system for at least 20 min before injection.  
 
Melting points were measured using a Gallenkamp Griffin MPA350 or Electrothermal 
9100 digital melting point apparatus and are uncorrected. 
 
Mass Spectroscopic analyses at the Biomedical Sciences Research Complex (BSRC) 
were conducted by Mrs. Caroline Horsburgh on a Micromass LCT electrospray time of 
flight mass spectrometer by electrospray ionisation. Samples sent to the EPSRC mass 
spectrometry service in Swansea were analysed on a Thermofisher LTQ Orbitrap XL 
mass spectrometer using either electrospray ionisation (ES) or atmospheric solids 
analysis probe techniques (ASAP).  
 
X-ray analysis of single crystals was conducted by Prof. Alexandra Slawin at the 
University of St Andrews on a Rigaku Cu MM007 high brilliance generator with Saturn 
92 CCD and XStream LT accessories. 
 
IR spectra were recorded a Perkin Elmer Spectrum GX FT-IR machine as either a KBr 
disc, neat on NaCl plates or on PTFE cards. Peptide samples were recorded neat on a 
Shimadzu Raffinity-1 FT-IR machine.  
 
UV-Vis spectra were recorded on Perkin Elmer Lambda 35 UV/VIS spectrometer with 
a quartz cell with a 1 cm path length using spectrophotometric grade methanol. Samples 
were prepared at a concentration of 1 mg in 1 mL and diluted until suitable spectra 
could be obtained. Extinction coefficients (ε) were calculated using the 
Beer-Lambert law: A = εcℓ and are quoted as log10 ε values in M-1 cm-1. 
 
TLC analysis was conducted on aluminium backed TLC silica gel 60 F254 plates, and 
followed by visualisation with UV light (254 or 365 nm) and/or staining with the 
appropriate staining solution. Typical solutions used included: aqueous alkaline 
potassium permanganate; ninhydrin spray; vanillin solution; or ethanolic ceric 
ammonium molybdate. Flash column chromatography was achieved using Merck 
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Geduran Si-60 silica-gel (40-63 µM particle size).224 Where required, reverse phase 
C-18 silica gel (2-10 µM particle size) aluminium backed TLC plates with 254nm 
indicator were used. Reverse phase flask chromatography was achieved with C-18 fully 
end-capped reverse phase silica gel (15-25 µM particle size). 
 
Miscellaneous - Brine referrers to a saturated solution of sodium chloride in deionised 
water. Reactions at -78 ºC were readily achieved with isopropanol and dry ice in a 
Dewar vacuum flask, -100 ºC was achieved with CH3OH and liquid nitrogen. Reactions 
that required a sustained low temperature were cooled with a LabPlant RP-60 
Refrigerated Immersion Probe. Celite was washed with aqueous HCl (0.1 M), followed 
by water and CH3OH prior to use. 
Chemicals - All chemicals were purchased from: Sigma-Aldrich, Alfa-Aesar, 
Fluorochem, TCI Europe or Fisher Scientific and were used as supplied unless 
otherwise noted. Triethylamine (distilled from KOH, stored over KOH), 
diisopropylethylamine (distilled from KOH, stored under N2), diallylamine (distilled 
from NaOH, stored under inert atmosphere) and dipropylamine (distilled from KOH, 
stored under inert atmosphere) were distilled before use. Phosphorus oxychloride 
(distilled and stored in the dark under inert atmosphere), 3-chloropropionyl chloride 
(distilled under reduced pressure, stored in dark under inert atmosphere) and DMF  
(distilled from CaH2 and stored over 3A molecular sieves under inert atmosphere) were 
distilled before use.223 
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7.2 - Experimental for Chapter 3 
7.2.1 -  
3,6-Bis(3-chloropropionamido)acridine[175] 146 
 
 
 
3,6-Diaminoacridine (1.00 g, 4.78 mmol, 1.0 eq) was heated under reflux in neat 
3-chloropropionyl chloride (5 mL) for 3 h. The solution was cooled to rt and ice-cold 
Et2O (20 mL) was added, resulting in formation of a precipitate. The precipitate was 
isolated by filtration, washed with Et2O (2 × 10 mL) and dried under vacuum. This solid 
was recrystallized from ethanol and DMF (1:5), to yield 
3,6-bis(3-chloropropionamido)acridine 146 (1.80 g, 4.30 mmol, 90%) as an orange 
amorphous solid: mp >300 °C (ethanol:DMF); 1H NMR (300 MHz, 
d6-DMSO) δH 11.55 (2H, br s, NHCO), 9.61 (1H, s, Ar H-9), 8.91 (2H, d, J 1.6 Hz, 
Ar H-4,5), 8.37 (2H, d, J 9.2 Hz, Ar H-1,8), 7.92 (2H, dd, J 9.2, 1.6 Hz, Ar H-2,7), 
4.00 (4H, t, J 6.2 Hz, 2 × COCH2), 3.11 (4H, t, J 6.2 Hz, 2 × CH2Cl).  
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7.2.2 -  
3,6-Bis(3-(3'-(R)-fluoropyrrolidin)propionamido)acridine (R,R)-144 
 
 
 
(3R)-Fluoropyrrolidine (340 mg, 3.8 mmol, 10.0 eq) in ethanol (1 mL) was added to a 
solution of 3,6-bis(3-chloropropionamido)acridine (150 mg, 0.38 mmol, 1.0 eq) and 
NaI (58 mg, 0.38 mmol 2.0 eq) in ethanol (5 mL) and the mixture was heated under 
reflux for 5 h. The reaction was cooled to 0 °C, resulting in formation of a precipitate, 
which was isolated by filtration and washed with Et2O (10 mL). The product was 
purified by silica gel column chromatography, eluting with CH2Cl2, CH3OH and Et3N 
(85:10:5), to yield 3,6-bis(3-(3'-(R)-fluoropyrrolindino)propionamido)acridine  
(R,R)-144 (121 mg, 0.24 mmol, 63%) as an orange amorphous solid: 
Rf 0.1 (CH2Cl2:CH3OH:Et3N, 94:5:1); IR (film/cm-1) 3689, 2958, 2918, 2780, 2310, 
2315, 1644, 1445, 1304, 1215, 1154, 1084, 1026; mp >300 °C (dec.); [!]!"#!"  -8.0 (c 0.44, CH3OH); 1H NMR (500 MHz, CD3OD/d6-DMSO) δH 8.82 (1H, s, 
Ar H-9), 8.54 (2H, d, J 1.9 Hz, Ar H-4,5), 8.01 (2H, d, J 9.1 Hz, Ar H-1,8), 7.64 (2H, 
dd, J 9.1, 1.9 Hz, Ar H-2,7), 5.36-5.23 (2H, m, 2 × CHF-7',7''), 3.20-3.10 (4H, m, 
2 × CHa -6',6'' and 2 × CHa-9',9''), 3.04 (4H, t, J 7.0 Hz, 2 × CH2-3',3''), 2.89-2.79 (2H, 
m, 2 × CHb-6',6''), 2.76 (4H, t, J 7.0 Hz, 2 × CH2-4',4''), 2.68-2.63 (2H, m, 
2 × CHb-9',9''), 2.36-2.23 (2H, m, 2 × CHa-8',8''), 2.16-2.05 (2H, m, 2 × CHb-8',8''); 
13C NMR (126 MHz, CD3OD/d6-DMSO) δC 172.6 (2 × CONH), 150.7(2 × Ar C-8a,9a), 
142.5 (2 × Ar C-4a,4b), 137.9 (Ar CH-9), 130.5 (2 × Ar CH-1,8), 124.5 (2 × Ar C-3,6), 
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121.6 (2 × Ar CH-2,7), 114.8 (2 × Ar CH-4,5), 94.3 (d, J 174.9 Hz, 2 × CHF-7',7''), 
61.3 (d, J 22.8 Hz, 2 × CH2-6',6''), 53.1 (2 × CH2-9',9''), 52.5 (2 × CH2-3',3''), 
36.3 (2 × CH2-4',4''), 33.4 (d, J 22.3 Hz, 2 × CH2-8',8''); 19F NMR (470 MHz, 
CD3OD/d6-DMSO) δF -169.0 (2F, m, 2 × CHF); HRMS m/z (ES+) calcd. for 
C27H32F2N5O2 [M+H]+ requires 496.2524, found 496.2540; m/z (ES+) 496 ([M+H]+, 
100%).  
7.2.3 - 
3,6-Bis(3-(3'-(S)-fluoropyrrolindino)propionamido)acridine (S,S)-144 
 
 
 
(3S)-Fluoropyrrolidine (340 mg, 3.8 mmol, 10.0 eq) in ethanol (1 mL) was added to a 
solution of 3,6-bis(3-chloropropionamido)acridine (150 mg, 0.38 mmol, 1.0 eq) and 
NaI (58 mg, 0.38 mmol 2.0 eq) in ethanol (5 mL) and the mixture was heated under 
reflux for 5 h. The reaction was cooled to 0 °C, resulting in formation of a precipitate, 
which was isolated by filtration and washed with Et2O (10 mL). The product was 
purified by silica gel column chromatography, eluting with CH2Cl2, CH3OH and Et3N 
(85:10:5), to yield 3,6-bis(3-(3'-(S)-fluoropyrrolindino)propionamido)acridine 
(S,S)-144 (123 mg, 0.26 mmol, 65%) as an orange amorphous solid: 
Rf 0.1 (CH2Cl2:CH3OH:Et3N, 94:5:1); IR (film/cm-1) 3689, 2958, 2918, 2780, 2310, 
2315, 1644, 1445, 1304, 1304, 1215, 1154, 1084, 1038, 1026; mp >300 °C (dec.); [!]!"#!"  +8.1 (c 0.44, CH3OH); 1H NMR (500 MHz, CD3OD/d6-DMSO) δH 8.85 (1H, s, 
Ar H-9), 8.56 (2H, d, J 1.9 Hz, Ar H-4,5), 8.04 (2H, d, J 9.1 Hz, Ar H-1,8), 7.66 (2H, 
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dd, J 9.1, 1.9 Hz, Ar H-2,7), 5.34-5.21 (2H, m, 2 × CHF-7',7''), 3.18-3.08 (4H, m, 
2 × CHa-6',6'' and 2 × CHa-9',9''), 3.02 (4H, t, J 7.0 Hz, 2 × CH2-3',3''), 2.89-2.79 (2H, 
m, 2 × CHb-6',6''), 2.75 (4H, t, J 7.0 Hz, 2 × CH2-4',4''), 2.64-2.59 (2H, m, 
2 × CHb-9',9''), 2.35-2.22 (2H, m, 2 × CHa-8',8''), 2.15-2.04 (2H, m, 2 × CHb-8',8''); 
13C NMR (126 MHz, CD3OD/d6-DMSO) δC 172.6 (2 × CONH), 
150.8 (2 × Ar C-8a,9a), 142.5 (2 × Ar C-4a,4b), 137.8 (Ar CH-9), 
130.5 (2 × Ar CH-1,8), 124.5 (2 × Ar C-3,6), 121.6 (2 × Ar CH-2,7), 
114.9 (2 × Ar CH-4,5), 94.5 (d, J 174.9 Hz, 2 × CHF-7',7''), 61.4 (d, J 22.8 Hz, 
2 × CH2-6', 6''), 53.1 (2 × CH2-9',9''), 52.5 (2 × CH2-3',3''), 36.5 (2 × CH2-4',4''), 33.5 (d, 
J 22.3 Hz, 2 × CH2-8', 8''); 19F NMR (470 MHz, CD3OD/d6-DMSO) δF -168.5 (2F, m, 
2 × CHF); HRMS m/z (ES+) calcd. for C27H32F2N5O2 [M+H]+ requires 496.2524, 
found 496.2520; m/z (ES+) 496 ([M+H]+, 100%).  
 
7.2.4 -  
3,6-Bis(3-(3'-(R)-hydroxypyrrolindino)propionamido)acridine  (R,R)-145 
 
 
 
(3R)-Hydroxypyrrolidine hydrochloride (335 mg, 3.8 mmol, 10.0 eq) in ethanol (1 mL) 
was added to a solution of 3,6-bis(3-chloropropionamido)acridine (150 mg, 0.38 mmol, 
1.0 eq) and NaI (58 mg, 0.38 mmol 2.0 eq) in ethanol (5 mL) and the mixture was 
heated under reflux for 5 h. The reaction was cooled to 0 °C, resulting in formation of a 
precipitate, which was isolated by filtration and washed with Et2O (10 mL). The product 
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was purified by silica gel column chromatography, eluting with CH2Cl2, CH3OH and 
Et3N (85:10:5), to yield 3,6-bis(3-(3'-(R)-hydroxypyrrolindino)propionamido)acridine 
(R,R)-145 (118 mg, 0.23 mmol, 59%) as an orange amorphous solid: mp >300 °C 
(dec.); IR (film/cm-1) 3680, 2963, 2918, 2789, 2352, 1672, 1549, 1448, 1205, 1150, 
1068, 1020; [!]!"#!"  +5.6 (c 0.53, CH3OH); 1H NMR (500 MHz, 
CD3OD/d6-DMSO) δH 8.82 (1H, s, Ar H-9), 8.53 (2H, d, J 1.7 Hz, Ar H-4,5), 8.01 (2H, 
d, J 9.1 Hz, Ar H-1,8), 7.67 (2H, dd, J 9.0, 1.7 Hz, Ar H-2,7), 4.44-4.41 (2H, m, 
2 × CH-7',7''), 3.03 (4H, t, J 6.9 Hz, 2 × CH2-3',3''), 3.04-2.93 (4H, m, 2 × CH2-6',6''), 
2.73 (4H, t, J 6.9 Hz, 2 × CH2-4',4''), 2.77-2.71 (4H, m, 2 × CH2-9',9''), 2.24-2.17 (2H, 
m, 2 × CHa-8',8''), 1.84-1.78 (2H, m, 2 × CHb-8',8''); 13C NMR (126 MHz, 
CD3OD/d6-DMSO) δC 172.9 (2 × CONH), 150.9 (2 × Ar C-8a,9a), 
142.4 (2 × Ar C-4a,4b), 137.8 (Ar CH-9), 130.4 (2 × Ar CH-1,8), 124.7 (2 × Ar C-3,6), 
121.7 (2 × Ar CH-2,7), 115.2 (2 × Ar CH-4,5), 71.4 (2 × CH-7',7''), 
63.3 (2 × CH2-6',6''), 53.5 (2 × CH2-9',9''), 52.8 (2 × CH2-3',3''), 36.2 (2 × CH2-4',4''), 
35.2 (2 × CH2-5',5''); HRMS m/z (ES+) calcd. for C27H34N5O4 [M+H]+ requires 
492.2611, found 492.2601; m/z (ES+) 492 ([M+H]+, 100%). 
 
7.2.5 - 
3,6-Bis(3-(3'-(S)-hydroxypyrrolindino)propionamido)acridine (S,S)-145 
 
 
(3S)-Hydroxypyrrolidine hydrochloride (335 mg, 3.8 mmol, 10.0 eq) in ethanol (1 mL) 
was added to a solution of 3,6-bis(3-chloropropionamido)acridine (150 mg, 0.38 mmol, 
7
6
5
4b
8a 8
N
10
4a
9a 9
4
3
2
1
N
H
1''
N
H
1'
2' 2''
O
3''
4''
N
5''
3'
O
4'
N
5'
9'' 8''
7''
6''6'
7'
8' 9'
OHHO
 Experimental  
 
 157 
1.0 eq) and NaI (58 mg, 0.38 mmol 2.0 eq) in ethanol (5 mL) and the mixture was 
heated under reflux for 5 h. The reaction was cooled to 0 °C, resulting in formation of a 
precipitate, which was isolated by filtration and washed with Et2O (10 mL). The product 
was purified by silica gel column chromatography, eluting with CH2Cl2, CH3OH and 
Et3N (85:10:5), to yield 3,6-bis(3-(3'-(S)-hydroxypyrrolindino)propionamido)acridine 
(S,S)-144 (110.9 mg, 0.225 mmol, 59%) as an orange amorphous solid: [!]!"#!"  -7.0 (c 0.44, CH3OH); 1H NMR (500 MHz, CD3OD/d6-DMSO) δH 8.80 (1H, s, 
Ar H-9), 8.51 (2H, d, J 1.7 Hz, Ar H-4,5), 7.99 (2H, d, J 9.1 Hz, Ar H-1,8), 7.67 (2H, 
dd, J 9.0, 1.7 Hz, Ar H-2,7), 4.44-4.41 (2H, m, 2 × CH-7',7''), 2.99 (4H, t, J 6.9 Hz, 
2 × CH2-3',3''), 3.01-2.90 (4H, m, 2 × CH2-6',6''), 2.71 (4H, t, J 6.9 Hz, 2 × CH2-4',4''), 
2.74-2.67 (4H, m, 2 × CH2-9',9''), 2.24-2.17 (2H, m, 2 × CHa-8',8''), 1.84-1.78 (2H, m, 
2 × CHb-8',8''); 13C NMR (126 MHz, CD3OD/d6-DMSO) δC 173.0 (2 × CONH), 
150.9 (2 × Ar C-8a,9a), 142.4 (2 × Ar C-4a,4b), 137.7 (Ar CH-9), 
130.4 (2 × Ar CH-1,8), 124.7 (2 × Ar C-3,6), 121.7 (2 × Ar CH-2,7), 
115.2 (2 × Ar CH-4,5), 71.4 (2 × CH-7',7''), 63.3 (2 × CH2-6',6''), 53.5 (2 × CH2-9',9''), 
52.8 (2 × CH2-3',3''), 36.4 (2 × CH2-4',4''), 35.1 (2 × CH2-5',5''); HRMS m/z (ES+) 
calcd. for C27H34N5O4 [M+H]+ requires 492.2611 found 492.2606; 
m/z (ES+) 492 ([M+H]+, 100%).  
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7.3 - Experimental for Chapter 4 
7.3.1 -  
D-Serine methyl ester hydrochloride[225] (R)-164 
 
 
 
Thionyl chloride (13.7 mL, 192 mmol, 1.1 eq) was added dropwise to CH3OH (180 mL) 
over 30 min at rt followed by D-serine (18.0 g, 170 mmol, 1.0 eq) portion wise. 
Following consumption of the starting material as indicated by TLC, the solvent was 
removed in vacuo and the resulting solids were triturated with petroleum ether. 
Trituration and subsequent evaporation was repeated to remove excess thionyl chloride. 
The product was recrystallised from CH3OH to yield D-serine methyl ester 
hydrochloride (R)-164 (21.0 g, 140 mmol, 80%) as a white crystalline solid: 
mp 163-165 °C (CH3OH) [Lit.[225] 163-166 ºC]; [!]!!"  -4.2 (c 4.0, 
CH3OH) [Lit.[225] [!]!!"  -3.7 (c 4.0, CH3OH)]; 1H NMR (400 MHz, 
CD3OD) δH 4.91 (1H, br s, OH), 4.19 (1H, dd, J 4.4, 3.5 Hz, CHN), 4.04 (1H, dd, 
J 11.9, 4.4 Hz, CHaHbOH), 3.98 (1H, dd, J 11.9, 3.5 Hz, CHaHbOH), 3.88 (3H, s, CH3).  
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7.3.2 -  
L-Serine methyl ester hydrochloride[225] (S)-164 
 
 
 
Thionyl chloride (13.7 mL, 190 mmol, 1.1 eq) was added dropwise to CH3OH (180 mL) 
over 30 min at rt followed by L-serine (18.0 g, 170 mmol, 1.0 eq) in a portion wise 
manner. Following consumption of the starting material as indicated by TLC, the 
solvent was removed in vacuo and the solids were triturated with petroleum ether. 
Trituration and subsequent evaporation was repeated to remove excess thionyl chloride. 
The product was recrystallised from CH3OH to yield L-serine methyl ester 
hydrochloride (S)-164 (21.3 g, 140 mmol, 80%) as a white crystalline solid: 
mp 162-165 ºC [Lit.[225] 163-166 ºC]; [!]!!" +4.3 (c 4.0, CH3OH), [Lit.[225] [!]!!" +3.7 
(c 4.0, CH3OH)]; 1H NMR (400 MHz, CD3OD) δH 4.91 (1H, br s, OH), 4.19 (1H, dd, 
J 4.4, 3.5 Hz, CHN), 4.04 (1H, dd, J 11.9, 4.4 Hz, CHaHbOH), 3.98 (1H, dd, J 11.9, 
3.5 Hz, CHaHbOH), 3.88 (3H, s, CH3).  
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7.3.3 -  
Methyl (±)-2-(dibenzylamino)-3-hydroxypropanoate[226] 119  
 
 
 
Benzyl bromide (19.3 mL, 162 mmol, 2.5 eq) was added to a solution of DL-serine 
methyl ester hydrochloride (10.0 g, 64.0 mmol, 1.0 eq) and K2CO3 (44.7 g, 323 mmol, 
5.0 eq) in acetonitrile. This mixture was stirred for 24 h at rt and quenched by the 
addition of water (300 mL). The aqueous phase was extracted with ethyl acetate 
(3 × 300 mL) and the combined organic fractions were dried over Na2SO4, filtered and 
concentrated in vacuo. The product was purified by silica gel column chromatography, 
eluting with hexane and ethyl acetate (80:20), to yield 
methyl 2-(dibenzylamino)-3-hydroxypropanoate 119 (18.1 g, 60.0 mmol, 94%) as a 
colorless oil: 1H NMR (400 MHz, CD3OD) δH 7.40-7.22 (10H, m, 10 × Ar H), 
3.94 (1H, dd, J 10.9, 7.8 Hz, CHaHbOH), 3.88 (2H, d, J 13.8 Hz, 2 × NCHaHb-benzyl), 
3.80 (3H, s, OCH3), 3.75 (1H, dd, J 10.9, 5.9 Hz, CHaHbOH), 3.61 (2H, d, J 13.8 Hz, 
2 × NCHaHb-benzyl), 3.47 (1H, dd, J 7.8, 5.9 Hz, CHN); m/z (ES+) 300 ([M+H]+, 
100%).  
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7.3.4 - 
Methyl (+)-(2R)-(dibenzylamino)-3-hydroxypropanoate[226] (R)-119  
 
 
 
Following the procedure set out for methyl 2-(dibenzylamino)-3-hydroxypropanoate 
119, starting from D-serine methyl ester hydrochloride (R)-164 (10.0 g, 64.0 mmol), 
methyl (2R)-(dibenzylamino)-3-hydroxypropanoate (R)-119 (18.3 g, 61.0 mmol, 95%) 
was obtained as a colourless oil: [!]!!"  +144 (c 1.0, CHCl3), [Lit.[226] ![!]!!"  +147 
(c 0.96, CHCl3)]; 1H NMR (400 MHz, CD3OD) δH 7.40-7.22 (10H, m, 10 × Ar H), 
3.94 (1H, dd, J 10.9, 7.8 Hz, CHaHbOH), 3.88 (2H, d, J 13.8 Hz, 2 × NCHaHb-benzyl), 
3.80 (3H, s, OCH3), 3.75 (1H, dd, J 10.9, 5.9 Hz, CHaHbOH), 3.61 (2H, d, J 13.8 Hz, 
2 × NCHaHb-benzyl), 3.47 (1H, dd, J 7.8, 5.9 Hz, CHN); m/z (ES+) 300 ([M+H]+, 
100%).  
 
7.3.5 -  
Methyl (–)-(2S)-(dibenzylamino)-3-hydroxypropanoate[227] (S)-119 
 
 
 
Following the procedure set out for methyl 2-(dibenzylamino)-3-hydroxypropanoate 
119, starting from L-serine methyl ester hydrochloride (S)-164  (10.0 g, 64.0 mmol), 
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methyl (2S)-(dibenzylamino)-3-hydroxypropanoate (S)-119 (18.0 g, 60.0 mmol, 94%) 
was obtained as a colourless oil: [!]!!" -140 (c 1.0, CHCl3) [Lit.[221] [!]!!" -105 (c 1.21, 
CH3OH)]; 1H NMR (300 MHz, CD3OD) δH 7.37-7.19 (10H, m, 10 × Ar H), 3.91 (1H, 
dd, J 10.9, 7.8 Hz, CHaHbCHN), 3.85 (2H, d, J 13.8 Hz, 2 × CHaHb-benzyl), 3.77 (3H, 
s, OCH3), 3.72 (1H, dd, J 10.9, 5.9 Hz, CHaHbCHN), 3.58 (2H, d, J 13.8 Hz, 
2 × CHaHb-benzyl), 3.47 (1H, dd, J 7.8, 5.9 Hz, CHN); m/z (ES+) 300 ([M+H]+, 100%).  
 
7.3.6 - 
Methyl (±)-3-(dibenzylamino)-2-fluoropropanoate  120 
 
 
 
Diethylaminosulfur trifluoride 32 (4.20 mL, 32.0 mmol, 1.2 eq) was added to a solution 
of methyl 2-(dibenzylamino)-3-hydroxypropanoate 119 (8.00 g, 26.7 mmol, 1.0 eq) in 
THF (45 mL) and the reaction was cooled to 0 °C. This solution was stirred for 1 h at 
0 °C before being quenched by the addition of cold water (90 mL), followed by an 
excess of solid K2CO3 and Et2O (90 mL). The organic phase was separated and the 
aqueous mixture re-extracted with Et2O (2 × 90 mL). The organic fractions were 
combined, dried over Na2SO4 and concentrated in vacuo. The product was purified by 
silica gel column chromatography, eluting with hexane and ethyl acetate (80:20), to 
yield methyl 3-(dibenzylamino)-2-fluoropropanoate 120 (7.25 g, 24.1 mmol, 90%) as a 
colourless oil: IR νmax (film, cm-1) 3027, 2802, 1763, 1494, 1438, 1352, 1368, 1291, 
1207, 1150, 1066; 1H NMR (400 MHz, CDCl3) δH 7.25-7.15 (10H, m, 10 × Ar-H), 
4.98 (1H, ddd, J 49.3, 5.8, 3.3 Hz, CHF), 3.76 (2H, d, J 13.6 Hz, 2 × NCHaHb-benzyl), 
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3.61 (3H, s, OCH3), 3.45 (2H, d, J 13.6 Hz, 2 × NCHaHb-benzyl), 3.03-2.85 (2H, m, 
CH2CHF); 13C NMR (101 MHz, CDCl3) δC 169.3 (d, J 24.2 Hz, CO2CH3), 
138.9 (2 × Ar-C), 129.1 (4 × Ar-CH), 128.4 (4 × Ar-CH), 127.2 (2 × Ar-CH), 89.5 (d, 
J 186.1 Hz, CHF), 58.9 (2 × CH2Ar), 54.3 (d, J 20.1 Hz, NCH2), 52.3 (OCH3); 
19F NMR (283 MHz, CDCl3) δF -192.2 (ddd, J 49.3, 29.2, 22.1 Hz, CHF); 
HRMS m/z (ES+) calcd. for C18H20NO2FNa [M+Na]+ requires 324.1376, 
found 324.1369; m/z (ES+) 324 ([M+Na]+, 100%).  
 
7.3.7 -  
Methyl (–)-(2S)-3-(dibenzylamino)-2-fluoropropanoate (S)-120 
 
 
 
Following the procedure set out for methyl 3-(dibenzylamino)-2-fluoropropanoate 120, 
starting from methyl (2R)-(dibenzylamino)-3-hydroxypropanoate (R)-119 (8.00 g, 
26.7 mmol) with diethylaminosulfur trifluoride 32 (4.20 mL, 32.0 mmol, 1.2 eq) in 
THF (45 mL), furnished methyl (2S)-3-(dibenzylamino)-2-fluoropropanoate (S)-120 
(7.19 g, 23.9 mmol, 89%) as a colourless oil: [!]!!"  -19.0 (c 2.0, CH3OH); 
1H NMR (300 MHz, CDCl3) δH 7.26-7.14 (10H, m, 10 × Ar H), 4.97 (1H, ddd, J 49.5, 
5.7, 3.3 Hz, CHF), 3.75 (2H, d, J 13.6 Hz, 2 × CHaHbPh), 3.61 (3H, s, OCH3), 3.44 (2H, 
d, J 13.6 Hz, 2 × CHaHbPh), 2.97 (1H, ddd, J 26.9, 14.7, 5.7 Hz, 2 × CHaHbCHF), 
2.90 (1H, ddd, J 24.3, 14.7, 3.3 Hz, 2 × CHaHbCHF); 13C NMR (75 MHz, CDCl3) 
δC 169.3 (d, J 24.2 Hz, CO2CH3), 138.9 (2 × Ar C), 129.1 (4 × Ar CH), 
128.4 (4 × Ar CH), 127.2 (2 × Ar CH), 89.5 (d, J 186.1 Hz, CHF), 58.9 (2 × CH2Ph), 
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54.3 (d, J 20.1 Hz, CH2CHF), 52.3 (OCH3); 19F NMR (282 MHz, 
CDCl3) δF -191.0 (ddd, J 49.5, 26.9, 24.3 Hz, CHF); HRMS m/z (ES+) calcd. for 
C18H20NO2FNa [M+Na]+ requires 324.1376, found 324.1375; m/z (ES+) 324 ([M+Na]+, 
100%). Enantiomeric excess determined by chiral HPLC (Chiralcel OD 5% iPrOH in 
hexane, 0.25 mL/min, tr maj = 14.51 min >95%, tr min = 15.70 min <5%). 
 
7.3.8 -  
Methyl (+)-(2R)-3-(dibenzylamino)-2-fluoropropanoate (R)-120 
 
 
 
Following the procedure set out for methyl 3-(dibenzylamino)-2-fluoropropanoate 120, 
starting from methyl (2S)-(dibenzylamino)-3-hydroxypropanoate (S)-119 (8.00 g, 
26.7 mmol) with diethylaminosulfur trifluoride 32 (4.20 mL, 32.0 mmol, 1.2 eq) in 
THF (45 mL), furnished methyl (2R)-3-(dibenzylamino)-2-fluoropropanoate (R)-120  
(7.23 g, 24.0 mmol, 90%) as a colourless oil: [!]!!"  +19.1 (c 2.0, CH3OH); 
1H NMR (300 MHz, CDCl3) δH 7.29-7.12 (10H, m, 10 × Ar H), 4.97 (1H, ddd, J 49.5, 
5.7, 3.3 Hz, CHF), 3.75 (2H, d, J 13.6 Hz, 2 × CHaHbPh), 3.61 (3H, s, OCH3), 3.44 (2H, 
d, J 13.6 Hz, 2 × CHaHbPh), 2.97 (1H, ddd, J 26.9, 14.7, 5.7 Hz, 2 × CHaHbCHF), 
2.90 (1H, ddd, J 24.3, 14.7, 3.3 Hz, 2 × CHaHbCHF); 13C NMR (75 MHz, 
CDCl3) δC 169.3 (d, J 24.2 Hz, CO2CH3), 138.9 (2 × Ar C), 129.1 (4 × Ar CH), 
128.4 (4 × Ar CH), 127.2 (2 × Ar CH), 89.5 (d, J 186.1 Hz, CHF), 58.9 (2 × CH2Ph), 
54.3 (d, J 20.1 Hz, CH2CHF), 52.3 (OCH3); 19F NMR (282 MHz, 
CDCl3) δF -191.0 (ddd, J 49.5, 26.9, 24.3 Hz, CHF); HRMS m/z (ES+) calcd. for 
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C18H21NO2F [M+H]+ requires 302.1556, found 302.1548; m/z (ES+) 324 ([M+Na]+, 
100%), 302 ([M+H], 80%). Enantiomeric excess determined by chiral HPLC (Chiralcel 
OD-H 5% iPrOH in hexane, 0.25 mL/min, tr maj = 15.70 min >95%, tr min = 14.51 min 
<5%). 
 
7.3.9 -  
Methyl (±)-3-amino-2-fluoropropanoate hydrochloride 166.HCl 
 
 
 
A solution of methyl (±)-3-(dibenzylamino)-2-fluoropropanoate 120 (200 mg, 
0.66 mmol, 1.0 eq) and 20% Pd(OH)2/C (40.0 mg, 10 mol%) in CH3OH (10 mL) was 
stirred under an H2 atmosphere. This suspension was stirred vigorously until 
TLC/19F NMR analysis had indicated complete debenzylation and HCl (0.5 M, 1.5 mL) 
was added. The mixture was filtered through a pad of Celite and the residue was washed 
with CH3OH (30 mL). The filtrate was concentrated in vacuo to yield methyl 
(±)-3-amino-2-fluoropropanoate hydrochloride 166.HCl (80 mg, 99%) as a colourless 
solid, which was used without purification: 1H NMR (400 MHz, CD3OD) δH 5.37 (1H, 
ddd, J 47.6, 7.5, 3.4 Hz, CHF), 3.86 (3H, s, OCH3), 3.61-3.42 (2H, m, CH2); 
13C NMR (101 MHz, CD3OD) δC 171.2 (d, J 22.9 Hz, CO2CH3), 86.7 (d, J 185.9 Hz, 
CHF), 53.6 (OCH3), 41.1 (d, J 21.4 Hz, CH2); 19F NMR (376 MHz, 
CD3OD) δF -200.3 (ddd, J 48.0, 25.0, 23.0 Hz, CHF); HRMS m/z (ES+) calcd. for 
C4H9NO2F [M+H]+ requires 122.0614, found 122.0621; m/z (ES+) 122 ([M+H]+, 
100%). 
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7.3.10 -  
Methyl (±)-3-(pyrrolidin-1-yl)-2-fluoropropanoate 153 
 
 
 
1,4-Dibromobutane (85 µL, 712 µmol, 1.1 eq) was added to a solution of 
tetrabutylammonium iodide (45 mg, 146 µmol, 0.2 eq), sodium carbonate (270 mg, 
2.55 mmol, 4.0 eq) and methyl (±)-3-amino-2-fluoropropanoate 166 (100 mg, 
634 µmol, 1.0 eq) in THF. The resulting solution was heated under reflux for 4 hr, 
cooled to rt and quenched with water (2 mL) and ethyl acetate (4 mL). The organics 
were separated and the aqueous layer further extracted with ethyl acetate (4 mL). The 
organic phases were combined, washed with brine (5 mL), dried over sodium sulfate, 
filtered and the solvent removed in vacuo. The product was purified by silica gel 
column chromatography eluting with CH2Cl2 and CH3OH (100:0, 99:1), to furnish 
methyl (±)-3-(pyrrolidin-1-yl)-2-fluoropropanoate 153 (85 mg, 485 µmol, 77%) as a 
colourless oil: Rf 0.13 (CH2Cl2:CH3OH, 99:1); 1H NMR (400 MHz, 
CDCl3) δH 5.09 (1H, ddd, J 49.5, 6.8, 2.8 Hz, CHF), 3.81 (3H, s, OCH3), 3.02 (1H, ddd, 
J 26.2, 14.0, 6.8 Hz, CHaHbCHF), 2.95 (1H, ddd, J 28.6, 14.0, 2.8 Hz, CHaHbCHF), 
2.67-2.56 (4H, m, 2 × CH2), 1.79-1.76 (4H, m, 2 × CH2); 13C NMR (101 MHz, 
CDCl3) δC 169.5 (d, J 24.0 Hz, CO2CH3), 89.5 (d, J 187.0 Hz, CHF), 57.2 (d, J 20.3 Hz, 
CH2CHF), 54.9 (2 × CH2), 52.5 (OCH3), 23.8 (2 × CH2); 19F{1H} NMR (376 MHz, 
CDCl3) δF -192.2 (s, CHF); HRMS m/z (ES+) calcd. for C8H15NO2F [M+H]+ requires 
176.1087, found 176.1087; m/z (ES+) 194 ([M+Na]+, 10%), 176 ([M+H]+, 100%).  
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7.3.11 - 
(+)-(2S)-3-(Dibenzylamino)-2-fluoropropanoic acid[228] (S)-170 
 
 
 
Methyl (2S)-3-(dibenzylamino)-2-fluoropropanoate (S)-120 (1.00 g, 3.32 mmol, 1.0 eq) 
was added to a solution of KOH (3.20 g, 57.1 mmol, 10.0 eq) in CH3OH (10 mL). The 
resulting solution was stirred for 36 h at rt. The reaction was diluted with HCl (1 M, 
10 mL) and the aqueous phase extracted with ethyl acetate (3 × 5 mL). The combined 
organic fractions were dried over Na2SO4, filtered and the solvent removed in vacuo to 
furnished (2S)-3-(dibenzylamino)-2-fluoropropanoic acid (S)-170 (0.91 g, 98%) as a 
colourless oil, which was used without any further purification: [!]!!" +0.8 (c 2.5, 
CHCl3); 
1H NMR (400 MHz, CD3OD) δH 7.31 (10H, m, 10 × Ar-H), 4.98 (1H, ddd, 
J 49.5, 7.3, 3.3 Hz, CHF), 3.79 (2H, d, J 13.8 Hz, 2 × NCHaHb), 3.66 (2H, d, J 13.8 Hz, 
2 × NCHaHb), 3.01 (2H, m, CH2CHF); 19F NMR (282 MHz, CD3OD) δF -189.0 (ddd, 
J 49.5, 22.5, 22.5 Hz, CHF); m/z (ES+) 310 ([M+Na]+, 80%), 288 ([M+H]+, 100%).  
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7.3.12 - 
(–)-(2R)-3-(Dibenzylamino)-2-fluoropropanoic acid[228,229]  (R)-170 
 
 
 
Methyl (2R)-3-(dibenzylamino)-2-fluoropropanoate (R)-120 (1.00 g, 3.32 mmol, 1.0 eq) 
was added to a solution of KOH (3.20 g, 57.1 mmol, 10.0 eq) in CH3OH (10 mL). The 
resulting solution was stirred for 36 h at rt. The reaction was diluted with HCl (1 M, 
10 mL) and the aqueous phase extracted with ethyl acetate (3 × 5 mL). The combined 
organic fractions were dried over Na2SO4, filtered and the solvent removed in vacuo to 
furnish (2R)-3-(dibenzylamino)-2-fluoropropanoic acid (R)-170  (0.90 g, 97%) as a 
colourless oil which was used without any further purification: [!]!!"  -0.8 (c 2.5, 
CHCl3); 1H NMR (300 MHz, CD3OD) δH 7.44-7.33 (10H, m, 10 × Ar-H), 5.08 (1H, 
ddd, J 49.5, 7.3, 3.3 Hz, CHF), 4.09 (2H, d, J 13.4 Hz, 2 × CHaHbPh), 3.95 (2H, d, 
J 13.4 Hz, 2 × CHaHbPh), 3.31-3.19 (2H, m, CH2CHF); 19F NMR (282 MHz, 
CD3OD) δF -189.0 (ddd, J 49.5, 22.5, 22.5 Hz, CHF); m/z (ES+) 288 ([M+H]+, 100%).  
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7.3.13 -  
2,2',4,4'-Tetranitrodiphenylmethane[191, 230] 172 
 
 
 
Finely powdered potassium nitrate (27.7 g, 270 mmol, 4.5 eq) was added to a solution 
of aqueous sulfuric acid (200 mL, 15 M) over 0.5 h at 30 °C. Diphenylmethane 
(10.0 mL, 60 mmol, 1.0 eq) was added dropwise over 1 h, with the temperature 
maintained below 30 °C. After stirring for a further 0.5 h at rt, the solution was heated 
to 70 °C for 1 h, cooled to rt before iced water (1.5 L) was added, which resulted in the 
immediate precipitation of yellow solid that was isolated by filtration. This solid was 
suspended in ethanol (75 mL) and was heated under reflux for 5 min, after which the 
solid was re-collected by hot filtration and recrystallised from acetic acid (~75 mL), to 
yield 2,2',4,4'-tetranitrodiphenylmethane 172 (15.3 g, 44 mmol, 74%) as large yellow 
crystals: mp 172-173 °C (acetic acid) [Lit. [191, 230] 173 ºC]; 1H NMR (300 MHz, 
d6-DMSO) δH 8.85 (2H, d, J 2.5 Hz, Ar H-3,3′), 8.52 (2H, dd, J 8.6, 2.5 Hz, Ar H-5,5′), 
7.62 (2H, d, J 8.6 Hz, Ar H-6,6′), 3.36 (2H, s, CH2); m/z (ASAP) 349 ([M+H]+, 100%), 
348 ([M]+, 55%).  
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7.3.14 - 
2,2',4,4'-Tetranitrobenzophenone[230] 173 
 
 
 
Chromium trioxide (6.90 g, 68.9 mmol, 2.0 eq) was slowly added to a solution of 
2,2',4,4'-tetranitrodiphenylmethane 172 (12.0 g, 34.5 mmol, 1.0 eq) in acetic acid 
(100 mL) under reflux. The resulting dark green solution was stirred under reflux for 
16 h, cooled to rt with the precipitate isolated by filtration and washed with acetic acid 
(20 mL). The precipitate was further washed with ethanol (200 mL), water (200 mL). 
and was re-crystallised from acetic acid to yield 2,2',4,4'-tetranitrobenzophenone 173 
(11.8 g, 32.7 mmol, 95%) as small light yellow crystals: mp 235-238 °C (acetic acid) 
[lit.[230] 232 °C]; 1H NMR (300 MHz, d6-DMSO) δH 8.98 (2H, d, J 2.1 Hz, Ar H-3,3′), 
8.67 (2H, dd, J 8.5, 2.1 Hz, Ar H-5,5′), 8.05 (2H, d, J 8.5 Hz, Ar H-6,6′); 
m/z (ASAP) 363 ([M+H]+, 100%).  
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7.3.15 -  
3,6-Diamino-9-(10H)-acridone[230, 231] 155 
 
 
 
A solution of stannous chloride (69.1 g, 360 mmol, 12 eq) in concentrated 
HCl (200 mL, 1.18 specific gravity) was heated under reflux for 0.5 h while a steady 
flow of argon removed HCl gas evolved from the reaction [NOTE: Evolved HCl was 
neutralised by passing through double Drechsel flask set up containing a solution of 
NaOH (30% w/v)]. 2,2',4,4'-tetranitrobenzophenone 174 (11.0 g, 30.4 mmol) and 
ethanol (30 mL) were added, followed by a further portion of concentrated HCl (30 mL, 
1.18 specific gravity). This mixture was heated under reflux for 3 h, cooled to rt and 
concentrated HCl (50 mL, 1.18 specific gravity) was added. The mixture was stirred for 
16 h at rt resulting in precipitation of the hydrochloride salt of 155, which was isolated 
by filtration. This salt was dissolved in hot aqueous HCl (0.1 M, 200 mL) and heated 
under reflux for 1 h before activated carbon was added. This suspension was heated 
under reflux for 1 h, filtered and the filtrate was basified (pH 13) with NaOH 
(30% w/v). The resulting precipitate was isolated by hot filtration, washed with hot 
aqueous NaOH (50 mL, 2 M) and hot water (200 mL), until the filtrate was neutral, to 
furnish 3,6-diamino-9-(10H)-acridone 155 (4.30 g, 19.0 mmol, 63%) as a light brown 
solid: mp >300 °C [lit. [230, 231] >300 ºC]; 1H NMR (300 MHz, d6-DMSO) δH 10.85 (1H, 
s, NH), 7.83 (2H, d, J 8.7 Hz, Ar H-1,8), 6.45 (2H, dd, J 8.7, 2.0 Hz, Ar H-2,7), 
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6.40 (2H, d, J 2.0 Hz, Ar H-4,5), 4.00 (4H, br s, 2 × NH2); m/z (ES+) 
289 ([M+Na+MeCN]+, 20%), 226 ([M+H]+, 80%).  
 
7.3.16 - 
(±)-3,6-Bis(3-N,N-dibenzylamino-2-fluoropropionamido)-9-(10H)-acridone rac-169 
 
 
 
Potassium hexamethyldisilazide (1.8 mL, 1 M in THF, 4.0 eq) was added dropwise to a 
suspension of 3,6-diaminoacridone 155 (102 mg, 0.45 mmol, 1.0 eq) in THF (5.0 mL) 
over 0.5 h at -78 °C and the mixture stirred for a further 1 h at -78 ºC. Methyl 
(±)-3-dibenzylamino-2-fluoropropanoate rac-120 (300 mg, 1.0 mmol, 2.2 eq) in 
THF (5.0 mL) was added and the mixture was stirred for 16 h whist warming to rt. The 
reaction was quenched by the addition of saturated aqueous NH4OH (20 mL) and ethyl 
acetate (20 mL) resulting in significant precipitation. The organic phase was separated 
and the solids were isolated from the aqueous phase by filtration. The aqueous filtrate 
was extracted with ethyl acetate (3 × 10 mL) and the combined organic phases were 
washed with brine (30 mL), dried over Na2SO4, filtered and solvent removed in vacuo 
to yield a dark orange solid. This solid was absorbed onto Na2SO4 for purification by 
silica gel column chromatography, eluting with ethyl acetate and hexane (60:40, 90:10, 
100:0) to furnish (±)-3,6-bis(3-N,N-dibenzylamino-2-fluoropropionamido)-9-(10H)-
acridone rac-169 (64.0 mg, 83.8 µmol, 19%) as a pale yellow solid: 
1H NMR (400 MHz, d6-DMSO) δH 11.84 (1H, s, NH-10), 10.45 (2H, s, 2 × CONH), 
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8.23 (2H, d, J 1.7 Hz, Ar H-4/5), 8.15 (2H, d, J 8.8 Hz, Ar H-1/8), 7.39-7.16 (22H, m, 
20 × ArH, Ar H-2/7), 5.38 (2H, ddd, J 49.2, 5.9, 3.6 Hz, 2 × CHF), 3.78 (4H, d, 
J 13.9 Hz, 4 × CHaHbPh), 3.58 (4H, d, J 13.9 Hz, 4 × CHaHbPh), 3.10-2.94 (4H, m, 
2 × CH2CHF); 19F{1H} NMR (376 MHz, d6-DMSO) δF -187.9 (2F, dt, J 49.2, 24.9 Hz, 
2 × CHF); HRMS m/z (ES-) calcd. for C47H42F2N5O3 [M-H]- 762.3256, 
found 762.3246; m/z (ES-) 762 ([M-H]-, 100%). 
 
7.3.17 - 
(±)-3,6-Bis(3-N,N-dibenzylamino-2-fluoropropionamido)-9-(4-
dimethylaminophenylamino)acridine rac-182 
 
 
 
Phosphorous oxychloride (5.0 mL) was added to (±)-3,6-bis(3-N,N-dibenzylamino-
2-fluoropropionamido)-9-(10H)-acridone rac-169  (20.0 mg, 26.2 µmol, 1.0 eq), with 
the resulting suspension stirred at reflux for 3 hr. The solution was cooled to 0 °C and 
cold Et2O (10 mL) was added, resulting in formation of a precipitate. The precipitate 
was isolated by filtration and washed with further Et2O (2 × 5 mL) and dissolved in 
CHCl3 (5 mL). The organic phase was washed with aqueous NH4OH (1 M, 5 mL), and 
brine (5 mL), dried over Na2SO4, filtered and the solvent removed in vacuo to yield 
(±)-3,6-bis(3-N,N-dibenzylamino-2-fluoropropionamido)-9-chloroacridine (18.2 mg) as 
a red brown solid, which was used in the next step without further purification. 
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N,N-dimethylaminoaniline (63.0 mg, 466 mmol, 20 eq) in CHCl3 (2 mL) was added 
dropwise to a refluxing solution of (±)-3,6-bis((3-
N,N-dibenzylamino-2-fluoropropionamido)-9-chloroacridine in CHCl3 (2 mL). The 
mixture was heated under reflux until TLC analysis had indicated the consumption of 
the chloride, at which point the solvent was removed in vacuo to yield a black oil. Cold 
Et2O (excess) was added, resulting in the precipitation of a red-brown solid. The solids 
were isolated by filtration and washed with further Et2O (5 mL), dissolved in 
CHCl3 (5 mL) and washed with aqueous NH4OH (1 M, 5 mL) followed by brine (5 mL). 
The organic phase was dried over Na2SO4, filtered and the solvent removed in vacuo to 
yield a red solid. The solid was purified by silica gel column chromatography, eluting 
with CHCl3 and CH3OH (95:5), to yield (±)-3,6-bis(3-N,N-dibenzylamino-2-
fluoropropionamido)-9-(4-dimethylaminophenylamino)acridine rac-182 (4.9 mg, 
5.5 µmol, 23%) as a dark red solid: 1H NMR (500 MHz, CD3OD) δH 8.28 (2H, s, 
Ar H-4/5), 7.93 (2H, d, J 9.0 Hz, Ar H-1/8), 7.29-7.00 (24H, m, 20 × Ar-H, Ar H-2/7, 
Ar H-14/14′), 6.77 (2H, d, J 8.9 Hz, Ar H-13/13′), 5.13 (2H, ddd, J 49.1, 5.3, 3.7 Hz, 
2 × CHF), 3.73 (4H, d, J 13.7 Hz, 4 × CHaHbPh), 3.50 (4H, d, J 13.7 Hz, 4 × CHaHbPh), 
3.07-2.95 (4H, m, 2 × CH2CHF), 2.89 (6H, s, 2 × NCH3); 19F{1H} NMR (470 MHz, 
CD3OD) -187.5 (2F, s, 2 × CHF); HRMS m/z (ES+) calcd. for C55H54F2N7O2 [M+H]+ 
882.4307, found 882.4299; m/z (ES+) 882 ([M+H]+, 100%). 
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7.3.18 - 
Methyl (+)-(2R)-(diallylamino)-3-hydroxypropanoate (R)-187 
 
 
Allyl bromide (12.2 mL, 141 mmol, 2.2 eq) was added to a suspension of D-serine 
methyl ester hydrochloride (R)-164 (10.0 g, 64.8 mmol, 1.0 eq) and K2CO3 (35.6 g, 
258 mmol, 4.0 eq) in acetonitrile (300 mL) and the resulting suspension was heated 
under reflux for 24 h. The reaction was cooled to rt, diluted with water (300 mL) and 
extracted with ethyl acetate (3 × 100 mL). The organic fractions were combined, 
washed with brine (100 mL), dried over Na2SO4, filtered and the solvent removed 
in vacuo. The resulting oil was purified by silica gel column chromatography, eluting 
with hexane and ethyl acetate (95:5 to 90:10), to yield methyl (2R)-3-hydroxy-2-N,N-
bisallylaminopropanoate (R)-187  (7.66 g, 39.8 mmol, 62%) as a colourless oil: 
Rf 0.1 (hexane:ethyl acetate, 90:10); ![!]!!"  +80.3 (c 3.0, CHCl3); IR νmax (neat, 
cm-1) 3446 (OH), 2953 (C=CH), 1730 (C=O), 1645, 993, 920; 1H NMR (400 MHz, 
CDCl3) δH 5.75 (2H, dddd, J 17.2, 10.1, 7.9, 4.8 Hz, 2 × =CH), 5.20 (2H, dddd, J 17.2, 
1.8, 1.1, 1.1 Hz, 2 × CHaHb=), 5.14 (2H, dddd, J 10.1, 1.8, 0.9, 0.9 Hz, 2 × CHaHb=), 
3.75 (1H, dd, J 9.2, 4.6 Hz, CHN), 3.70 (3H, s, OCH3), 3.67-3.64 (2H, m, OCH2), 
3.36 (2H, dddd, J 14.3, 4.8, 1.1, 0.9 Hz, 2 × NCHaHb), 3.20-3.14 (2H, dddd, J 14.3, 7.9, 
1.1, 0.9 Hz, 2 × NCHaHb), 2.63 (1H, br s, OH); 13C NMR (101 MHz, 
CDCl3) δc 171.8 (CO2CH3), 135.9 (2 × =CH), 118.1 (2 × CH2=), 62.5 (CHN), 
59.1 (CH2OH), 53.7 (2 × NCH2-allyl), 51.5 (OCH3); HRMS m/z (ES+) calcd. for 
C10H17NO3Na [M+Na]+ 222.1106, found 222.1100; m/z (ES+) 222 ([M+Na]+, 100%). 
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7.3.19 -  
Methyl (–)-(2S)-(diallylamino)-3-hydroxypropanoate (S)-187 
 
 
 
Allyl bromide (12.2 mL, 141 mmol, 2.2 eq) was added to a suspension of L-serine 
methyl ester hydrochloride (S)-164 (10.0 g, 64.8 mmol, 1.0 eq) and K2CO3 (35.6 g, 
258 mmol, 4.0 eq) in acetonitrile (300 mL) and the resulting suspension was heated 
under reflux for 24 h. The reaction was cooled to rt, diluted with water (300 mL) and 
extracted with ethyl acetate (3 × 100 mL). The organic fractions were combined, 
washed with brine (100 mL), dried over Na2SO4, filtered and the solvent removed 
in vacuo. The resulting oil was purified by silica gel column chromatography, eluting 
with hexane and ethyl acetate (95:5 to 90:10), to yield methyl (2S)-3-hydroxy-2-N,N-
bisallylaminopropanoate (S)-187   (7.02 g, 36.5 mmol, 57%) as a colourless oil: 
Rf 0.1 (hexane:ethyl acetate, 90:10); [!]!!"  -81.3 (c 2.9, CHCl3); ! IR νmax (neat, 
cm-1) 3446 (OH), 2926 (C=CH), 1730 (C=O), 1645, 993, 920; 1H NMR (400 MHz, 
CDCl3) δH 5.75 (2H, dddd, J 17.2, 10.1, 7.9, 4.8 Hz, 2 × =CH), 5.20 (2H, dddd, J 17.2, 
1.8, 1.1, 1.1 Hz, 2 × CHaHb=), 5.14 (2H, dddd, J 10.1, 1.8, 0.9, 0.9 Hz, 2 × CHaHb=), 
3.70 (3H, s, OCH3), 3.75 (1H, dd, J 9.2, 4.6 Hz, CHN), 3.67 (1H, dd, J 14.3, 4.6 Hz, 
OCHaHb), 3.64 (1H, d, J 14.3, 9.2 Hz, OCHaHb), 3.36 (2H, dddd, J 14.3, 4.8, 1.1, 
0.9 Hz, 2 × NCHaHb-allyl), 3.20-3.14 (2H, m, 2 × NCHaHb-allyl), 2.63 (1H, br s, OH); 
13C NMR (101 MHz, CDCl3) δC 171.8 (CO2CH3), 135.9 (2 × =CH), 118.1 (2 × CH2=), 
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62.5 (CHN), 59.1 (CH2OH), 53.7 (2 × CH2N), 51.5 (OCH3); HRMS m/z (ES+) calcd. 
for C10H18NO3 [M+H]+ 200.1276, found 200.1277; m/z (ES+) 200 ([M+H]+, 100%). 
 
7.3.20 -  
Methyl (–)-(2S)-3-diallylamino-2-fluoropropanoate (S)-188 
 
 
 
Diethylaminosulfur trifluoride 32 (2.2 mL, 18.1 mmol, 1.2 eq) was added to a solution 
of methyl (2R)-(diallylamino)-3-hydroxypropanoate (R)-187  (3.00 g, 15.1 mmol, 
1.0 eq) in THF (80 mL) over a period of 5 min at 0 ºC. The resulting solution was 
stirred at 0 °C for 1 h and the reaction was quenched by the addition of solid 
K2CO3 (excess) and water (1 mL). As the effervescence subsided, the solution was 
diluted further with water (20 mL) and the organic fractions extracted with diethyl ether 
(3 × 20 mL). The organic fractions were combined and washed with brine (20 mL), 
dried over Na2SO4, filtered and the solvent removed in vacuo. The resulting oil was 
purified by silica gel column chromatography, eluting with hexane:ethyl acetate (95:5), 
to yield methyl (2S)-3-diallylamino-2-fluoropropanoate (S)-188  (2.06 g, 9.2 mmol, 
61%) as a colourless oil: Rf 0.15 (hexane:ethyl acetate, 95:5);![!]!!"  -9.7 (c 0.97, 
CHCl3); IR νmax (neat, cm-1) 2956, 2814, 1767 (C=O), 1643, 1440, 1213, 922; 
1H NMR (500 MHz, CDCl3) δH 5.80 (2H, dddd, J 16.9, 10.4, 6.9, 5.9 Hz, 2 × =CH), 
5.20-5.13 (4H, m, 2 × CH2=), 5.05 (1H, ddd, J 49.7, 6.4, 3.2 Hz, CHF), 3.79 (3H, s, 
OCH3), 3.28-3.24 (2H, m, 2 × NCHaHb-allyl), 3.14-3.10 (2H, m, 2 × NCHaHb-allyl), 
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2.99 (1H, ddd, J 25.8, 14.7, 6.4 Hz, CHaHbCHF), 2.96 (1H, ddd, J 26.6, 14.7, 3.2 Hz, 
CHaHbCHF); 13C NMR (101 MHz, CDCl3) δC 169.5 (d, J 23.5 Hz, CO2CH3), 
135.3 (2 × =CH), 118.0 (2 × CH2=), 89.5 (d, J 187.1 Hz, CHF), 57.6 (2 × NCH2-allyl), 
54.2 (d, J 20.2 Hz, CH2), 52.4 (OCH3); 19F NMR (470 MHz, CDCl3) δC -191.4 (ddd, 
J 49.7, 26.6, 25.8 Hz, CHF); HRMS m/z (ES+) calcd. for C10H16NO2FNa [M+Na]+ 
224.1058, found 224.1064; m/z (ES+) 224 ([M+Na]+, 100%), 202 ([M+H]+, 20%). 
Enantiomeric excess determined by chiral HPLC (Chiralcel OD-H 5% iPrOH in hexane, 
0.5 mL/min, tr maj = 9.57 min >95%, tr min = 9.33 min <5%). 
 
7.3.21 -  
Methyl (+)-(2R)-3-diallylamino-2-fluoropropanoate (R)-188 
 
 
 
Following the procedure set out for methyl (2S)-3-diallylamino-2-fluoropropanoate 
(S)-188, starting from methyl 2-(S)-3-hydroxypropanoate (S)-187   (3.10 g, 15.6 mmol, 
1.0 eq) with diethylaminosulfur trifluoride 32 (2.3 mL, 18.7 mmol, 1.2 eq) in 
THF (80 mL), the reaction yielded methyl (2R)-3-diallylamino-2-fluoropropanoate 
(R)-188   (2.19 g, 10.9 mmol, 69%) as a colourless oil: Rf 0.15 (hexane:ethyl acetate, 
95:5); IR νmax (neat, cm-1) 2956, 2815, 1767 (C=O), 1643, 1440, 1214, 1069, 
923;![!]!!"  +9.8 (c 0.97, CHCl3); 1H NMR (400 MHz, CDCl3) δH 5.80 (2H, dddd, 
J 17.2, 10.2, 7.0, 6.0 Hz, 2 × =CH), 5.20-5.13 (4H, m, 2 × CH2=), 5.05 (1H, ddd, J 49.7, 
6.3, 3.2 Hz, CHF), 3.73 (3H, s, OCH3), 3.29-3.23 (2H, m, 2 × NCHaHb-allyl), 
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3.15-3.09 (2H, m, 2 × NCHaHb-allyl), 2.99 (1H, ddd, J 25.8, 14.7, 6.3 Hz, CHaHbCHF), 
2.97 (1H, ddd, J 26.6, 14.7, 3.2 Hz, CHaHbCHF); 13C NMR (101 MHz, 
CDCl3) δC 169.5 (d, J 23.5 Hz, CONH), 135.3 (2 × =CH), 118.0 (2 × CH2=), 89.5 (d, 
J 186.1 Hz, CHF), 57.6 (2 × NCH2-allyl), 54.2 (d, J 20.2 Hz, CH2CHF), 52.4 (OCH3); 
19F NMR (376 MHz, CDCl3) δF -191.9 (ddd, J 49.7, 26.6, 25.8 Hz, CHF); 
HRMS m/z (ES+) calcd. for C10H17NO2F [M+H]+, 202.1233, found 202.1235; 
m/z (ES+) 202 ([M+H]+, 100%). Enantiomeric excess determined by chiral HPLC 
(Chiralcel OD-H 5% iPrOH in hexane, 0.5 mL/min, tr maj = 9.33 min >95%, tr min = 9.57 
min <5%). 
 
7.3.22 -  
3,6-Bis((2R)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-acridone 
(R,R)-195 
 
 
 
Potassium hexamethyldisilazide (4.4 mL, 1M in THF, 5.0 eq) was added dropwise to a 
suspension of 3,6-diaminoacridone 155 (200 mg, 0.88 mmol, 1.0 eq) in THF (10 mL) 
over 0.5 h at -78 °C and the mixture stirred for a further 1 h at -78 ºC. 
Methyl (2R)-3-diallylamino-2-fluoropropanoate (R)-188 (450 mg, 2.2 mmol, 2.5 eq) in 
THF (10 mL) was gradually added via cannula to the homogeneous orange solution and 
the mixture was stirred for 16 h whist warming to rt. The reaction was quenched by the 
addition of saturated aqueous Na2CO3 (20 mL) resulting in significant precipitation. The 
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solids were removed by filtration and the filtrate was extracted with ethyl 
acetate (3 × 20 mL). The combined organic phases were washed with brine (30 mL), 
dried over Na2SO4, filtered and solvent removed in vacuo to yield a dark orange solid. 
This solid was absorbed onto Na2SO4 for purification by silica gel column 
chromatography, eluting with ethyl acetate and hexane (60:40, 90:10, 100:0) to furnish 
3,6-bis((2R)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-acridone (R,R)-195 
(132 mg, 0.19 mmol, 22%) as a pale yellow solid: Rf 0.31 (ethyl acetate:hexane, 80:20); 
mp 240 ºC (dec.) ; [!]!"#!"  3.7 (c 0.9, CH3OH); IR νmax (KBr, cm-1) 3271, 3200, 2851, 
1688, 1629, 1599, 1462, 1300, 1269, 1190, 1118, 997, 921; 1H NMR (400 MHz, 
CD3OD) δH 8.14 (2H, d, J 8.9 Hz, Ar H-1,8), 8.08 (2H, d, J 1.8 Hz, Ar H-4,5), 
7.17 (2H, dd, J 8.9, 1.8 Hz, Ar H-2,7), 5.77 (4H, dddd, J 17.0, 10.4, 6.6, 6.6 Hz, 
4 × =CH), 5.15-5.03 (10H, m, 4 × CH2=, 2 × CHF), 3.21-3.08 (8H, m, 4 × NCH2-allyl), 
2.99 (4H, dd, J 25.8, 5.0 Hz, 2 × CH2CHF); 13C NMR (101 MHz, 
CD3OD) δC 178.5 (Ar C-9), 170.1 (d, J 20.6 Hz, 2 × CONH), 143.7 (2 × C-8a,9a & 
2 × Ar C-4a,4b), 136.5 (4 × =CH), 128.2 (2 × Ar CH-1,8), 118.8 (4 × CH2=), 
118.6 (2 × Ar C-3,6), 115.9 (2 × Ar CH-2,7), 107.7 (2 × Ar CH-4,5), 92.1 (d, 
J 187.9 Hz, 2 × CHF), 58.5 (4 × NCH2-allyl), 55.5 (d, J 20.4 Hz, 2 × CH2CHF); 
19F NMR (376 MHz, CD3OD) δF -191.2 (2F, dt, J 49.5, 24.7 Hz, 2 × CHF); 
HRMS m/z (ES-) calcd. for C31H34F2N5O3 [M-H]- requires 562.2630, found 562.2637; 
m/z (ES-) 562 ([M-H]-, 100%).  
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7.3.23 - 
3,6-Bis((2S)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-acridone (S,S)-195 
 
 
 
Following the procedure set out for 3,6-bis((2R)-3-N,N-diallylamino-
2-fluoropropionamido)-9-(10H)-acridone (R,R)-195, starting from methyl 
(2S)-3-diallylamino-2-fluoropropanoate (S)-188  (450 mg, 2.2 mmol, 2.5 eq) the 
reaction furnished 3,6-bis((2S)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-
acridone (S,S)-195 (138 mg, 0.20 mmol, 23%) as a pale yellow solid: Rf 0.31 (ethyl 
acetate:hexane, 80:20); mp 240 ºC (dec.); [!]!"#!"  -3.6 (c 1.1, CH3OH); IR νmax (KBr, 
cm-1) 3269, 3200, 2850, 1691, 1628, 1598, 1462, 1299, 1268, 1190, 1118, 997, 922; 
1H NMR (400 MHz, CD3OD) δH 8.24 (2H, d, J 8.9 Hz, Ar H-1,8), 8.17 (2H, d, 
J 2.0 Hz, Ar H-4,5), 7.27 (2H, dd, J 8.9, 2.0 Hz, Ar H-2,7), 5.92-5.82 (4H, m, 
4 × =CH), 5.26-5.11 (10H, m, 4 × CH2= and 2 × CHF), 3.32-3.17 (8H, m, 
4 × NCH2-allyl), 3.09 (4H, dd, J 25.9, 5.0 Hz, 2 × CH2CHF); 13C NMR (101 MHz, 
CD3OD) δC 178.5 (Ar C-9), 170.0 (d, J 20.6 Hz, 2 × CONH), 143.7 (2 × Ar C-8a,9a & 
2 × Ar C-4a,4b), 136.1 (4 × =CH), 128.2 (2 × Ar CH-1,8), 118.7 (4 × CH2=), 
118.6 (2 × Ar C-3,6), 115.9 (2 × Ar CH-2,7), 107.7 (2 × Ar CH-4,5), 92.1 (d, 
J 187.9 Hz, 2 × CHF), 58.4 (4 × NCH2-allyl), 55.6 (d, J 20.4 Hz, 2 × CH2CHF); 
19F NMR (376 MHz, CD3OD) δF -191.2 (2F, dt, J 49.5, 24.7 Hz, 2 × CHF); 
HRMS m/z (ES+) calcd. for C31H36F2N5O3 [M+H]+ requires 564.2786, found 564.2789; 
m/z (ES+) 564 ([M+H]+, 100%), 586 ([M+H]+, 50%).  
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7.3.24 - 
3,6-Bis((2R)-3-amino-2-fluoropropionamido)-9-(10H)-acridone (R,R)-196.HCl 
 
 
 
1,4-Di(phenylphosphino)butane (30 mg, 71 µmol, 10 mol%/allyl group) was added to a 
solution of palladium acetylacetonate (33 mg, 36 µmol, 5 mol%/allyl group) in 
degassed THF (5.0 mL) and the resulting solution was stirred at rt for 15 min. 
3,6-Bis((2R)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-acridone (R,R)-195  
(100 mg, 0.18 mmol, 1.0 eq) and 2-mercaptosalicylic acid (137 mg, 890 mmol, 5.0 eq) 
in THF (5.0 mL) were added via cannula to the catalyst solution and the reaction was 
heated under reflux for 3 h. The reaction was cooled to rt and water (10 mL) and 
HCl (1 M, 60 µL) were added, resulting in precipitation of a yellow solid. The 
precipitate was isolated by filtration and the residue was washed repeatedly with 
water (3 × 10 mL). The filtrate was reduced in vacuo to furnish a yellow solid. This 
solid was reconstituted in water, filtered and the filtrate was lyophilised to yield 
3,6-bis(3-amino-(2R)-fluoropropionamido)-9-(10H)-acridone dihydrochloride (R,R)-
196.HCl (81 mg, 0.17 mmol, 95% based on dichloride salt) as a pale yellow amorphous 
solid: mp 160 ºC (dec.); [!]!"#!"  27.8 (c 0.9, CH3OH); IR (KBr, cm-1) 2960, 2921, 1677, 
1563, 1416, 1207, 1149, 1063, 1042, 741; 1H NMR (300 MHz, D2O) δH 7.73 (2H, d, 
J 9.0 Hz, Ar H-1,8), 7.27 (2H, d, J 1.9 Hz, Ar H-4,5), 6.95 (2H, dd, J 9.0, 1.9 Hz, 
Ar H-2,7), 5.45 (2H, ddd, J 48.5, 8.1, 3.2 Hz, 2 × CHF), 3.77-3.51 (4H, m, 
2 × CH2CHF); 13C NMR (126 MHz, D2O/d6-DMSO) δC 178.3 (Ar C-9), 167.4 (d, 
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J 19.6 Hz, 2 × CONH), 142.6 (2 × Ar C-8a,9a), 142.5 (2 × Ar C-4a,4b), 
128.3 (2 × Ar CH-1,8), 118.2 (2 × Ar C-3,6), 116.3 (2 × Ar CH-2,7), 
107.9 (2 × Ar CH-4,5), 88.7 (d, J 188.2 Hz, 2 × CHF), 41.9 (d, J 20.6, 2 × CH2CHF); 
19F NMR (286 MHz, D2O/d6-DMSO) δF -196.9 (2F, ddd, J 48.5, 29.1, 19.3 Hz, 
2 × CHF); HRMS m/z (ES+) calcd. for C19H20F2N5O3 [M+H]+ requires 404.1529, 
found 404.1530; m/z (ES+) 404 ([M+H]+, 100%).  
 
7.3.25 - 
3,6-Bis((2S)-3-amino-2-fluoropropionamido)-9-(10H)-acridone (S,S)-196.HCl 
 
 
 
Following the procedure set out for 3,6-bis((2S)-3-amino-2-fluoropropionamido)-9-
(10H)-acridone dihydrochloride (R,R)-196, starting from 3,6-bis((2S)-3-N,N-
diallylamino-2-fluoropropionamido)-9-(10H)-acridone (S,S)-195  (51 mg, 0.09 mmol) 
the reaction yielded 3,6-bis((2S)-3-amino-2-fluoropropionamido)-9-(10H)-acridone 
dihydrochloride (S,S)-196.HCl (38 mg, 0.08 mmol, 89%) as a pale yellow amorphous 
solid: mp 160 ºC (dec.); [!]!"#!"  -22.5 (c 1.1, CH3OH); 1H NMR (300 MHz, 
D2O) δH 7.73 (2H, d, J 9.0 Hz, Ar H-1,8), 7.27 (2H, d, J 1.6 Hz, Ar H-4,5), 6.95 (2H, 
dd, J 9.0, 1.6 Hz, Ar H-2,7), 5.45 (2H, ddd, J 48.4, 8.1, 3.1 Hz, 2 × CHF), 3.68 (2H, 
ddd, J 29.0, 14.4, 3.1 Hz, 2 × CHaHbCHF), 3.58 (2H, ddd, J 19.4, 14.4, 8.1 Hz, 
2 × CHaHbCHF); 13C NMR (126 MHz, D2O) δC 178.3 (Ar C-9), 167.4 (d, J 19.7 Hz, 
2 × CONH), 142.6 (2 × Ar C-8a,9a), 142.5 (2 × Ar C-4a,4b), 128.3 (2 × Ar CH-1,8), 
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118.2 (2 × Ar C-3,6), 116.3 (2 × Ar CH-2,7), 107.9 (2 × Ar CH-4,5), 88.7 (d, 
J 188.2 Hz, 2 × CHF), 41.9 (d, J 20.7 Hz, 2 × CH2CHF); 19F NMR (282 MHz, 
D2O) δF -195.5 (2F, ddd, J 48.4, 29.0, 19.4 Hz, 2 × CHF); HRMS m/z (ES+) calcd. for 
C19H20F2N5O3 [M+H]+ requires 404.1529, found 404.1528; m/z (ES+) 404 ([M+H]+, 
100%).  
 
7.3.26 - 
3,6-Bis((2R)-3-N,N-bisallylamino-2-fluoropropionamido)-9-(4-dimethylamino 
phenylamino)acridine (R,R)-206 
 
 
 
Phosphorous oxychloride (10 mL) was added to 
3,6-bis((2R)-3-amino-2-fluoropropionamido)-9-(10H)-acridone (R,R)-195 (100 mg, 
0.18 mmol, 1.0 eq). The resulting bright orange suspension was stirred at rt until TLC 
analysis had indicated consumption of the starting material. The solution was cooled to 
0 °C and cold Et2O (20 mL) was added, resulting in formation of a precipitate. The 
precipitate was isolated by filtration and washed with further Et2O (2 × 10 mL) and 
dissolved in CHCl3 (10 mL). The organic phase was washed with aqueous NH4OH (1 M, 
10 mL), and brine (10 mL), dried over Na2SO4, filtered and the solvent removed 
in vacuo to yield 3,6-bis((2R)-3-N,N-diallylamino-2-fluoropropionamido)-9-chloro 
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acridine (74 mg, 72%) as a red brown solid, which was used in the next step without 
further purification. N,N-dimethylaminoaniline monohydrochloride (445 mg, 
2.60 mmol, 20 eq) was dissolved in saturated aqueous Na2CO3 and extracted with 
Et2O (3 × 20 mL). The organic fractions were combined, washed with brine (20 mL), 
dried over Na2SO4, filtered and the solvent was removed in vacuo to yield 
N,N-dimethylaminoaniline as a light brown oil. This oil was dissolved in 
CHCl3 (10 mL) and the solution was gradually added via cannula to a refluxing solution 
of 3,6-bis((2R)-3-N,N-diallylamino-2-fluoropropionamido)-9-chloroacridine (74 mg, 
0.13 mmol, 1.0 eq) in CHCl3 (10 mL) over 30 min. The mixture was heated under 
reflux until TLC analysis had indicated the consumption of the chloride, at which point 
the solvent was removed in vacuo to yield a purple oil. Cold Et2O (excess) was added, 
resulting the precipitation of a red-brown solid. The solids were isolated by filtration 
and washed with further Et2O (20 mL), dissolved in CHCl3 (20 mL) and washed with 
aqueous NH4OH (1 M, 10 mL) followed by brine (10 mL). The organic phase was dried 
over Na2SO4, filtered and the solvent removed in vacuo to yield a red solid. The solid 
was purified by silica gel column chromatography, eluting with CHCl3 and 
CH3OH (95:5), to yield 3,6-bis((2R)-3-N,N-bisallylamino-2-fluoropropionamido)-9-(4-
dimethylamino phenylamino)acridine (R,R)-206 (53 mg, 0.08 mmol, 61%) as a dark red 
solid: Rf 0.09 (CHCl3:CH3OH, 95:5); mp 195 ºC (dec.); IR νmax (KBr disc, cm-1) 3428, 
3077, 1700 (C=O), 1633 (C=O), 1521, 1469, 1446, 1359, 1257, 1065, 922; 
1H NMR (400 MHz, CD3OD) δH 8.37 (2H, d, J 1.9 Hz, Ar H-4,5), 7.96 (2H, d, 
J 9.4 Hz, Ar H-1,8), 7.27 (2H, dd, J 9.4, 1.9 Hz, Ar H-2,7), 7.10 (2H, d, J 8.9 Hz, 
Ar H-14,14'), 6.78 (2H, d, J 8.9 Hz, Ar H-13,13'), 5.85 (4H, dddd, J 17.0, 10.4, 6.5, 
6.5  Hz, 4 × =CH), 5.24-5.14 (8H, m, 4 × CH2=), 5.20 (2H, dt, J 49.3, 5.0 Hz, 2 × CHF), 
3.31-3.25 (4H, m, 4 × NCHaHb-allyl), 3.24-3.19 (4H, m, 4 × NCHaHb-allyl), 3.09 (4H, 
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dd, J 26.0, 5.0 Hz, 2 × CH2CHF), 3.00 (6H, s, 2 × NCH3); 13C NMR (101 MHz, 
CD3OD) δC 170.3 (d, J 20.9 Hz, 2 × CONH), 153.9 (Ar C-9), 151.0 (Ar C-15), 
144.3 (2 × Ar C-4a,4b), 143.8 (2 × Ar C-8a,9a), 136.2 (4 × =CH), 132.0 (Ar C-12), 
127.7 (2 × Ar CH-1,8), 126.2 (2 × Ar CH-14,14'), 118.7 (4 × CH2=), 
117.9 (2 × Ar CH-2,7), 114.4 (2 × Ar CH-13,13'), 112.2 (2 × Ar C-3,6), 
109.0 (2 × Ar CH-4,5), 92.2 (d, J 187.9 Hz, 2 × CHF), 58.4 (4 × NCH2-allyl), 55.5 (d, 
J 20.0 Hz, 2 × CH2CHF), 40.9 (2 × NCH3); 19F NMR (376 MHz, 
CD3OD) δF 191.2 (2F, dt, J 49.3, 26.0 Hz, 2 × CHF); HRMS m/z (ES+) calcd. for 
C39H46F2N7O2 [M+H]+ requires 682.3676, found 682.3670; m/z (ES+) 682 ([M+H]+, 
100%).  
 
7.3.27 -  
3,6-Bis((2S)-3-N,N-bisallylamino-2-fluoropropionamido)-9-(4-dimethylamino 
phenylamino) acridine (S,S)-206 
 
 
 
Following the procedure set out for 3,6-bis((2R)-3-bisallylamino-2-
fluoropropionamido)-9-(4-dimethylaminophenylamino) acridine (R,R)-206, starting 
from 3,6-bis((2S)-3-N,N-diallylamino-2-fluoropropionamido)-9-(10H)-acridone 
(S,S)-195  (100 mg, 0.18 mmol), the reaction yielded 3,6-bis((2S)-3-N,N-bisallylamino-
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2-fluoropropionamido)-9-(4-dimethylaminophenylamino) acridine (S,S)-206  (41.7 mg, 
0.063 mmol, 48%) as a red solid: Rf 0.09 (CHCl3:CH3OH, 95:5); mp 195 ºC (dec.); 
IR νmax (KBr disc, cm-1) 3453, 3077, 1697 (C=O), 1633 (C=O), 1521, 1469, 1446, 1359, 
1257, 1064, 922; UV-vis (CH3OH) λmax 268 nm (log10 ε 11.34), 293 nm (log10 ε 8.04), 
364 nm (log10 ε 4.00), 425 nm (log10 ε 1.63); 1H NMR (400 MHz, 
CD3OD) δH 8.39 (2H, d, J 1.9 Hz, Ar H-4,5), 7.97 (2H, d, J 9.4 Hz, Ar H-1,8), 
7.31 (2H, dd, J 9.4, 1.9 Hz, Ar H-2,7), 7.15 (2H, d, J 9.0 Hz, Ar H-14,14'), 6.81 (2H, d, 
J 9.0 Hz, Ar H-13,13'), 5.85 (4H, dddd, J 17.0, 10.4, 6.5, 6.5 Hz, 4 × =CH), 
5.28-5.13 (8H, m, 4 × CH2=), 5.20 (2H, dt, J 49.4, 4.9 Hz, 2 × CHF), 3.32-3.16 (8H, m, 
4 × NCH2-allyl), 3.09 (4H, dd, J 26.0, 4.9 Hz, CH2CHF), 3.00 (6H, s, 2 × NCH3); 
13C NMR (101 MHz, CD3OD) δC 170.3 (d, J 20.9 Hz, 2 × CONH), 154.4 (Ar C-9), 
151.3 (Ar C-15), 144.2 (2 × Ar C-4a,4b), 143.8 (2 × Ar C-8a,9a), 136.2 (4 × =CH), 
131.2 (Ar C-12), 127.8 (2 × Ar CH-1,8) 126.6 (2 × Ar CH-14,14'), 118.7 (4 × CH2=), 
118.0 (2 × Ar CH-2,7), 114.3 (2 × Ar CH-13,13´), 111.8 (2 × Ar C-3,6), 
108.4 (2 × Ar CH-4,5), 92.2 (d, J 187.9 Hz, 2 × CHF), 58.4 (4 × NCH2-allyl), 55.5 (d, 
J 20.0 Hz, 2 × CH2CHF), 40.8 (2 × NCH3); 19F NMR (376 MHz, 
CD3OD) δF 191.4 (2F, dt, J 49.4, 26.0 Hz, 2 × CHF); HRMS m/z (ES+) calcd. for 
C39H46F2N7O2 [M+H]+ requires 682.3676, found 682.3666; m/z (ES+) 682 ([M+H]+, 
100%).  
 
 
 
 
 
 Experimental  
 
 188 
7.3.28 -  
3,6-Bis((2R)-3-amino-2-fluoropropionamido)-9-(4-dimethylaminophenylamino) 
acridine dihydrochloride (R,R)-208.HCl 
 
 
 
1,4-Di(phenylphosphino)butane (25.2 mg, 59 µmol, 20 mol%/allyl group) was added to 
a solution of tris(dibenzylideneacetone)dipalladium (26.5 mg, 29 µmol, 10 mol%/allyl 
group) in THF (8 mL) and stirred for 15 min until the solution turned yellow. The 
solution was added to a solution of 3,6-bis((2R)-3-N,N-bisallylamino-2-
fluoropropionamido)-9-(4-dimethylaminophenylamino) acridine (R,R)-206 (48.8 mg, 
72 µmol, 1.0 eq) and 2-mercaptosalicylic acid (55.0 mg, 0.356 mmol, 5.0 eq) in 
THF (5.0 mL) via cannula. The resulting solution was heated under reflux for 3 h before 
being cooled to rt and diluted with distilled water (5 mL) and HCl (1 M, 60 µL), which 
caused precipitation of a solid. The precipitate was isolated by filtration and the residue 
was washed repeatedly with distilled water (3 × 10 mL). The water/THF filtrate was 
concentrated in vacuo to yield a yellow solid. The solid was redissolved in water and 
filtered. The filtrate was lyophilised to yield 3,6-bis((2R)-3-amino-2-
fluoropropionamido)-9-(4-dimethylaminophenylamino)acridine dihydrochloride 
(R,R)-208.HCl (25.2 mg, 42 µmol, 59% based on dichloride salt) as a red amorphous 
solid: IR νmax (KBr disc, cm-1) 3424, 1700 (C=O), 1633 (C=O), 1610, 1594, 1546, 1516, 
1467, 1447, 1386, 1257; 1H NMR (500 MHz, D2O) δH 8.01 (2H, s, Ar H-4,5), 
2
3
4
4a
9a
1
N
10
4b
8a9
5
6
7
8
N
H
N
H
HN
12
O
NH3Cl
O
ClH3N
13
14
15
14'
13' N
FF
 Experimental  
 
 189 
7.70 (2H, d, J 9.4 Hz, Ar H-1,8), 7.45 (2H, d, J 8.7 Hz, Ar H-14,14´), 7.25 (2H, d, 
J 8.7 Hz, Ar H-13,13´), 7.19 (2H, d, J 9.4 Hz, Ar H-2,7), 5.49 (2H, ddd, J 48.3, 8.3, 
3.0 Hz, 2 × CHF), 3.63 (2H, ddd, J 29.3, 14.4, 3.0 Hz, 2 × CHaHbCHF), 3.53 (2H, ddd, 
J 19.1, 14.4, 8.3 Hz, 2 × CHaHbCHF), 3.15 (6H, s, 2 × N CH3); 13C NMR (126 MHz, 
D2O) δC 166.8 (d, J 20.0 Hz, 2 × CONH), 153.2 (Ar C-9), 152.0 (Ar C-15), 
142.1 (2 × Ar C-4a,4b), 140.7 (2 × Ar C-8a,9a), 133.1 (Ar C-12), 
126.5 (2 × Ar CH-1,8), 125.5 (2 × Ar CH-14,14'), 117.5 (2 × Ar CH-2,7), 
110.3 (2 × Ar C-3,6), 106.9 (2 × Ar CH-4,5), 87.4 (d, J 189.2 Hz, 2 × CHF), 
65.9 (2 × NCH3), 40.5 (d, J 20.6 Hz, 2 × CH2CHF); 19F NMR (470 MHz, 
D2O) δF -195.7 (2F, ddd, J 48.3, 29.3, 19.1 Hz, 2 × CHF); HRMS m/z (ES+) calcd. for 
C27H30F2N7O2 [M+H]+ requires 522.2429, found 522.2421; m/z (ES+) 522 ([M+H]+, 
100%). 
 
7.3.29 - 
3,6-Bis((2S)-3-amino-2-fluoropropionamido)-9-(4-dimethylaminophenylamino) 
acridine dihydrochloride (S,S)-208.HCl 
 
 
 
Following the procedure set out for 3,6-bis((2R)-3-amino-2-fluoropropionamido)-9-(4-
dimethylaminophenylamino) acridine dihydrochloride (R,R)-208.HCl, starting from 
3,6-bis((2S)-3-N,N-bisallylamino-2-fluoropropionamido)-9-(4-dimethylaminophenyl 
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amino)acridine (S,S)-206 (41.7 mg, 61 µmol), the reaction yielded 3,6-bis((2S)-
3-amino-2-fluoropropionamido)-9-(4-dimethylaminophenylamino)acridine 
dihydrochloride (S,S)-208.HCl  (19.3 mg, 33 µmol, 53%) as a red solid: 
IR νmax (KBr disc, cm-1) 3424, 2927, 1700 (C=O), 1633 (C=O), 1610, 1595, 1517, 1446, 
1257; 1H NMR (500 MHz, D2O) δH 8.01 (2H, d, J 1.9 Hz, Ar H-4,5), 7.70 (2H, d, 
J 9.4 Hz, Ar H-1,8), 7.45 (2H, d, J 8.7 Hz, Ar H-14,14'), 7.25 (2H, d, J 8.7 Hz, 
Ar H-13,13'), 7.19 (2H, dd, J 9.4, 1.9 Hz, Ar H-2,7), 5.49 (2H, ddd, J 48.3, 8.2, 3.0 Hz, 
2 × CHF), 3.63 (2H, ddd, J 29.3, 14.4, 3.0 Hz, 2 × CHaHbCHF), 3.53 (2H, ddd, J 19.2, 
14.4, 8.2 Hz, 2 × CHaHbCHF), 3.15 (6H, s, 2 × NCH3); 13C NMR (126 MHz, 
D2O) δC 166.8 (d, J 20.0 Hz, 2 × CONH), 153.2 (Ar C-9), 152.0 (Ar C-15), 
142.1 (2 × Ar C-4a,4b), 140.7 (2 × Ar C-8a,9a), 133.1 (Ar C-12), 
126.5 (2 × Ar CH-14,14´), 125.5 (2 × Ar CH-1,8), 117.5 (2 × Ar CH-2,7), 
110.3 (2 × Ar C-3,6), 106.9 (2 × Ar CH-4,5), 87.4 (d, J 189.2 Hz, 2 × CHF), 
65.9 (2 × NCH3), 40.5 (d, J 20.6 Hz, 2 × CH2CHF); 19F NMR (470 MHz, 
D2O) δF -195.7 (2F, ddd, J 48.3, 29.3, 19.2 Hz, 2 × CHF); HRMS m/z (ES+) calcd. for 
C27H30F2N7O2 [M+H]+ requires 522.2429, found 522.2440; m/z (ES+) 522 ([M+H]+, 
100%). 
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7.3.30 -  
Methyl (–)-(2R)-3-dipropylamino-2-fluoropropanoate (R)-209 
 
 
 
Palladium on carbon (20%, 205 mg, 10 mol%) was added to a solution of 
methyl (2R)-3-diallylamino-2-fluoropropanoate (R)-188  (755 mg, 3.88 mmol, 1.0 eq) 
in ethyl acetate (10 mL). The resulting suspension was stirred vigorously under a 
hydrogen atmosphere at rt for 24 h. The solids were removed by filtration and the 
residue was washed repeatedly with ethyl acetate (3 × 20 mL). The filtrate was made 
deliberately wet with water (1 mL) followed by the addition of MgSO4 to remove any 
remaining fine particulate. The solvent was removed in vacuo to yield a oil that was 
purified by silica gel column chromatography, eluting with ethyl acetate and hexane 
(20:80), to yield methyl (2R)-3-dipropylamino-2-fluoropropanoate (R)-209 (393 mg, 
1.91 mmol, 51%) as a colourless oil: Rf 0.16 (hexane:ethyl acetate, 95:5); [!]!!" -23.0 (c 1.0, CHCl3); IR νmax (neat, cm-1) 2960, 1769 (C=O), 1462, 1212, 1074; 
1H NMR (400 MHz, CDCl3) δH 4.95 (1H, ddd, J 49.8, 5.5, 5.5 Hz, CHF), 3.72 (3H, s, 
OCH3), 2.90-2.88 (2H, m, CH2CHF), 2.47-2.33 (4H, m, 2 × NCH2CH2), 1.41-1.32 (4H, 
m, 2 × NCH2CH2), 0.79 (6H, t, J 7.4 Hz, 2 × CH2CH3); 13C NMR (101 MHz, 
CDCl3) δC 169.8 (d, J 23.9 Hz, CO2CH3), 89.6 (d, J 186.5 Hz, CHF), 
57.0 (2 × NCH2CH2), 55.8 (d, J 20.2 Hz, CH2CHF), 52.3 (OCH3), 20.5 (2 × NCH2CH2), 
11.8 (2 × CH2CH3); 19F NMR (376 MHz, CDCl3) δF -192.0 (ddd, J 49.8, 25.9, 25.9 Hz, 
CHF); HRMS m/z (ES+) calcd. for C10H21FNO2 [M+H]+, requires 206.1551, 
found 206.1550; m/z (ES+) 206 ([M+H]+, 100%).  
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7.3.31 - 
Methyl (+)-(2S)-3-dipropylamino-2-fluoropropanoate (S)-209 
 
 
 
Following the procedure set out for methyl 3-dipropylamino-(2R)-fluoropropanoate 
(R)-209, starting from methyl (2S)-3-diallylamino-2-fluoropropanoate (S)-188   
(830 mg, 414 mmol) the reaction yielded methyl 
(2S)-3-dipropylamino-2-fluoropropanoate (S)-209 (520 mg, 2.25 mmol, 61%) as a 
colourless oil: Rf 0.16 (hexane:ethyl acetate, 95:5); [!]!!"! +22.5 (c 1.0, CHCl3); 
IR νmax (neat, cm-1) 2959, 1769 (C=O), 1461, 1212, 1073; 1H NMR (300 MHz, 
CDCl3) δH 5.01 (1H, ddd, J 49.7, 5.4, 5.4 Hz, CHF), 3.79 (3H, s, OCH3), 3.01-2.92 (2H, 
m, CH2CHF), 2.55-2.38 (4H, m, 2 × NCH2CH2), 1.43 (4H, tq, J 7.4, 7.4 Hz, 
2 × NCH2CH2), 0.86 (6H, t, J 7.4 Hz, 2 × CH2CH3); 13C NMR (75 MHz, 
CDCl3) δC 169.8 (d, J 23.8, CO2CH3), 89.7 (d, J 187.1, CHF), 57.0 (2 × NCH2CH2), 
55.8 (d, J 20.2, CH2CHF), 52.3 (OCH3), 20.5 (2 × CH2CH2CH3), 11.8 (2 × CH2CH3); 
19F NMR (282 MHz, CDCl3) δF -191.9 (ddd, J 49.7, 26.0, 26.0 Hz, CHF); 
HRMS m/z (ES+) calcd. for C10H21FNO2 [M+H]+, requires 206.1551, found 206.1550; 
m/z (ES+) 206 ([M+H]+, 100%).  
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7.3.32 -  
3,6-Bis((2R)-3-N,N-dipropylamino-2-fluoropropionamido)-9-(10H)-acridone 
(R,R)-210 
 
 
 
Potassium hexamethyldisilazide (4.1 mL, 1 M in THF, 5.0 eq) was added dropwise to a 
suspension of 3,6-diaminoacridone (188 mg, 0.83 mmol, 1.0 eq) in THF (10 mL) 
at -78 °C over 30 min and stirred for a further 1 h at -78 ºC. Methyl 
(2R)-3-dipropylamino-2-fluoropropanoate (R)-209  (375 mg, 1.83 mmol, 2.2 eq) in 
THF (10 mL) was gradually added via cannula to the homogeneous orange solution and 
the mixture was stirred for 16 h while gently warming through to rt. The reaction was 
quenched by the addition of saturated aqueous Na2CO3 (20 mL), resulting in significant 
precipitation, which was removed by filtration. The filtrate was extracted with ethyl 
acetate (3 × 20 mL). The organic phases were combined and washed with brine 
(30 mL), dried over Na2SO4, filtered and solvent removed in vacuo to yield a dark 
orange solid. The solids were absorbed onto Na2SO4 for purification by silica gel 
column chromatography, eluting with ethyl acetate and hexane (30:70, 90:10, 100:0) to 
furnish 3,6-bis((2R)-3-N,N-dipropylamino-2-fluoropropionamido)-9-(10H)-acridone 
(R,R)-210  (142 mg, 0.14 mmol, 30%) as a pale yellow solid: Rf 0.17 (ethyl 
acetate:hexane, 80:20); mp 215 ºC (dec.); [!]!"#!"  +3.7 (c 0.88, CH3OH), [!]!"#!"  +4.0 (c 0.88, CH3OH); IR νmax (KBr, cm-1) 3286, 2961, 1685 (C=O), 
1633 (C=O), 1600, 1536, 1464; 1H NMR (300 MHz, CD3OD) δH 8.25 (2H, d, J 8.9 Hz, 
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Ar H-1,8), 8.21 (2H, d, J 1.9 Hz, Ar H-4,5), 7.29 (2H, dd, J 8.9, 1.9 Hz, Ar H-2,7), 
5.16 (2H, dt, J 49.4, 4.9 Hz, 2 × CHF), 3.07 (4H, dd, J 27.9, 4.9 Hz, 2 × CH2CHF), 
2.62-2.47 (8H, m, 4 × CH2N), 1.54-1.48 (8H, m, 4 × CH3CH2CH2), 0.89 (12H, t, 
J 7.4 Hz, 4 × CH3CH2); 13C NMR (75.5 MHz, CD3OD) δC 178.6 (Ar C-9), 
170.3 (d,  20.6 Hz, 2 × CONH), 143.7 (2 × Ar C-8a,9a & 2 × Ar C-4a,4b), 
128.2 (2 × Ar CH-1,8), 118.8 (2 × Ar C-3,6), 115.6 (2 × Ar CH-2,7), 
107. (2 × Ar CH-4,5), 92.1 (d, J 187.8 Hz, 2 × CHF), 58.0 (4 × CH2N), 56.9 (d, 
J 20.6 Hz, 2 × CH2CHF), 21.2 (4 × CH3CH2CH2), 12.1 (4 × CH2CH3); 
19F NMR (282 MHz, CD3OD) δF 191.2 (2F, dt, J 49.4, 27.9 Hz, 2 × CHF); 
HRMS m/z (ES-) calcd. for C31H42F2N5O3 [M-H]- requires 570.3251, found 570.3242; 
m/z (ES-) 570 ([M-H]-, 100%).  
 
7.3.33 - 
3,6-Bis((2S)-3-N,N-dipropylamino-2-fluoropropionamido)-9-(10H)-acridone 
(S,S)-210 
 
 
 
Following the procedure set out for 3,6-bis((2R)-3-N,N-dipropylamino-2-
fluoropropionamido)-9-(10H)-acridone (R,R)-210 starting from methyl 
2(S)-fluoropropanoate (S)-209 (370 mg, 1.8 mmol), the reaction yielded 
3,6-bis((2S)-3-N,N-dipropylamino-2-fluoropropionamido)-9-(10H)-acridone (S,S)-210  
(124 mg, 0.22 mmol, 26%) as a pale yellow solid: Rf 0.17 (ethyl acetate:hexane, 80:20); 
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mp 215 ºC (dec.); [!]!"#!"  -11.7 (c 1.02, CH3OH), [!]!"#!"  -5.4 (c 1.02, CH3OH), [!]!"#!"  -4.1 (c 1.02, CH3OH); IR νmax (KBr, cm-1) 3283, 2959, 1687 (C=O), 1637 (C=O), 
1600, 1537, 1464; 1H NMR (300 MHz, CD3OD) δH 8.25 (2H, d, J 8.9 Hz, Ar H-1,8), 
8.21 (2H, d, J 1.9 Hz, Ar H-4,5), 7.29 (2H, dd, J 8.9, 1.9 Hz, Ar H-2,7), 5.16 (2H, dt, 
J 49.4, 4.9 Hz, 2 × CHF), 3.07 (4H, dd, J 27.9, 4.9 Hz, 2 × CH2CHF), 2.62-2.47 (8H, m, 
4 × CH2N), 1.54-1.48 (8H, m, 4 × CH3CH2CH2), 0.89 (12H, t, J 7.4 Hz, 4 × CH3CH2); 
13C NMR (75.5 MHz, CD3OD) δC 178.5 (Ar C-9), 170.3 (d, J 20.6 Hz, 2 × CONH), 
143.7 (2 × Ar C-8a,9a & 2 × Ar C-4a,4b), 128.2 (2 × Ar CH-1,8), 118.6 (2 × Ar C-3,6), 
115.9 (2 × Ar CH-2,7), 107.7 (2 × Ar CH-4,5), 92.1 (d, J 187.8-Hz, 2 × CHF), 
58.0 (4 × CH2N), 57.0 (d, J 20.6 Hz, 2 × CH2CHF), 21.2 (4 × CH3CH2CH2), 
12.1 (4 × CH3CH2); 19F NMR (282 MHz, CD3OD) δF -191.2 (2F, dt, J 49.4, 27.9 Hz, 
2 × CHF); HRMS m/z (ES-) calcd. for C31H42F2N5O3 [M-H]- requires 570.3251, 
found 570.3263; m/z (ES-) 570 ([M-H]-, 100%).  
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7.3.34 -  
3,6-Bis((2R)-3-N,N-bispropylamino-2-fluoropropionamido)-9-(4-dimethylamino 
phenylamino)acridine (R,R)-212 
 
 
 
Phosphorous oxychloride (5 mL) was added to 3,6-bis((2R)-3-dipropylamino-
2-fluoropropionamido)-9-(10H)-acridone (R,R)-210  (115 mg, 0.20 mmol, 1.0 eq). The 
resulting bright orange suspension was stirred at rt until TLC analysis indicated 
consumption of the starting material. The solution was cooled to 0 °C and cold 
Et2O (10 mL) was added, resulting in formation of a precipitate. The precipitate was 
isolated by filtration and washed with further Et2O (2 × 10 mL) and dissolved in 
CHCl3 (10 mL). The organic phase was washed with aqueous NH4OH (1 M, 10 mL) and 
brine (10 mL), dried over Na2SO4, filtered and the solvent removed in vacuo to yield 
3,6-bis((2R)-3-N,N-dipropylamino-2-fluoropropionamido)-9-chloroacridine (R,R)-211  
as a red brown solid, which was used directly in the next step without further 
purification. N,N-dimethylaminoaniline monohydrochloride (700 mg, 4.05 mmol, 
20 eq) was dissolved in saturated aqueous Na2CO3 and extracted with 
Et2O (3 × 20 mL). The organic fractions were combined, washed with brine, dried over 
Na2SO4, filtered and the solvent removed in vacuo to yield N,N-dimethylaminoaniline 
as a light brown oil. This oil was dissolved in CHCl3 (20 mL) and added via cannula to 
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a refluxing solution of 3,6-bis((2R)-3-N,N-dipropylamino-2-fluoropropionamido)-9-
chloroacridine in CHCl3 (10 mL) over 30 min. This mixture was heated under reflux 
until TLC analysis indicated the consumption of the chloride, at which point the solvent 
was removed in vacuo to yield a purple oil. Cold Et2O (excess) was added, resulting in 
the precipitation of a red-brown solid. The solid was isolated by filtration and washed 
with further Et2O (excess). The residue was dissolved in CHCl3 (20 mL) and washed 
with aqueous NH4OH (1 M, 10 mL) followed by brine (10 mL). The organic phase was 
dried over Na2SO4, filtered and the solvent removed in vacuo to yield a red solid, which 
was purified by silica gel column chromatography, eluting with CHCl3 and 
CH3OH (95:5), to yield 3,6-bis((2R)-3-bispropylamino-2-fluoropropanamide)-9-(4-
dimethylamino phenylamino) acridine (R,R)-212   (34.6 mg, 50.6 µmol, 25% over two 
steps) as a dark red solid: Rf 0.06 (CHCl3:CH3OH, 95:5); mp 190 ºC (dec.); 
IR νmax (KBr disc, cm-1) 3421, 2960, 1701 (C=O), 1611 (C=O), 1518, 1277; 
1H NMR (500 MHz, CD3OD) δH 8.46 (2H, d, J 1.5 Hz, Ar CH-4,5), 8.02 (2H, d, 
J 9.4 Hz, Ar CH-1,8), 7.33 (2H, dd, J 9.4, 1.5 Hz, Ar CH-2,7), 7.17 (2H, d, J 8.8 Hz, 
Ar CH-14,14′), 6.85 (2H, d, J 8.8 Hz, Ar CH-13,13′), 5.18 (2H, dt, J 49.5, 4.8 Hz, 
2 × CHF), 3.08 (4H, dd, J 26.0, 4.8 Hz, 2 × CH2CHF), 2.97 (6H, s, 2 × NCH3), 
2.60-2.49 (8H, m, 4 × CH2CH2N), 1.54-1.46 (8H, m, 4 × CH3CH2CH2), 0.88 (12H, t, 
J 7.3 Hz, 4 × CH3CH2); 13C NMR (126 MHz, CD3OD) δC 170.7 (d, J 20.8 Hz, CONH), 
154.5 (Ar C-9), 151.3 (Ar C-15), 144.2 (2 × Ar C-4a,4b), 144.0 (2 × Ar C-8a,9a), 
131.2 (Ar C-12), 127.8 (2 × Ar CH-1,8), 126.5 (2 × Ar CH-14,14′), 
118.0 (2 × Ar CH-2,7), 114.5 (2 × Ar CH-13,13′), 112.0 (2 × Ar C-3,6), 
108.7 (2 × Ar CH-4,5), 92.3 (d, J 188.4 Hz, 2 × CHF), 58.0 (4 × CH2CH2N), 56.9 (d, 
J 19.9 Hz, 2 × CH2CHF), 40.8 (2 × NCH3), 21.3 (4 × CH3CH2CH2), 
12.1 (4 × CH3CH2); 19F NMR (470 MHz, CD3OD) δF -191.2 (2F, dt, J 49.5, 26.0 Hz, 
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2 × CHF); HRMS m/z (ES+) calcd. for C39H54F2N7O2 [M+H]+ requires 690.4302, 
found 690.4309; m/z (ES+) 690 ([M+H]+, 100%).  
 
7.3.35 -  
3,6-Bis((2S)-3-bispropylamino-2-fluoropropanamide)-9-(4-dimethylamino 
phenylamino)acridine (S,S)-212 
 
 
 
Following the procedure set out for 3,6-bis((2R)-3-bispropylamino-2-
fluoropropanamide)-9-(4-dimethylaminophenylamino)acridine (R,R)-212 , starting from 
3,6-bis((2S)-3-N,N-dipropylamino-2-fluoropropionamido)-9-(10H)-acridone (S,S)-210  
(118 mg, 0.209 mmol), the reaction yielded 3,6-bis((2S)-3-bispropylamino-2-
fluoropropanamide)-9-(4-dimethylaminophenylamino) acridine (S,S)-212   (29.7 mg, 
44 µmol, 21% over two steps) as a dark red solid: Rf 0.06 (CHCl3:CH3OH, 95:5); 
mp 190 ºC (dec.); IR νmax (KBr disc, cm-1) 3420, 2959, 1701 (C=O), 1610 (C=O), 
1520, 1276; 1H NMR (400 MHz, CD3OD) δH 8.33 (2H, d, J 2.1 Hz, Ar H-4,5), 
7.92 (2H, d, J 9.4 Hz, Ar H-1,8), 7.27 (2H, dd, J 9.4, 2.1 Hz, Ar H-2,7), 7.11 (2H, d, 
J 9.0 Hz, Ar H-14,14′), 6.77 (2H, d, J 9.0 Hz, Ar H-13,13′), 5.16 (2H, dt, J 49.4, 4.9 Hz, 
2 × CHF), 3.09-3.02 (4H, m, 2 × CH2CHF), 2.97 (6H, s, 2 × NCH3), 2.58-2.46 (8H, m, 
4 × CH2CH2N), 1.54-1.44 (8H, m, 4 × CH3CH2CH2), 0.87 (12H, t, J 7.4 Hz, 
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4 × CH3CH2); 13C NMR (101 MHz, CD3OD) δC 170.5 (d, J 20.1 Hz, 2 × CONH), 
154.1 (Ar C-9), 151.1 (Ar C-15), 144.0 (2 × Ar C-4a,4b), 143.9 (2 × Ar C-8a,9a), 
131.1 (Ar C-12), 127.7 (2 × Ar CH-1,8), 126.4 (2 × Ar CH-14,14′), 
117.9 (2 × Ar CH-2,7), 114.3 (2 × Ar CH-13,13′), 111.8 (2 × Ar C-3,6), 
108.5 (2 × Ar CH-4,5), 92.1 (d, J 188.4 Hz, 2 × CHF), 57.9 (4 × CH2CH2N), 56.9 (d, 
J 19.9 Hz, 2 × CH2CHF), 40.8 (2 × NCH3), 21.2 (4 × CH3CH2CH2), 
12.1 (4 × CH3CH2); 19F NMR (376 MHz, CD3OD) δF -191.1 (2F, dt, J 49.4, 26.2 Hz, 
2 × CHF); HRMS m/z (ES+) calcd. for C39H54F2N7O2 [M+H]+ requires 690.4302, 
found 690.4294; m/z (ES+) 690 ([M+H]+, 100%).  
 
7.3.36 -  
3,6-Bis(3-chloropropionamido)-9-(10H)-acridone[191] 174 
 
 
 
3,6-Diamino-9-(10H)-acridone 155 (500 mg, 2.2 mmol, 1.0 eq) was heated under reflux 
in neat 3-chloropropionyl chloride (5.0 mL) for 5 h. The solution was cooled to rt and 
ice-cold Et2O (30 mL) was added, resulting in formation of a precipitate. The precipitate 
was isolated by filtration, washed with Et2O (2 × 30 mL) and dried under vacuum to 
yield 3,6-bis(3-chloropropionamido)-9(10H)-acridone 174 (241 mg, 0.59 mmol, 27%) 
as an orange amorphous solid which was used without further purification: 
mp 295-297 ºC [Lit.[191] 300 ºC]; 1H NMR (300 MHz; d6-DMSO) δH 11.48 (2H, s, 
2 × CONH), 9.58 (1H, s, NH-10), 8.88 (2H, d, J 1.7 Hz, Ar H-4/5), 8.35 (2H, d, 
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J 9.1 Hz, Ar H-1/8), 7.87 (2H, dd, J 9.1, 1.7 Hz, Ar H-2/7), 3.96 (4H, t, J 6.2 Hz, 
2 × CH2CH2Cl), 3.06 (4H, t, J 6.2 Hz, 2 × CH2CH2Cl); m/z (ES-) 404 ([M[35Cl]-H], 
100%). 
 
7.3.37 -  
3,6-Bis(3-N,N-bisallylaminopropionamido)-9-(10H)-acridone 140i 
 
 
 
Diallylamine (320 µL, 2.6 mmol, 10 eq) was added dropwise to a refluxing solution of 
3,6-bis(3-chloropropionamido)-9-(10H)-acridone 174 (100 mg, 0.25 mmol, 1.0 eq) and 
NaI (96 mg, 0.64 mmol, 2.5 eq) in EtOH (10 mL) and the resulting mixture was stirred 
for 3 h at reflux. The solution was cooled to rt and the solvent removed in vacuo and 
Et2O (20 mL) was added, resulting in the formation of a precipitate. The precipitate was 
isolated by filtration, and washed with further Et2O (2 × 10 mL) and dissolved in ethyl 
acetate (20 mL). The organic phase was washed with NH4OH (1 M, 2 × 10 mL) and 
brine (10 mL), dried over Na2SO4, filtered and the solvent removed in vacuo. The 
material was purified by silica gel chromatography, eluting with CHCl3, CH3OH and 
triethylamine (90:9:1), to yield 3,6-bis(3-N,N-bisallylaminopropionamido)-
9-(10H)-acridone 140i (62 mg, 0.12 mmol, 46%) as a yellow solid: mp 300 ºC dec.; 
IR νmax (NaCl plate, cm-1) 3417, 2928, 1600 (C=O), 1554, 1493, 1458; 
1H NMR (500 MHz, CDCl3) δH 11.17 (1H, br s, ArH-10), 11.05 (2H, br s, 2 × CONH), 
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8.20 (2H, d, J 8.8 Hz, ArH-1/8), 8.06 (2H, d, J 1.6 Hz, ArH-4/5), 6.82 (2H, dd, J 8.8, 
1.6 Hz, ArH-2/7), 5.81-5.76 (4H, m, 4 × =CH), 5.19-5.15 (8H, m, 4 × CH2=), 3.14 (8H, 
s, 4 × NCH2-allyl), 2.77 (4H, t, J 6.3 Hz, 2 × CH2CH2), 2.50 (4H, t, J 6.3 Hz, 
2 × CH2N); 13C NMR (126 MHz, CD3OD) δC 178.5 (ArC-9), 173.5 (2 × CONH), 
144.6 (ArC-8a/9a), 143.9 (ArC-4a/4b), 135.6 (4 × =CH), 128.2 (ArCH-1/8), 
119.2 (4 × CH2=), 118.1 (ArC-3/6), 115.3 (ArCH-2/7), 106.6 (ArCH-4/5), 
57.5 (4 × NCH2-allyl), 50.0 (2 × CH2CH2), 35.1 (2 × CH2CH2N); 
HRMS m/z  (ES+ calcd. for C31H38N5O3 [M+H]+ requires 528.2975, found 528.2963; 
m/z (ES+) 528 ([M+H]+, 100%), 550 ([M+Na]+, 20%).  
 
7.3.38 - 
3,6-Bis(3-N,N-bispropylaminopropionamido)-9-(10H)-acridone 140j 
 
 
 
Following the proceedure set out for 3,6-bis(3-N,N-bisallylamino-propionamido)-9-
(10H)-acridone 140i, starting from diproplyamine (350 µL, 2.5 mmol, 10 eq) with 
3,6-bis(3-chloropropionamido)-9-(10H)-acridone 174 (103 mg, 0.25 mmol, 1.0 eq) and 
NaI (95 mg, 0.63 mmol, 2.5 eq), the reacton yielded 3,6-bis(3-N,N-
bispropylaminopropionamido)-9-(10H)-acridone 140j (35.8 mg, 0.067 mmol, 26%) as 
a yellow solid: mp 320 ºC (dec.); IR νmax (NaCl plate, cm-1) 3420, 2930, 1602 (C=O), 
1545, 1459; 1H NMR (500 MHz, CDCl3) δH 11.72 (1H, s, ArH-10), 10.83 (2H, s, 
2 × CONH), 8.49 (2H, d, J 1.6 Hz, ArH-4/5), 8.35 (2H, d, J 8.7 Hz, ArH-1/8), 6.73 (2H, 
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dd, J 8.7, 1.6 Hz, ArH-2/7), 2.81 (4H, t, J 5.6 Hz, 2 × CH2N), 2.68 (4H, t, J 5.6 Hz, 
2 × CH2CH2), 2.56-2.53 (8H, m, 4 × NCH2CH2), 1.62-1.55 (8H, m, 4 × CH2CH3), 
0.92 (12H, t, J 7.3 Hz, 4 × CH2CH3); 13C NMR (126 MHz, CDCl3) δC 176.9 (ArC-9), 
172.3 (2 × CONH), 142.7 (ArC-8a/9a), 142.5 (ArC-4a/4b), 127.9 (ArCH-1/8), 
117.7 (ArC-3/6), 113.6 (ArCH-2/7), 106.2 (ArCH-4/5), 55.3 (4 × NCH2), 
50.3 (2 × CH2CH2), 33.5 (2 × CH2CH2N) , 19.9 (4 × CH2CH3), 12.1 (4 × CH2CH3); 
HRMS m/z (ES+) calcd. for C31H45N5O2 [M+H]+ requires 536.3601, found 536.3594; 
m/z (ES+) 536 ([M+H]+, 100%).  
 
7.3.39 - 
3,6-Bis(3-N,N-diallylamino-propanamide)-9-(4-dimethylaminophenylamino) 
acridine 219 
 
 
 
Phosphorous oxychloride (5.0 mL) was added to 3,6-bis(3-N,N-diallylamino-
propionamido)-9-(10H)-acridone 140i   (30.0 mg, 0.20 mmol, 1.0 eq). The resulting 
suspension was stirred at rt until TLC analysis indicated consumption of the starting 
material. The solution was cooled to 0 °C and cold Et2O (10 mL) was added, resulting 
in formation of a precipitate. The precipitate was isolated by filtration and washed with 
further Et2O (2 × 10 mL) and dissolved in CHCl3 (10 mL). The organic phase was 
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washed with aqueous NH4OH (1 M, 10 mL) and brine (10 mL), dried over Na2SO4, 
filtered and the solvent removed in vacuo to yield 
3,6-bis(3-N,N-diallylamino-propionamido)-9-chloroacridine as a red brown solid, which 
was used directly in the next step without further purification. 
N,N-dimethylaminoaniline monohydrochloride (200 mg, 1.16 mmol, 20 eq) was 
dissolved in saturated aqueous Na2CO3 (10 mL) and extracted with Et2O (3 × 5 mL). 
The organic fractions were combined, washed with brine, dried over Na2SO4, filtered 
and the solvent removed in vacuo to yield N,N-dimethylaminoaniline as a light brown 
oil. This oil was dissolved in CHCl3 (5 mL) and added via cannula to a refluxing 
solution of 3,6-bis(3-N,N-diallylamino-propionamido)-9-chloroacridine in 
CHCl3 (5 mL) over 30 min. This mixture was heated under reflux until TLC analysis 
indicated the consumption of the chloride, at which point the solvent was removed 
in vacuo to yield a purple oil. Cold Et2O (20 mL) was added, resulting in the 
precipitation of a red-brown solid. The solid was isolated by filtration and washed with 
further Et2O (excess). The residue was dissolved in CHCl3 (10 mL) and washed with 
aqueous NH4OH (1 M, 10 mL) followed by brine (10 mL). The organic phase was dried 
over Na2SO4, filtered and the solvent reduced in vacuo to yield a dark red solution. The 
material was prepared as its HCl salt by the addition of HCl (1 M, diethyl ether), which 
resulted in precipitation. This salt solution was loaded onto silica gel and purified by 
column chromatography, eluting with CHCl3, CH3OH and triethylamine (100:0:0, 
95:5:0, 90:5:5). The desired fractions were collected and washed with NH4OH (1.0 M, 
2 × 10 mL), brine (10 mL), dried over Na2SO4, filtered and the solvent was removed 
in vacuo to yield 3,6-bis(3-N,N-diallylamino-propanamide)-9-(4-dimethylamino 
phenylamino) acridine 219 (13.5 mg, 20.9 µmol, 37%) as a dark red solid: 
Rf 0.09 (CHCl3:CH3OH:Et3N, 90:8:2); mp >320 ºC; IR νmax (NaCl plate, cm-1) 3419, 
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2930, 1603, 1548, 1488, 1398; 1H NMR (500 MHz, CD3OD) δH 8.37 (2H, s, ArH-4/5), 
8.00 (2H, d, J 8.5, ArH-1/8), 7.28 (2H, d, J 8.5, ArH-2/7), 7.22 (2H, d, J 8.7, 
ArH-14/14′), 6.85 (2H, d, J 8.7, ArH-13/13′), 6.03-6.11 (4H, m, 4 × =CH), 
5.59-5.69 (8H, m, 4 × CH2=), 3.85 (8H, s, 4 × NCH2-allyl), 3.50 (4H, t, J 6.7 Hz, 
2 × CH2CH2), 3.07 (4H, t, J 6.7 Hz, 2 × CH2CH2N), 3.03 (6H, s, 2 × NCH3); 
13C NMR (75 MHz, CDCl3) δC 171.9 (2 × CONH), 153.9 (Ar C-9), 150.3 (Ar C-15), 
145.7 (2 × Ar C-4a/4b), 143.4 (2 × Ar C-8a/9a), 134.0 (4 × =CH), 133.2 (Ar C-12), 
127.3 (2 × Ar CH-1/8), 123.7 (2 × Ar CH-14/14′), 119.4 (4 × CH2=), 
116.4 (2 × Ar CH-2/7), 115.9 (2 × Ar CH-13/13′), 113.6 (2 × Ar C-3/6), 
107.5 (2 × Ar CH-4/5), 48.8 (2 × CH2CH2), 46.2 (4 × NCH2-allyl), 40.9 (2 × NCH3), 
33.7 (2 × CH2CH2N); HRMS m/z (ES+) calcd. for C39H47N7O2 
[M+H]+ requires 646.3869, found 646.3870; m/z (ES+) 646 ([M+H]+, 100%). 
 
7.3.40 - 
3,6-Bis(3-N,N-dipropylamino-propionamido)-9-(4-dimethylaminophenylamino) 
acridine 214 
 
 
 
Following the proceedure set out for 3,6-bis(3-N,N-diallylamino-propanamide)-9-(4-
dimethylaminophenylamino) acridine 219, starting from 3,6-bis(3-N,N-bispropylamino-
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propionamido)-9-(10H)-acridone 140j (25.0 mg, 46.9 µmol, 1.0 eq) and 
N,N-dimethylaminoaniline monohydrochloride (160 mg, 0.93 mmol, 20 eq), the reacton 
yielded 3,6-bis(3-N,N-dipropylamino-propanamide)-9-(4-dimethylaminophenylamino) 
acridine 214 (8.9 mg, 13.6 µmol, 29%) as a red solid: IR νmax (NaCl plate, cm-1) 3401, 
2928, 1601, 1491, 1454, 1405; 1H NMR (500 MHz, CD3OD) δH 8.47 (2H, d, J 1.8 Hz, 
ArH-4/5), 8.05 (2H, d, J 9.3 Hz, ArH-1/8), 7.23 (2H, dd, J 9.3, 1.8 Hz, ArH-2/7), 
7.22 (2H, d, J 9.0 Hz, ArH-14/14′), 6.87 (2H, d, J 9.0 Hz, ArH-13/13′), 3.07 (4H, t, 
J 6.8 Hz, CH2CH2N), 3.03 (6H, s, 2 × NCH3), 2.73 (4H, t, J 6.8 Hz, 2 × CH2CH2N), 
2.68-2.65 (8H, m, 4 × NCH2CH2), 1.66-1.58 (8H, m, 4 × CH2CH3), 0.95 (12H, t, 
J 7.4 Hz, 4 × CH2CH3); 13C NMR (126 MHz, CDCl3) δC 173.6 (2 × CONH), 
154.9 (Ar C-9), 151.5 (Ar C-15), 145.4 (2 × Ar C-4a/4b), 143.8 (2 × Ar C-8a/9a), 
130.5 (Ar C-12), 127.9 (2 × Ar CH-1/8), 126.9 (2 × Ar CH-14/14′), 
117.6 (2 × Ar CH-2/7), 114.3 (2 × Ar CH-13/13′), 111.0 (2 × Ar C-3/6), 
106.8 (2 × Ar CH-4/5), 56.7 (4 × NCH2CH2), 50.6 (2 × CH2CH2), 40.7 (2 × NCH3), 
34.5 (2 × CH2CH2N), 20.5 (4 × CH2CH3), 12.1 (4 × CH2CH3); HRMS m/z (ES+) calcd. 
for C39H56N7O2 [M+H]+ requires 654.4495, found 654.4513; m/z (ES+) 654 ([M+H]+, 
100%). 
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7.3.41 -  
3,6-Bis(3-amino-propionamido)-9-(4-dimethylaminophenylamino) acridine 
diformate  213 
 
 
 
1,4-Di(phenylphosphino)butane (4.2 mg, 9.8 µmol, 20 mol%/allyl group) was added to 
a solution of tris(dibenzylideneacetone)dipalladium (4.5 mg, 4.9 µmol, 10 mol%/allyl 
group) in THF (1.0 mL) and stirred for 15 min until the solution turned yellow. The 
solution was added to a solution of 3,6-bis(3-N,N-diallylamino-propionamido)-9-(4-
dimethylaminophenylamino) acridine 219  (8.1 mg, 13 µmol, 1.0 eq) and 
2-mercaptosalicylic acid (9.8 mg, 64 µmol, 5.0 eq) in THF (1.0 mL). The resulting 
solution was heated under reflux for 3 h before being cooled to rt and diluted with 
distilled water (2.0 mL) and HCl (0.1 M, 250 µL), which caused precipitation of a solid. 
The precipitate was isolated by filtration and the residue was washed repeatedly with 
distilled water (3 × 1.0 mL). The water/THF filtrate was concentrated in vacuo to yield 
a yellow solid, which was purified by reverse phase silica gel chromatography eluting 
with water and CH3OH (90:10 with 1% formic acid) to yield 
3,6-bis(3-amino-propionamido)-9-(4-dimethylaminophenylamino) acridine 213 as its 
diformic acid salt (1.2 mg, 2.1 µmol, 17%) as a red powder: 
Rf 0.12 (H2O:CH3OH:HCO2H, 90:9:1); 1H NMR (500 MHz, D2O) δH 8.14 (2H, s, 
Ar H-4,5), 7.91 (2H, d, J 9.2 Hz, Ar H-1,8), 7.23 (2H, d, J 8.9 Hz, Ar H-14/14'), 
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7.15 (2H, d, J 9.2 Hz, Ar H-2,7), 7.02 (2H, d, J 8.9 Hz, Ar H-13,13'), 3.36 (4H, t, 
J 6.5 Hz, 2 × CH2), 2.94 (4H, t, J 6.5 Hz, 2 × CH2), 2.92 (6H, s, 2 × NCH3); 
HRMS m/z (ES+) calcd. for C27H32N7O2 [M+H]+ requires 486.2617, found 486.2621; 
m/z (ES+) 486 ([M+H]+, 100%).   
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7.4 - Experimental for Chapter 5 
7.4.1 - General proceedures  
General procedure (GP) 1 - The appropriate quantities of                                                 
(–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoic acid (S)-230 
(1.0 eq), diisopropylethylamine (4.0 eq) and amino ester (2.0 eq) in 
CH2Cl2 (1.0 mL mmol-1) were cooled to 0 ºC and propylphosphonic anhydride (T3P) 
(50% w/w in ethyl acetate, 2.0 eq) was added dropwise. The solution was maintained at 
0 ºC for a further 30 min before being warmed to rt and stirred until TLC analysis 
indicated consumption of the starting material. The reaction mixture was quenched by 
the addition of HCl (1 M, 10 mL) and the aqueous phase was extracted with ethyl 
acetate (2 × 10 mL). The combined organic phases were washed sequentially with 
HCl (1 M, 3 × 10 mL), saturated aqueous Na2CO3 (3 × 10 mL), brine (20 mL) and dried 
over Na2SO4. The solvent was removed in vacuo and the product purified by silica gel 
chromatography, eluting with mixtures of ethyl acetate and hexane.  
 
General Procedure (GP) 2 - Tetrabutylammonium fluoride (1 M in THF, 4.0 eq) was 
added dropwise to the appropriate silyl protected dipeptide 232a-c (1.0 eq) and acetic 
acid (5.0 eq) in THF (8.0 mL mmol-1) and the resulting reaction mixture stirred at rt. 
The reaction was quenched by the addition of water (5 mL) followed by ethyl acetate 
(10 mL). The organic phases were washed successively with water (2 × 5 mL) and brine 
(10 mL), dried over Na2SO4 and the solvent removed in vacuo. The product was 
purified by silica gel column chromatography, eluting with mixtures of ethyl acetate and 
hexane.  
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General procedure (GP) 3 - Diethylaminosulfur trifluoride 32 (1.5 eq) was added 
dropwise to a solution of the appropriate amino alcohol dipeptide 224a-c (1.0 eq) in 
THF (5.0 mL mmol-1) at 0 ºC. The resulting solution was stirred at 0 ºC for 1 h before 
being quenched by the addition of NaHCO3 (solid) and water until the solution was 
basic (pH >9) and effervescence subsided. The aqueous phase was extracted with 
diethyl ether (3 × 10 mL) and the combined organic phases were washed with brine, 
dried over Na2SO4, filtered and the solvent removed in vacuo. The product mixtures 
were purified by silica gel column chromatography, eluting with mixtures of ethyl 
acetate and hexane, separating the α- and β-fluorinated regioisomers where applicable. 
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7.4.2 - 
Methyl (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoate (S)-229 
 
 
 
Triethylamine (16.0 mL, 115 mmol, 4.5 eq) was added dropwise over 30 min to a 
solution of methyl (2S)-2-diallylamino-3-hydroxy-propanoate (S)-187 (5.00 g, 
25.1 mmol, 1.0 eq) and tert-butyldimethylsilyl trifluoromethanesulfonate (9.00 mL, 
39.1 mmol, 1.8 eq) in CH2Cl2 (230 mL) at 0 ºC. The mixture was brought to rt and 
stirred for 16 h, quenched by the addition of CH3OH (40 mL) followed by saturated 
aqueous Na2CO3 (100 mL). The organic phase was separated and the aqueous phase 
was extracted with CH2Cl2 (3 × 100 mL). The organic phases were combined, dried 
over Na2SO4 and the solvent removed in vacuo. The oil was purified by silica gel 
chromatography, eluting with hexane and ethyl acetate (95:5), to yield methyl (–)-(2S)- 
3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoate (S)-229 (6.52 g, 20.8 mmol, 
83%) as a colourless oil: Rf 0.5 (hexane:ethyl acetate, 90:10); [!]!!"  -18.1 (c 0.6, 
CHCl3); IR νmax (neat, cm-1) 2951, 2929, 1735 (C=O), 1251 (Si–C), 1103, 918 (Si–C); 
1H NMR (400 MHz, CDCl3) δH 5.78 (2H, dddd, J 17.2, 10.1, 7.0, 5.4 Hz, 2 × =CH), 
5.21-5.09 (4H, m, 2 × CH2=), 3.93 (1H, dd, J 9.9, 7.0 Hz, OCHaHb), 3.82 (1H, dd, J 9.9, 
5.6 Hz, OCHaHb), 3.61 (1H, dd, J 7.0, 5.6 Hz, CHN), 3.38-3.32 (4H, m, 2 × NCH2), 
3.15 (3H, OCH3), 0.86 (9H, s, (CH3)3), 0.03 (3H, s, SiCH3), 0.03 (3H, s, SiCH3); 
13C NMR (101 MHz, CDCl3) δC 172.4 (CO2CH3), 136.7 (2 × =CH), 117.2 (2 × CH2=), 
64.2 (CHN), 62.9 (CH2), 54.6 (2 × NCH2-allyl), 51.2 (OCH3), 25.9 (C(CH3)3), 
18.3 (SiC), -5.4 (SiCH3), -5.4 (SiCH3); HRMS m/z (ES+) calcd. 
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for C16H32NO3Si [M+H]+ requires 314.2151, found 314.2156; m/z (ES+) 314 ([M+H]+, 
100%). Enantiomeric excess determined by chiral HPLC (Chiralcel OD-H, 5% iPrOH in 
hexane, 0.25 mL/min, tr maj = 7.08 min). 
 
7.4.3 -  
(–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoic acid (S)-230 
 
 
 
Lithium hydroxide monohydrate (3.37 g, 80.4 mmol, 4.0 eq) was added portionwise to a 
solution of methyl (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoate 
(S)-229 (6.30 g, 20.1 mmol, 1.0 eq) in THF:H2O:CH3OH (20:20:60, 150 mL) and was 
stirred for 24 h at rt. The reaction was quenched by neutralisation with HCl (1 M, 
60 mL) and the aqueous phase extracted with CH2Cl2 (3 × 50 mL). The combined 
organics were dried with Na2SO4, filtered and the solvent removed in vacuo to yield                                
(–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-propanoic acid (S)-230 (5.41 g, 
18.1 mmol, 90%) as a colourless gum, which was used without any further purification: [!]!!"  -3.1 (c 1.7, CH3OH); IR νmax (neat, cm-1) 2927, 2856, 1635 (C=O), 1417, 
1257 (Si–C), 1087, 918 (Si–C); 1H NMR (300 MHz, CD3OD) δH 5.90 (2H, dddd, 
J 17.0, 10.3, 6.6, 6.6 Hz, 2 × =CH), 5.27-5.12 (4H, m, 2 × CH2=), 4.01 (1H, dd, J 10.7, 
5.2 Hz, OCHaHb), 3.92 (1H, dd, J 10.7, 6.8 Hz, OCHaHb), 3.47 (1H, dd, J 6.8, 5.2 Hz, 
CHN), 3.40 (4H, m, NCH2-allyl), 0.91 (9H, s, C(CH3)3), 0.08 (3H, s, SiCH3), 0.08 (3H, 
s SiCH3); 13C NMR (75 MHz, CD3OD) δC 178.3 (CO2H), 135.0 (2 × =CH), 
118.5 (2 × CH2=), 68.5 (CHN), 64.4 (OCH2), 55.5 (2 × NCH2-allyl), 26.5 (C(CH3)3), 
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19.2 (SiC), -5.1 (2 × SiCH3); HRMS m/z (ES+) calcd. for C15H30NO3Si [M+H]+ 
requires 300.1995, found 300.2004; m/z (ES+) 322 ([M+Na]+, 100%), 300 ([M+H]+, 
5%). 
 
7.4.4 - 
Methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-
phenylalaninate  232a 
 
 
 
Following GP1: Starting with (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-
propanoic acid (S)-230 (1.00 g, 3.34 mmol), L-phenylalanine methyl ester hydrochloride 
231a (1.44 g, 6.68 mmol), diisopropylethylamine (2.30 mL, 13.2 mmol) and 
T3P (50% w/w in ethyl acetate, 2.33 mL), the reaction yielded methyl (+)-N-[O-(tert-
butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-phenylalaninate  232a (1.25 g, 
2.71 mmol, 81%) as a colourless oil: Rf 0.35 (hexane:ethyl acetate, 90:10); [!]!!"  +15.0 (c 0.6, CHCl3); IR νmax (neat, cm-1) 3361 (NH), 2953, 1747 (C=O), 
1670 (C=O), 1496 (NH), 1093, 920 (Si–C); 1H NMR (400 MHz, CDCl3) δH 7.90 (1H, 
d, J 7.9 Hz, CONH), 7.28-7.08 (5H, m, 5 × Ar-H), 5.61 (2H, dddd, J 17.0, 10.4, 6.4, 
6.4 Hz, 2 × =CH), 5.14-5.04 (4H, m, 2 × CH2=), 4.80 (1H, dt, J 7.9, 6.2 Hz, Cα+1H), 
4.14 (1H, dd, J 11.1, 4.0 Hz, OCHaHb), 3.90 (1H, dd, J 11.1, 8.3 Hz, OCHaHb), 
3.71 (3H, s, OCH3), 3.53 (1H, dd, J 8.3, 4.0 Hz, CαH), 3.21 (4H, m, 2 × NCH2-allyl), 
3.17-3.02 (2H, m, CH2Ph), 0.86 (9H, s, C(CH3)3), 0.03 (3H, s, SiCH3), 0.03 (3H, s, 
SiCH3); 13C NMR (101 MHz, CDCl3) δC 172.1 (CONH), 171.9 (CO2CH3), 
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136.4 (Ar-C), 136.2 (2 × =CH), 129.3 (2 × Ar-CH), 128.6 (2 × Ar-CH), 127.1 (Ar-CH), 
117.3 (2 × CH2=), 63.9 (CαH), 61.3 (OCH2), 53.9 (2 × NCH2-allyl), 53.0 (Cα+1H), 
52.3 (OCH3), 38.1 (CH2Ph), 26.0 (C(CH3)3), 18.2 (SiC), -5.5 (SiCH3), -5.5 (SiCH3); 
HRMS m/z (ES+) calcd. for C25H40N2O4SiNa [M+Na]+ requires 483.2655, 
found 483.2643; m/z (ES+) 483 ([M+Na]+, 30%), 461 ([M+H]+, 100%). 
 
7.4.5 -  
Methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-alaninate 
232b 
 
 
 
Following GP1: Starting with (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-
propanoic acid (S)-230 (198 mg, 0.661 mmol), L-alanine methyl ester hydrochloride 
231b (185 mg, 1.32 mmol), diisopropylethylamine (460 µL, 2.64 mmol) and 
T3P (460 µL, 50% w/w in ethyl acetate), methyl (–)-N-[O-(tert-butyldimethyl)silyl-
N',N'-diallyl-(S)-seryl]-(S)-alaninate 232b (215 mg, 0.559 mmol, 85%) was isolated as 
a colourless oil: Rf 0.2 (hexane:ethyl acetate 90:10); [!]!!"  -7.5 (c 0.4, CHCl3); 
1H NMR (400 MHz, CDCl3) δH 7.94 (1H, d, J 7.6 Hz, CONH), 5.83 (2H, dddd, J 17.1, 
10.3, 6.8, 5.6 Hz, 2 × =CH), 5.24-5.13 (4H, m, 2 × CH2=), 4.54 (1H, dq, J 7.6, 7.2 Hz, 
Cα+1H), 4.17 (1H, dd, J 11.1, 4.1 Hz, OCHaHb), 3.97 (1H, dd, J 11.1, 7.6 Hz, OCHaHb), 
3.72 (3H, s, OCH3), 3.53 (1H, dd, J 7.6, 4.1 Hz, CαH), 3.39-3.29 (4H, m, 2 × NCH2), 
1.37 (3H, d, J 7.2 Hz, CHCH3), 0.89 (9H, s, C(CH3)3), 0.06 (6H, s, 2 × SiCH3); 
13C NMR (101 MHz, CDCl3) δC 173.5 (CONH), 171.8 (CO2CH3), 136.2 (2 × =CH), 
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117.5 (2 × CH2=), 64.1 (CαH), 61.3 (OCH2), 54.0 (2 × NCH2-allyl), 52.5 (OCH3), 
47.7 (Cα+1H), 25.9 (C(CH3)3), 18.7 (CHCH3), 18.2 (SiC), -5.4 (SiCH3), -5.5 (SiCH3); 
HRMS m/z (ES+) calcd. for C19H36N2O4NaSi [M+Na]+ requires 407.2342, 
found 407.2339; m/z (ES+) 407 ([M+Na]+, 50%), 385 ([M+H]+, 100%). 
 
7.4.6 -  
Methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-valinate  232c 
 
 
 
Following GP1: starting with (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-
propanoic acid (S)-230 (205 mg, 0.685 mmol), L-valine methyl ester hydrochloride 
231c (330 mg, 1.37 mmol), diisopropylethylamine (480 µL, 2.76 mmol) and 
T3P (480 µL, 50% w/w in ethyl acetate), the reaction yielded methyl (–)-N-[O-(tert-
butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-valinate  232c (224 mg, 0.590 mmol, 
79%) as a colourless oil: Rf 0.3 (hexane:ethyl acetate, 90:10); [!]!!"!-37.0 (c 0.8, 
CHCl3); IR νmax (neat, cm-1) 3365 (NH), 2954, 1745 (C=O), 1680 (C=O), 1496 (NH), 
920 (Si–C); 1H NMR (400 MHz, CDCl3) δH 8.01 (1H, d, J 9.3 Hz, CONH), 5.83 (2H, 
dddd, J 17.2, 10.2, 7.0, 4.8 Hz, 2 × =CH), 5.26-5.14 (4H, m, 2 × CH2=), 4.49 (1H, dd, 
J 9.3, 4.7 Hz, Cα+1H), 4.20 (1H, dd, J 11.1, 4.0 Hz, OCHaHb), 4.00 (1H, dd, J 11.1, 
8.0 Hz, OCHaHb), 3.75 (3H, s, OCH3), 3.59 (1H, dd, J 8.0, 4.0 Hz, CαH), 3.43-3.30 (4H, 
m, NCH2-allyl), 2.21-2.13 (1H, m, CH(CH3)2), 0.92-0.86 (15H, m, C(CH3)2 and 
C(CH3)3), 0.06 (6H, s, 2 × SiCH3); 13C NMR (101 MHz, CDCl3) δC 172.4 (CONH), 
172.0 (CO2CH3), 136.2 (2 × =CH), 117.4 (2 × CH2=), 64.0 (CαH), 61.3 (OCH2), 
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56.9 (Cα+1H), 54.0 (2 × NCH2-allyl), 52.1 (OCH3), 31.3 (CH), 26.0 (C(CH3)3), 
19.3 (CH3), 18.2 (SiC), 17.8 (CH3), -5.5 (SiCH3), -5.5 (SiCH3); HRMS m/z (ES+) calcd. 
for C21H40N2O4SiNa [M+Na]+ requires 435.2655, found 435.2654; 
m/z (ES+) 435 ([M+Na]+, 5%), 413 ([M+H]+, 100%). 
 
7.4.7 - 
Cyclo-(N,N-bisallyl-(S)-seryl-(S)-phenylalanine) 234 
 
 
 
Tetrabutylammonium fluoride (870 µL, 1 M in THF, 4.0 eq) was added dropwise to 
methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(S)-phenylalaninate 
232a (100 mg, 0.217 mmol, 1.0 eq) in dry THF (1.5 mL) and was stirred at rt for 2 h. 
The reaction was quenched by the addition of water (5 mL) followed by ethyl acetate 
(10 mL). The organic phases were washed successively with water (2 × 5 mL) and brine 
(10 mL), dried over Na2SO4 and the solvent removed in vacuo. The product was 
purified by silica gel column chromatography, eluting with ethyl acetate and hexane 
(20:80), to yield cyclo-(N,N-bisallyl-(S)-seryl-(S)-phenylalanine) 234 (18.4 mg, 
0.029 mmol, 27%) as a colourless solid: mp 170-172 ºC (ethyl acetate); [!]!!"  -83.9 (c 0.3, CH3OH); IR νmax (NaCl plate, cm-1) 3359 (NH), 3303, 2928, 
1716 (C=O), 1663 (C=O), 1551 (NH), 1261 (C–O–C); 1H NMR (400 MHz, 
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CDCl3) δH 7.31-7.14 (10H, m, 10 × Ar-H), 6.65 (2H, d, J 7.5 Hz, 2 × NH), 5.57 (4H, 
dddd, J 17.0, 10.4, 6.6, 5.7 Hz, 4 × =CH), 5.12-5.06 (8H, m, 4 × CH2=), 4.52 (2H, dd, 
J 11.1, 3.3 Hz, 2 × CHaHbCHN), 4.54-4.38 (2H, m, 2 × Cα+1H), 4.40 (2H, dd, J 11.1, 
6.2 Hz, 2 × CHaHbCHN), 3.39 (2H, dd, J 6.2, 3.3 Hz, 2 × CαH), 3.30 (2H, dd, J 14.3, 
4.8 Hz, 2 × CHaHbPh), 3.16 (2H, dd, J 14.3, 10.0 Hz, 2 × CHaHbPh), 3.10-3.05 (4H, m, 
4 × NCHaHb-allyl), 2.99-2.93 (4H, m, 4 × NCHaHb-allyl); 13C NMR (101 MHz, 
CDCl3) δC 170.6 (2 × CO2CH2), 170.1 (2 × CONH), 137.5 (2 × Ar C), 135.8 (4 × =CH), 
129.3 (4 × Ar CH), 128.8 (4 × Ar CH), 127.0 (2 × Ar CH), 117.9 (4 × CH2=), 
61.4 (2 × CαH), 60.1 (2 × CH2CHN), 53.9 (2 × Cα+1H), 53.7 (4 × NCH2-allyl), 
35.7 (2 × CH2Ph); HRMS m/z (ES+) calcd. for C36H44N4O6Na [M+Na]+ 
requires 651.3153, found 651.3154; m/z (ES+) 667 ([M+K]+, 40%), 651 ([M+Na]+, 
100%). 
 
7.4.8 -  
Methyl (+)-(N,N-bisallyl-(S)-seryl)-(S)-phenylalaninate  224a 
 
 
 
Following GP2: Starting with methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-
(S)-seryl]-(S)-phenylalaninate 232a (220 mg, 0.478 mmol), acetic acid (140 µL, 2.45 
mmol) and TBAF (1.88 mL, 1 M in THF), the reaction yielded methyl 
(+)-(N,N-bisallyl-(S)-seryl)-(S)-phenylalaninate 224a (121 mg, 0.349 mmol, 73%) as a 
colourless oil: Rf 0.10 (hexane:ethyl acetate, 70:30); [!]!!"  +28.1 (c 1.15, CHCl3); 
IR νmax (neat, cm-1) 3349 (OH), 2955, 1744 (C=O), 1659 (C=O), 1513, 1254, 1032; 
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1H NMR (500 MHz, CDCl3) δH 7.75 (1H, d, J 7.7 Hz, CONH), 7.31-7.09 (5H, m, 
5 × Ar-H), 5.57 (2H, dddd, J 17.3, 10.0, 7.5, 4.5 Hz, 2 × =CH), 5.16-5.10 (4H, m, 
2 × CH2=), 4.85 (1H, ddd, J 7.7, 7.3, 5.7 Hz, Cα+1H), 3.85 (1H, dd, J 11.2, 7.6 Hz, 
OCHaHb), 3.76 (3H, s, OCH3), 3.75 (1H, dd, J 11.2, 4.1 Hz, OCHaHb), 3.41 (1H, dd, 
J 7.6, 4.1 Hz, CαH), 3.25 (1H, dd, J 14.0, 5.7 Hz, CHaHbPh), 3.15-3.11 (3H, m, 
2 × NCHaHb-allyl and CH2OH), 3.06 (1H, dd, J 14.0, 7.3 Hz, CHaHbPh), 2.96-2.92 (2H, 
m, 2 × NCHaHb-allyl); 13C NMR (126 MHz, CDCl3) δC 174.3 (CONH), 
172.0 (CO2CH3), 135.9 (Ar-C), 135.5 (2 × =CH), 129.2 (2 × Ar-CH), 
128.8 (2 × Ar-CH), 127.3 (Ar-CH), 118.1 (2 × CH2=), 62.9 (CαH), 58.5 (OCH2), 
53.5 (2 × NCH2-allyl), 52.9 (Cα+1H), 52.6 (OCH3), 38.0 (CH2Ph); 
HRMS m/z (ES+) calcd. for C19H26N2O4Na [M+Na]+ requires 369.1790, 
found 369.1782; m/z (ES+) 369 ([M+Na]+, 100%). 
 
7.4.9 -  
Methyl (+)-(N,N-bisallyl-(S)-seryl)-(S)-alaninate  224b 
 
 
 
Following GP2: Starting with methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-
(S)-seryl]-(S)-alaninate 232b (195 mg, 0.507 mmol), acetic acid (150 µL, 2.62 mmol) 
and TBAF (2.10 mL, 1 M in THF), the reaction yielded methyl 
(+)-(N,N-bisallyl-(S)-seryl)-(S)-alaninate 224b (121 mg, 0.448 mmol, 88%) as a 
colourless oil: Rf 0.1 (hexane:ethyl acetate, 80:20); [!]!!"  +12.0 (c 0.7, CHCl3); 
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IR νmax (neat, cm-1) 3356 (OH/NH), 3076, 2981, 1743 (C=O), 1653 (C=O), 1521 (NH), 
1219, 1155; 1H NMR (400 MHz, CDCl3) δH 7.83 (1H, d, J 7.0 Hz, CONH), 5.79 (2H, 
dddd, J 17.3, 10.1, 7.3, 4.7 Hz, 2 × =CH), 5.27-5.17 (4H, m, 2 × CH2=), 4.57 (1H, dq, 
J 7.2, 7.0 Hz, Cα+1H), 3.95 (1H, dd, J 11.2, 7.7 Hz, OCHaHb), 3.84-3.81 (1H, dd, J 11.2, 
4.1 Hz, OCHaHb), 3.76 (3H, s, OCH3), 3.48 (1H, dd, J 7.7, 4.1 Hz, CαH), 3.41 (1H, br s, 
OH), 3.33-3.28 (2H, m, 2 × NCHaHb-allyl), 3.11-3.06 (2H, m, 2 × NCHaHb-allyl), 
1.42 (3H, d, J 7.2 Hz, CH3); 13C NMR (101 MHz, CDCl3) δC 174.1 (CONH), 
173.2 (CO2CH3), 135.4 (2 × =CH), 118.2 (2 × CH2=), 62.8 (CαH), 58.4 (OCH2), 
53.7 (2 × NCH2-allyl), 52.7 (OCH3), 47.8 (Cα+1H), 18.6 (CHCH3); 
HRMS m/z (ES+) calcd. for C13H22N2O4Na [M+Na]+ requires 293.1477, 
found 293.1471; m/z (ES+) 293 ([M+Na]+, 100%). 
 
7.4.10 -  
Methyl (+)-(N,N-bisallyl-(S)-seryl)-(S)-valinate  224c 
 
 
 
Following GP2: Starting with methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-
(S)-seryl]-(S)-valinate 232c (201 mg, 0.487 mmol), acetic acid (140 µL, 2.45 mmol) and 
TBAF (1.90 mL, 1 M in THF), the reaction yielded methyl 
(+)-(N,N-bisallyl-(S)-seryl)-(S)-valinate 224c (108 mg, 0.363 mmol, 75%) as a 
colourless oil: Rf 0.13 (hexane:ethyl acetate, 80:20); [!]!!"  +6.9 (c 0.5, CHCl3); 
IR νmax (neat, cm-1) 3361 (OH), 2960, 2821, 1741 (C=O), 1660 (C=O), 1500 (NH), 
1149; 1H NMR (300 MHz, CDCl3) δH 7.87 (1H, d, J 9.0 Hz, CONH), 5.80 (2H, dddd, 
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J 17.3, 10.1, 7.3, 4.4 Hz, 2 × =CH), 5.30-5.18 (4H, m, 2 × CH2=), 4.53 (1H, dd, J 9.0, 
4.7 Hz, Cα+1H), 3.99-3.83 (2H, m, CH2OH), 3.75 (3H, s, OCH3), 3.51 (1H, dd, J 7.5, 
4.1 Hz, CαH), 3.43 (1H, br s, OH), 3.39-3.32 (2H, m, 2 × NCHaHb-allyl), 3.13-3.06 (2H, 
m, 2 × NCHaHb-allyl), 2.21 (1H, qqd, J 6.9, 6.9, 4.7 Hz, CH(CH3)2), 0.94 (3H, d, 
J 6.9 Hz, CH3), 0.90 (3H, d, J 6.9 Hz, CH3); 13C NMR (75.0 MHz, 
CDCl3) δC 174.4 (CONH), 172.2 (CO2CH3), 135.4 (2 × =CH), 118.1 (2 × CH2=), 
63.1 (CαH), 58.5 (Cα+1H), 56.9 (OCH3), 53.6 (2 × NCH2-allyl), 52.3 (OCH2), 
31.3 (CH(CH3)2), 19.3 (CHCH3), 17.9 (CHCH3); HRMS m/z (ES+) C15H26N2O4Na 
[M+Na]+ requires 321.1790, found 321.1787; m/z (ES+) 321 ([M+Na]+, 100%). 
 
7.4.11 -  
Methyl (+)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-phenylalanate  227a & 
Methyl (+)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-phenylalanate  228a 
 
 
227a 
 
Following GP3: Starting with methyl (+)-(N,N-bisallyl-(S)-seryl)-(S)-phenylalaninate 
224a (181 mg, 0.522 mmol) and diethylaminosulfur trifluoride 32 (90.0 µL, 
0.682 mmol), to yield methyl (+)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-
phenylalanate 227a (78.1 mg, 0.224 mmol, 43%) as a colourless oil: 
Rf 0.24 (hexane:ethyl acetate, 7:3); [!]!!"  +69.8 (c 2.3, CHCl3); IR νmax (neat, 
cm-1) 3429 (NH), 3070, 2924, 1747 (C=O), 1676 (C=O), 1525 (NH), 1278, 1217; 
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1H NMR (500 MHz, CDCl3) δH 7.22-7.03 (5H, m, 5 × Ar-H), 6.94 (1H, br d, J 4.7 Hz, 
CONH), 5.71 (2H, dddd, J 17.0, 10.3, 6.5, 6.5 Hz, 2 × =CH), 5.11-5.05 (4H, m, 
2 × CH2=), 4.90 (1H, ddd, J 49.9, 7.1, 2.8 Hz, CHF), 4.83-4.79 (1H, m, Cα+1H), 
3.67 (3H, s, OCH3), 3.14-3.03 (6H, m, 2 × NCH2-allyl and CH2Ph), 2.94 (1H, ddd, 
J 30.1, 14.9, 2.8 Hz, CHaHbCHF), 2.84 (1H, ddd, J 23.9, 14.9, 7.1 Hz, CHaHbCHF); 
13C NMR (125 MHz, CDCl3) δC 171.5 (CO2CH3), 168.6 (d, J 20.0 Hz, CONH), 
135.6 (Ar-C), 135.1 (2 × =CH), 129.3 (2 × Ar-CH), 128.7 (2 × Ar-CH), 127.3 (Ar-CH), 
118.1 (2 × CH2=), 91.2 (d, J 187.8 Hz, CHF), 57.4 (Cα+1H), 54.5 (d, J 19.3 Hz, 
CH2CHF), 52.9 (2 × NCH2-allyl), 52.5 (OCH3), 38.0 (CH2Ph); 19F NMR (470 MHz, 
CDCl3) δF -190.7 (dddd, J 49.9, 30.1, 23.9, 4.0 Hz, CHF); HRMS m/z (ES+) calcd. for 
C19H25FN2O3Na [M+Na]+ requires 371.1747, found 371.1741; 
m/z (ES+) 371 ([M+Na]+, 100%).  
 
 
228a 
 
Further elution of the reaction mixture from the above preparation furnished methyl 
(+)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-phenylalanate  228a (68.8 mg, 
0.197 mmol, 38%) as a colourless oil: Rf 0.15 (hexane:ethyl acetate, 70:30); [!]!!"  +21.9 (c 2.8, CHCl3); IR νmax (neat, cm-1) 3360 (NH) , 2951, 1743 (C=O), 
1674 (C=O), 1496 (NH), 1201, 1006; 1H NMR (500 MHz, CDCl3) δH 7.75 (1H, d, 
J 7.7 Hz, CONH), 7.21-7.02 (5H, m, 5 × Ar-H), 5.53 (2H, dddd, J 17.4, 10.0, 7.5, 
4.6 Hz, 2 × =CH), 5.10-5.03 (4H, m, 2 × CH2=), 4.89-4.70 (3H, m, CH2F and Cα+1H), 
3.68 (3H, s, OCH3), 3.62 (1H, ddd, J 23.9, 6.7, 3.5 Hz, CH2FCαH), 3.17-2.99 (6H, m, 
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2 × NCH2-allyl and CH2Ph); 13C NMR (125 MHz, CDCl3) δC 172.0 (CO2CH3), 
170.1 (d, J 10.3 Hz, CONH), 135.9 (Ar-C), 135.4 (2 × =CH), 129.2 (2 × Ar-CH), 
128.7 (2 × Ar-CH), 127.2 (Ar-CH), 118.1 (2 × CH2=), 81.1 (d, J 171.1 Hz, CH2F), 
62.6 (d, J 18.9 Hz, CαH), 53.9 (2 × NCH2-allyl), 53.0 (Cα+1H), 52.5 (OCH3), 
37.9  (CH2Ph); 19F NMR (470 MHz, CDCl3) δF -227.1 (dt, J 47.2, 23.9 Hz, CH2F); 
HRMS m/z (ES+) calcd. for C19H25FN2O3Na [M+Na]+ requires 371.1747, 
found 371.1746; m/z  (ES+) 371 ([M+Na]+, 100%).  
 
7.4.12 -  
Methyl (+)-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-alaninate  227b &  
Methyl (–)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-alaninate  228b 
 
 
227b 
Following GP3: Starting with methyl (+)-(N,N-diallyl-(S)-seryl)-(S)-alaninate 224b 
(98.5 mg, 0.366 mmol) and diethylaminosulfur trifluoride 32 (65.9 mg, 54 µL, 0.409 
mmol), the reaction yielded methyl (+)-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-
alaninate  227b (18.9 mg, 69.4 µmol, 18%) as a colourless oil: Rf 0.34 (hexane:ethyl 
acetate, 80:20); ![!]!!"  +15.2 (c 1.8, CHCl3); 1H NMR (400 MHz, 
CDCl3) δH 7.03-7.02 (1H, br m, CONH), 5.83 (2H, dddd, J 17.0, 10.3, 6.6, 6.6 Hz, 
2 × =CH), 5.21-5.14 (4H, m, 2 × CH2=), 5.00 (1H, ddd, J 50.1, 7.2, 2.8 Hz, CHF), 
4.63-4.59 (1H, dq, J 7.2, 6.7 Hz, Cα+1H), 3.76 (3H, s, OCH3), 3.26-3.14 (4H, m, 
2 × NCH2-allyl), 3.05 (1H, ddd, J 30.7, 14.9, 2.8 Hz, CHaHbCHF), 2.94 (1H, ddd, 
J 24.0, 14.9, 7.2 Hz, CHaHbCHF), 1.45 (3H, d, J 7.2 Hz, CH3); 13C NMR (101 MHz, 
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CDCl3) δC 173.0 (CO2CH3), 168.6 (d, J 19.1 Hz, CONH), 135.2 (2 × =CH), 
118.2 (2 × CH2=), 91.4 (d, J 187.9 Hz, CHF), 57.6 (2 × NCH2-allyl), 54.7 (d, J 19.1 Hz, 
CH2), 52.7 (Cα+1H), 47.8 (OCH3), 18.5 (CH3); 19F NMR (376 MHz, 
CDCl3) δ -191.0 (dddd, J 50.1, 30.7, 24.0, 3.7 Hz, CHF); HRMS m/z (ES+) calcd. for 
C13H22FN2O3 [M+H]+ requires 273.1614, found 273.1621; m/z (ES+) 273 ([M+H]+, 
100%).  
 
228b 
 
Further elution of the reaction mixture from the above preparation furnished methyl         
(–)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-alaninate 228b (36.3 mg, 
0.133 mmol, 36%) as a colourless oil: Rf 0.20 (hexane:ethyl acetate, 
80:20); [!]!!" -1.7 (c 3.6, CHCl3); IR νmax (neat, cm-1) 3365 (NH), 2983, 1745 (C=O), 
1674 (C=O), 1500 (NH), 1450, 1157; 1H NMR (400 MHz, CDCl3) δH 7.88 (1H, d, 
J 7.2 Hz, CONH), 5.82 (2H, dddd, J 17.3, 10.1, 7.3, 4.9 Hz, 2 × =CH), 5.28-5.18 (4H, 
m, 2 × CH2=), 4.96 (1H, ddd, J 46.7, 10.3, 3.5 Hz, CHaHbF), 4.90 (1H, ddd, J 47.8, 
10.3, 6.6 Hz, CHaHbF), 4.56 (1H, dq, J 7.2, 7.2 Hz, Cα+1H), 3.75 (3H, s, OCH3), 
3.74 (1H, ddd, J 23.8, 6.6, 3.5 Hz, CH2FCαH), 3.41-3.19 (4H, m, 2 × NCH2-allyl) 
1.39 (3H, d, J 7.2 Hz, CH3); 13C NMR (101 MHz, CDCl3) δC 173.3 (CO2CH3), 
169.9 (d, J 16.1 Hz, CONH), 135.3 (2 × =CH), 118.2 (2 × CH2=), 81.1 (d, J 170.8 Hz, 
CH2F), 62.5 (d, J 19.1 Hz, CαH), 54.0 (2 × NCH2-allyl), 52.6 (Cα+1H), 47.8 (OCH3), 
18.6 (CH3); 19F NMR (376 MHz, CDCl3) δF -228.9 (ddd, J 47.8, 46.7, 23.8 Hz, CH2F); 
HRMS m/z (ES+) calcd. for C13H22FN2O3 [M+H]+ requires 273.1614, found 273.1612; 
m/z (ES+) 273 ([M+H]+, 100%). 
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7.4.13 - 
Methyl (+)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-valinate  227c & 
Methyl (+)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-valinate  228c 
 
 
227c 
 
Following GP3: Starting with methyl (+)-(N,N-bisallyl-(S)-seryl)-(S)-valinate 224c 
(136 mg, 0.455 mmol) and diethylaminosulfur trifluoride (65.0 µL, 0.492 mmol), to 
yield methyl (+)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-(S)-valinate  
227c (12.7 mg, 42.3 µmol, 12%) as a colourless oil: Rf 0.50 (hexane:ethyl acetate, 
80:20); [!]!!" +24.1 (c 1.3, CHCl3); 1H NMR (400 MHz, CDCl3) δH 6.97 (1H, br d, 
J 5.3 Hz, CONH), 5.83 (2H, dddd, J 17.0, 10.3, 6.6, 6.6 Hz, 2 × =CH), 5.21-5.14 (4H, 
m, 2 × CH2=), 5.04 (1H, ddd, J 50.1, 7.0, 2.8 Hz, CHF), 4.56 (1H, dd, J 8.9, 5.3 Hz, 
Cα+1H), 3.75 (3H, s, OCH3), 3.26-3.14 (4H, m, 2 × NCH2-allyl), 3.05 (1H, ddd, J 29.4, 
14.9, 2.8 Hz, CHaHbCHF), 2.95 (1H, ddd, J 24.9, 14.9, 7.0 Hz, CHaHbCHF), 
2.24-2.16 (1H, m, CH(CH3)2), 0.95 (3H, d, J 6.9 Hz, CH3), 0.93 (3H, d, J 6.9 Hz, CH3); 
13C NMR (101 MHz, CDCl3) δC 172.0 (CO2CH3), 169.0 (d, J 19.1 Hz, CONH), 
135.2 (2 × =CH), 118.2 (2 × CH2=), 91.5 (d, J 187.9 Hz, CHF), 57.6 (2 × NCH2-allyl), 
56.9 (Cα+1H), 54.6 (d, J 19.1 Hz, CH2CHF), 52.4 (OCH3), 31.5 (CH(CH3)2), 19.1 (CH3), 
17.9 (CH3); 19F NMR (376 MHz, CDCl3) δF -190.8 (dddd, J 50.1, 29.4, 24.9, 4.3 Hz, 
CHF); HRMS m/z (ES+) calcd. for C15H26FN2O3 [M+H]+ requires 301.1927, 
found 301.1925; m/z (ES+) 301 ([M+H]+, 100%).  
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228c 
 
Further elution provided methyl (+)-N-[(2R)-2-(diallylamino)-3-fluoropropanoyl]-(S)-
valinate  228c (50.8 mg, 0.169 mmol, 35%) as a colourless oil: Rf 0.4 (hexane:ethyl 
acetate, 80:20);![!]!!"  +2.1 (c 5.0, CHCl3); IR νmax (neat, cm-1) 3367 (NH), 2962, 
1741 (C=O), 1680 (C=O), 1500 (NH), 1149,; 1H NMR (400 MHz, CDCl3) δH 7.91 (1H, 
br d, J 9.2 Hz, CONH), 5.83 (2H, dddd, J 17.3, 10.2, 7.3, 4.6 Hz, 2 × =CH), 
5.30-5.19 (4H, m, 2 × CH2=), 4.96 (1H, ddd, J 46.8, 10.3, 3.5 Hz, CHaHbF), 4.92 (1H, 
ddd, J 47.8, 10.3, 6.3 Hz, CHaHbF), 4.53 (1H, dd, J 9.2, 4.6 Hz, Cα+1H), 3.74 (1H, ddd, 
J 24.8, 6.3, 3.5 Hz, CH2FCαH), 3.74 (3H, s, OCH3), 3.45-3.39 (2H, m, 
2 × NCHaHb-allyl), 3.25-3.20 (2H, m, 2 × NCHaHb-allyl), 2.25-2.15 (1H, m, 
CH(CH3)2), 0.92 (3H, d, J 6.9 Hz, CHCH3), 0.87 (3H, d, J 6.9 Hz, CHCH3); 
13C NMR (101 MHz, CDCl3) δC 172.3 (CO2CH3), 170.2 (d, J 10.1 Hz, CONH), 
135.3 (2 × =CH), 118.2 (2 × CH2=), 81.1 (d, J 171.5 Hz, CH2F), 62.8 (d, J 11.1 Hz, 
CH2FCαH), 56.9 (Cα+1H), 53.9 (2 × NCH2-allyl), 52.3 (OCH3), 31.3 (CH(CH3)2), 
19.2 (CH3), 17.7 (CH3); 19F NMR (376 MHz, CDCl3) δF -227.6 (ddd, J 47.8, 46.8, 
24.8 Hz, CH2F); HRMS m/z (ES+) calcd. for C15H26FN2O3 [M+H]+ requires 301.1927, 
found 301.1921; m/z (ES+) 301 ([M+H]+, 100%).  
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7.4.14 -  
(–)-(2S)-3-[(tert-Butyldimethylsilyl)oxy]-2-(diallylamino)-N-methyl-N-[(S)-1-
phenylethyl]propanamide  240a 
 
 
 
Following GP1: Starting with (2S)-3-[(tert-butyldimethylsilyl)oxy]-2-diallylamino-
propanoic acid (S)-230 (205 mg, 0.685 mmol), (S)-(–)-N,α-dimethylbenzylamine 
(188 mg, 200 µL, 1.39 mmol), diisopropylethylamine (450 µL, 2.58 mmol) and 
T3P (470 µL, 50% w/w ethyl acetate), the reaction yielded (–)-(2S)-3-[(tert-
butyldimethylsilyl)oxy]-2-(diallylamino)-N-methyl-N-[(S)-1-phenylethyl]propanamide 
240a (231 mg, 0.561 mmol, 82%) as a colourless oil: Rf 0.25 (hexane:ethyl acetate, 
90:10); [!]!!" -87.0 (c 1.3, CHCl3); IR νmax (neat, cm-1) 2927, 2854, 1635 (C=O), 1404, 
1095, 920 (Si–C); 1H NMR (400 MHz, CDCl3) δH (major rotamer) 7.34-7.21 (5H, m, 
5 × Ar-H), 6.07 (1H, q, J 7.1 Hz, Cα+1H), 5.84-5.73 (2H, m, 2 × =CH), 5.18-5.03 (4H, 
m, 2 × CH2=), 4.07 (1H, dd, J 9.5, 7.6 Hz, OCHaHb), 3.91 (1H, dd, J 9.5, 5.4 Hz, 
OCHaHb), 3.84 (1H, dd, J 7.6, 5.4 Hz, CαH), 3.32-3.28 (4H, m, 2 × NCH2-allyl), 
2.70 (3H, s, NCH3), 1.44 (3H, d, J 7.1 Hz, CHCH3), 0.85 (9H, s, C(CH3)3), 0.05 (3H, s, 
SiCH3), 0.03 (3H, s, SiCH3); 13C NMR (101 MHz, CDCl3) δC 172.0 (CONH), 
140.8 (Ar-C), 137.2 (2 × =CH), 128.4 (2 × Ar-CH), 127.5 (2 × Ar-CH), 117.5 (Ar-CH), 
116.9 (2 × CH2=), 62.1 (CH2), 60.9 (CαH), 54.0 (2 × NCH2-allyl), 50.3 (Cα+1H), 
29.6 (NCH3), 26.0 (C(CH3)3), 18.4 (SiC), 15.7 (CHCH3), -5.3 (SiCH3), -5.4 (SiCH3); 
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HRMS m/z (ES+) calcd. for C24H41N2O2Si [M+H]+ requires 417.2937, found 417.2941; 
m/z (ES+) 417 ([M+H]+, 100%). 
 
7.4.15 -  
(–)-(2S)-3-[(tert-Butyldimethylsilyl)oxy]-2-(diallylamino)-N-[(S)-1-
phenylethyl]propanamide  240b 
 
 
 
Following GP1: Starting with (2S)-3-[(tert-butyldimethylsilyl)oxy]-2-bisallylamino-
propanoic acid (S)-230 (104 mg, 0.347 mmol), (S)-(-)-α-methylbenzylamine (85.0 µL, 
0.668 mmol), diisopropylethylamine (230 µL, 1.34 mmol) and T3P (390 µL, 
50% w/w in ethyl acetate), the reaction yielded (–)-N′-α-(S)-methylbenzyl-((2S)-N,N-
bisallylamino-3-(tert-butyldimethylsilyloxy)) propanamide 240b (109 mg, 0.270 mmol, 
78%) as a colourless oil: Rf 0.5 (hexane:ethyl acetate, 80:20); [!]!!"  -50.3 (c 1.0, 
CHCl3); IR νmax (neat, cm-1) 3365 (NH), 2953, 1747 (C=O), 1674 (C=O), 1498 (NH), 
1259, 920 (Si–C); 1H NMR (400 MHz, CDCl3) δH 7.73 (1H, d, J 8.0 Hz, CONH), 
7.33-7.20 (5H, m, 5 × Ar-H), 5.81-5.71 (2H, m, 2 × =CH), 5.18-5.08 (4H, m, 
2 × CH2=), 5.02 (1H, dq, J 8.0, 6.9 Hz, Cα+1H), 4.20 (1H, dd, J 11.1, 4.2 Hz, OCHaHb), 
3.98 (1H, dd, J 11.1, 7.8 Hz, OCHaHb), 3.51 (1H, dd, J 7.8, 4.2 Hz, CαH), 
3.36-3.27 (4H, m, 2 × NCH2-allyl), 1.42 (3H, d, J 6.9 Hz, CHCH3), 0.88 (9H, s, 
C(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (101 MHz, 
CDCl3) δC 171.2 (CONH), 143.6 (Ar-C), 136.2 (2 × =CH), 128.7 (2 × Ar-CH), 
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127.3 (Ar-CH), 126.1 (2 × Ar-CH), 117.5 (2 × CH2=), 64.1 (CαH), 61.5 (OCH2), 
54.0 (2 × NCH2-allyl), 48.4 (Cα+1H), 26.0 (C(CH3)3), 22.5 (CH3), 
18.2 (SiC), -5.4 (SiCH3), -5.5 (SiCH3); HRMS m/z (ES+) C23H39N2O2Si [M+H]+ 
403.2781, found 403.2787; m/z (ES+) 425 ([M+Na]+, 30%), 403 ([M+H]+, 100%). 
 
7.4.16 -  
(–)-(2S)-2-(Diallylamino)-3-hydroxy-N-methyl-N-[(S)-1-phenylethyl]propanamide  
241a  
 
 
 
Following GP2: Starting with (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-
(diallylamino)-N-methyl-N-[(S)-1-phenylethyl]propanamide 240a (102 mg, 
0.245 mmol), acetic acid (60.0 µL, 1.00 mmol) and TBAF (1.00 mL, 1 M in THF), the 
reaction yielded (–)-(2S)-2-(diallylamino)-3-hydroxy-N-methyl-N-[(S)-1-
phenylethyl]propanamide  241a (58 mg, 0.192 mmol, 78%) as a colourless oil: 
Rf 0.15 (hexane:ethyl acetate, 80:20); [!]!!"  -54.2 (c 0.8, CHCl3); IR νmax (neat, 
cm-1) 3419 (OH), 2926, 1630 (C=O), 1404, 1282, 1122, 995; 1H NMR (500 MHz, 
CDCl3) δH (major rotamer) 7.31-7.17 (5H, m, 5 × Ar-H), 5.98 (1H, q, J 7.1 Hz, Cα+1H), 
5.74-5.61 (2H, m, 2 × =CH), 5.15-5.11 (4H, m, 2 × CH2=), 3.94 (1H, dd, J 10.9, 6.9 Hz, 
CαH), 3.76-3.70 (2H, m, CH2OH), 3.41 (1H, br s, CH2OH), 3.32 (2H, m, 
2 × NCHaHb-allyl), 3.17 (2H, m, 2 × NCHaHb-allyl), 2.70 (3H, s, OCH3), 1.41 (3H, d, 
J 7.1 Hz, CH3); 13C NMR (126 MHz, CDCl3) δC 172.5 (CONH), 140.2 (Ar-C), 
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136.1 (2 × =CH), 128.8 (2 × Ar-CH), 127.5 (2 × Ar-CH), 118.4 (Ar-CH), 
117.8 (2 × CH2=), 60.8 (CαH), 58.0 (OCH2), 53.8 (2 × NCH2-allyl), 50.7 (Cα+1H), 
29.7 (NCH3), 15.7 (CH3); HRMS m/z (ES+) calcd. for C18H26N2O2Na [M+Na]+ requires 
325.1892, found 325.1885; m/z (ES+) 325 ([M+Na]+, 100%).  
 
7.4.17 -  
(–)-(2S)-2-(Diallylamino)-3-hydroxy-N-[(S)-1-phenylethyl]propanamide  241b 
 
 
 
Following GP2: Starting with (–)-(2S)-3-[(tert-butyldimethylsilyl)oxy]-2-
(diallylamino)-N-[(S)-1-phenylethyl]propanamide 240b (93 mg, 0.231 mmol), acetic 
acid (66 µL, 1.16 mmol) and TBAF (900 µL, 1 M in THF), the reaction yielded                
(–)-(2S)-2-(diallylamino)-3-hydroxy-N-[(S)-1-phenylethyl]propanamide 241b (51.0 mg, 
0.180 mmol, 77%) as a colourless oil: Rf 0.11 (hexane:ethyl acetate, 80:20); [!]!!"  -25.2 (c 0.7, CHCl3); IR νmax (neat, cm-1) 3325 (OH/NH), 3064, 2926, 
1647 (C=O), 1521 (NH), 1494, 1280, 1128, 993; 1H NMR (300 MHz, 
CDCl3) δH (major rotamer) 7.63 (1H, d, J 7.8 Hz, CONH), 7.35-7.22 (5H, m, 5 × Ar-H), 
5.74 (2H, dddd, J 17.3, 10.1, 7.3, 4.6 Hz, 2 × =CH), 5.23-5.12 (4H, m, 2 × CH2=), 
5.06 (1H, dq, J 7.8, 6.9 Hz, Cα+1H), 3.94 (1H, dd, J 11.1, 7.9 Hz, OCHaHb), 3.79 (1H, 
dd, J 11.1, 3.9 Hz, OCHaHb), 3.58 (1H, br s, OH), 3.42 (1H, dd, J 7.9, 3.9 Hz, CαH), 
3.34-3.26 (2H, m, 2 × NCHaHb-allyl), 3.08-3.01 (2H, m, 2 × NCHaHb-allyl), 1.45 (3H, 
d, J 6.9 Hz, CH3); 13C NMR (75 MHz, CDCl3) δC 173.6 (CONH), 143.1 (Ar-C), 
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135.4 (2 × =CH), 128.9 (2 × Ar-CH), 127.5 (Ar-CH), 126.0 (2 × Ar-CH), 
118.1 (2 × CH2=), 62.7 (CαH), 58.2 (OCH3), 53.7 (2 × CH2-allyl), 48.5 (Cα+1H), 
22.4 (CH3); HRMS m/z (ES+) calcd. for C17H24N2O2Na [M+Na]+ requires 311.1735, 
found 311.1739; m/z (ES+) 311 ([M+Na]+, 100%), 289 ([M+H]+, 20%). 
 
7.4.18 -  
(–)-(2R)-3-(Diallylamino)-2-fluoro-N-methyl-N-[(1S)-1-phenylethyl]propanamide  
242a 
 
 
 
Following GP3: Starting with (–)-(2S)-2-(diallylamino)-3-hydroxy-N-methyl-N-[(S)-1-
phenylethyl]propanamide 241a (50.0 mg, 0.165 mmol) and diethylaminosulfur 
trifluoride 32 (25 µL, 0.189 mmol), to yield (–)-(2R)-3-(diallylamino)-2-fluoro-N-
methyl-N-[(1S)-1-phenylethyl]propanamide  242a (41.0 mg, 0.135 mmol, 81%) as a 
colourless oil: Rf  0.09 (hexane:ethyl acetate, 90:10); [!]!!"  -125 (c 1.8, CHCl3); 
1H NMR (400 MHz, CDCl3) δH (major rotamer) 7.32-7.18 (5H, m, 5 × Ar-H), 
5.96 (1H, qq, J 7.1, 1.6 Hz, Cα+1H), 5.83-5.70 (2H, m, 2 × =CH), 5.48-5.23 (1H, m, 
CHF), 5.16-5.03 (4H, m, 2 × CH2=), 3.20-3.10 (4H, m, 2 × NCH2-allyl), 3.04-2.90 (2H, 
m, CH2CHF), 2.63 (3H, d, J 1.6 Hz, NCH3), 1.43 (3H, d, J 7.1 Hz, CH3); 
13C NMR (101 MHz, CDCl3) δC 168.2 (d, J 20.0 Hz, CONH), 139.9 (Ar-C), 
135.3 (2 × =CH), 128.6 (2 × Ar-CH), 127.5 (2 × Ar-CH), 126.8 (Ar-CH), 
118.2 (2 × CH2=), 89.0 (d, J 181.3 Hz, CαHF), 57.9 (2 × NCH2-allyl), 54.4 (d, 
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J 21.9 Hz, CH2CHF), 51.0 (Cα+1H), 28.5 (NCH3), 15.5 (CH3); 19F NMR (376 MHz, 
CDCl3) δF -184.5 (ddd, J 50.3, 28.9, 21.0 Hz, CHF-minor), -186.8 (ddd, J 49.3, 28.3, 
20.6 Hz, CHF-major); HRMS m/z (ES+) calcd. for C18H25FN2O3Na [M+Na]+ requires 
327.1849, found 327.1844; m/z (ES+) 327 ([M+Na]+, 100%), 305 ([M+Na]+, 30%). 
 
7.4.19 -  
Methyl (+)-(2S)-N-allyl-phenylalanine[232]  247 
 
 
 
Allyl bromide (1.0 mL, 12 mmol, 2.5 eq) was added to a solution of L-phenylalanine 
methyl ester hydrochloride 231a (1.00 mg, 4.6 mmol, 1.0 eq) and 
diisopropylethylamine (2.80 mL, 16 mmol, 3.5 eq) in DMF (15 mL) at 0 ºC. The 
solution was slowly warmed to rt and stirred for 48 h and quenched by the addition of 
water (10 mL) and the organics extracted with ether (3 × 20 mL). The organics were 
combined, washed with brine (20 mL), dried over Na2SO4, filtered and the solvent 
remove in vacuo. The product was purified by silica gel chromatography eluting with 
ethyl acetate, hexane and triethylamine (8:2 with 5% triethylamine), to yield methyl 
(2S)-N-allyl-phenylalaninate 247 (385 mg, 1.76 mmol, 38%) as a colourless oil: [!]!!" +23.2 (c 1.0, CH3OH) [Lit.[233] [!]!!" +23 (c 1.0, CH3OH)]; 1H NMR (300 MHz, 
CDCl3) δH 7.32-7.09 (5H, m, 5 × Ar-H), 5.80 (1H, dddd, J 17.2, 10.2, 6.0, 6.0 Hz, 
=CH), 5.15-5.04 (2H, m, CH2=), 3.64 (3H, s, OCH3), 3.56 (1H, t, J 6.9 Hz, CH2CHN), 
3.26 (1H, dddd, J 13.9, 6.0, 1.5, 1.5 Hz, NCHaHb-allyl), 3.11 (1H, dddd, J 13.9, 6.0, 1.4, 
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1.4 Hz, NCHaHb-allyl), 2.96 (2H, d, J 6.9 Hz, CH2Ph), 1.74 (1H, br s, NH); m/z (ES+) 
242 ([M+Na]+, 60%), 220 ([M+H]+, 100%).  
 
7.4.20 -  
Methyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-diallyl-(S)-seryl]-N-allyl-(S)-
phenylalaninate  248 
 
 
 
tBu P4 phosphazene 255 (1 M in hexanes, 1.00 mL, 1.00 mmol, 0.93 eq) was gradually 
added dropwise to a solution of methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-
(S)-seryl]-(S)-phenylalaninate 232a (500 mg, 1.09 mmol, 1.0 eq) and allyl 
bromide (500 µL, 5.79 mmol, 5.3 eq) in THF (15 mL) at -100 ºC. The resulting mixture 
was gradually warmed to -78 ºC and stirred at this temperature for 20 h before being 
diluted with ethyl acetate (10 mL) and washed with HCl (1 M, 2 × 10 mL). The organic 
fractions were dried over Na2SO4, filtered and the solvent removed in vacuo. The 
reaction mixture was purified by silica gel column chromatography, eluting with hexane 
and ethyl acetate (90:10), to yield methyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-
diallyl-(S)-seryl]-N-allyl-(S)-phenylalaninate 248 (286 mg, 0.57 mmol, 53%) as a 
colourless oil: Rf 0.10 (hexane:ethyl acetate, 90:10); [!]!!"  -102.3 (c 2.3, CHCl3); 
IR νmax (neat, cm-1) 2951, 2856, 1747 (C=O), 1670 (C=O), 1259, 1093, 920 (Si–C); 
1H NMR (300 MHz, CDCl3) δH (major rotamer) 7.30-7.17 (5H, m, 5 × Ar-H), 
5.79-5.67 (2H, m, 2 × =CH), 5.66-5.58 (1H, m, =CH), 5.17-5.06 (4H, m, 2 × CH2=), 
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5.09-4.96 (2H, m, CH2=), 4.19 (1H, dd, J 9.6, 5.4 Hz, Cα+1H), 4.06-3.88 (4H, m, 
OCH2 and N′CH2-allyl), 3.71-3.67 (1H, m, CαH), 3.64 (3H, s, OCH3), 3.40-3.08 (6H, m, 
2 × NCH2-allyl and CH2Ph), 0.91 (9H, s, C(CH3)3), 0.10 (3H, s, SiCH3), 0.08 (3H, s, 
SiCH3); 13C NMR (101 MHz, CDCl3) δC 171.4 (CONH), 171.3 (CO2CH3), 
138.5 (Ar-C), 136.7 (2 × =CH), 134.5 (=CH), 129.6 (2 × Ar-CH), 128.6 (2 × Ar-CH), 
126.6 (Ar-CH), 118.0 (CH2=), 117.5 (2 × CH2=), 61.3 (CαH), 60.4 (Cα+1H), 
59.9 (OCH2), 53.6 (2 × NCH2-allyl), 52.0 (OCH3), 51.3 (N′CH2-allyl), 34.9 (CH2Ph), 
26.1 (C(CH3)3), 18.5 (SiC), -5.2 (SiCH3), -5.3 (SiCH3); HRMS m/z (ES+) calcd. for 
C28H44N2O4SiNa [M+Na]+ requires 523.2968, found 523.2969; 
m/z (ES+) 523 ([M+Na]+, 100%), 501 ([M+H]+, 80%).  
 
7.4.21 - 
Methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(R,S)-a-allyl-
phenylalaninate  254 
 
 
 
Potassium hexamethyldisilazide (1 M soln. in THF, 0.1 mL, 0.10 mmol, 0.90 eq) was 
added dropwise to a solution of methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-
(S)-seryl]-(S)-phenylalaninate 232a (50 mg, 0.11 mmol, 1.0 eq) and allyl 
bromide (50 µL, 0.58 mmol, 5.3 eq) in dry THF (2.5 mL) at -78 ºC. The resulting 
mixture was stirred at -78 ºC for 20 h before being diluted with ethyl acetate (5 mL) and 
washed with HCl (1 M, 2 × 5 mL). The organic fractions were dried over Na2SO4, 
filtered and the solvent removed in vacuo. The reaction mixture was purified by silica 
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gel column chromatography, eluting with hexane and ethyl acetate (90:10), to yield 
methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-(R,S)-a-allyl-
phenylalaninate 254 (27.1 mg, 0.31 mmol, 53%) as a colourless oil: [!]!!"  -21.4 (1:1 mix of diastereoisomers, c 2.7, CHCl3); 1H NMR (400 MHz, 
CDCl3) δH (diastereoisomer A) 8.45 (1H, s, CONH), 7.25-6.98 (5H, m, 5 × Ar-H), 
5.63-5.51 (3H, m, 3 × =CH), 5.10-4.99 (6H, m, 3 × CH2=), 4.28 (1H, dd, J 11.0, 4.1 Hz, 
OCHaHb), 3.99 (1H, dd, J 11.0, 9.1 Hz, OCHaHb), 3.76 (3H, s, OCH3), 3.73 (1H, d, 
J 13.4 Hz, CHaHbPh), 3.57 (1H, dd, J 9.1, 4.1 Hz, CαH), 3.44-3.06 (6H, m, CHaHbPh, 
2 × NCH2-allyl and NCHaHb-allyl), 2.66-2.61 (1H, m, NCHaHb-allyl), 0.92 (9H, s, 
C(CH3)3), 0.10 (6H, s, 2 × SiCH3); δH (diastereomer B) 8.39 (1H, s, NH), 7.25-6.98 (5H, 
m, 5 × Ar-H), 5.63-5.51 (3H, m, 3 × =CH), 5.10-4.99 (6H, m, 3 × CH2=), 4.28 (1H, dd, 
J 11.0, 4.1 Hz, OCHaHb), 3.93 (1H, dd, J 11.0, 9.1 Hz, OCHaHb), 3.79 (3H, s, OCH3), 
3.67 (1H, d, J 13.4 Hz, CHaHbPh), 3.56 (1H, dd, J 9.1, 4.1 Hz, CαH), 3.44-3.06 (6H, m, 
CHaHbPh, 2 × NCH2-allyl and NCHaHb-allyl), 2.61-2.56 (1H, m, NCHaHb-allyl), 
0.92 (9H, s, C(CH3)3), 0.10 (6H, s, 2 × SiCH3); 13C NMR (75 MHz, 
CDCl3) δC (diastereoisomer A) 173.3 (CONH), 171.5 (CO2CH3), 136.8 (2 × =CH), 
136.6 (Ar-C), 132.6 (=CH), 129.8 (2 × Ar-CH), 128.3 (2 × Ar-CH), 127.0 (Ar-CH), 
119.1 (CH2=), 117.5 (2 × CH2=), 65.9 (Cα+1), 63.6 (CαH), 61.4 (OCH2), 
54.1 (2 × NCH2-allyl), 52.6 (OCH3), 40.6 (CH2Ph), 39.6 (NCH2-allyl), 26.1 (C(CH3)3), 
18.3 (SiC), -5.4(8) (SiCH3), -5.4(3) (SiCH3); δC (diastereoisomer B) 173.1 (CONH), 
171.4 (CO2CH3), 136.7 (2 × =CH), 136.5 (Ar-C), 132.4 (=CH), 129.7 (2 × Ar-CH), 
128.3 (2 × Ar-CH), 126.9 (Ar-CH), 118.9 (CH2=), 117.3 (2 × CH2=), 65.5 (Cα+1), 
63.6 (CαH), 61.1 (OCH2), 53.9 (2 × NCH2-allyl), 52.5 (OCH3), 40.5 (CH2Ph), 
39.5 (NCH2-allyl), 26.1 (C(CH3)3), 18.3 (SiC), -5.4(8) (SiCH3), -5.4(3) (SiCH3); 
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HRMS m/z (ES+) calcd. for C28H45N2O4Si [M+H]+ requires 501.3149, found 501.3153; 
m/z (ES+) 523 ([M+Na]+, 100%), 501 ([M+H]+, 70%).  
 
7.4.22 -  
Methyl (–)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-dibenzylglycinate  
256,  Methyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-diallyl-(S)-seryl]-N-benzyl-
(S)-phenylalaninate   257 & Benzyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-diallyl-
(S)-seryl]-(S)-phenylalaninate  258 
 
 
256 
 
P4 phosphazene 255 (1 M soln. in hexanes, 0.10 mL, 1.00 mmol, 0.90 eq) was added 
dropwise to a solution of methyl (+)-N-[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-
seryl]-(S)-phenylalaninate 232a (50.0 mg, 0.11 mmol, 1.0 eq) and benzyl 
bromide (50 µL, 0.58 mmol, 5.3 eq) in THF (2 mL) at -78 ºC. The resulting mixture was 
stirred at -78 ºC for 20 h before being diluted with ethyl acetate (5 mL) and washed with 
HCl (1 M, 2 × 5 mL). The organic fractions were dried over Na2SO4, filtered and the 
solvent removed in vacuo. The reaction mixture was purified by silica gel column 
chromatography, eluting with hexane and ethyl acetate (90:10), to yield methyl (–)-N-
[O-(tert-butyldimethyl)silyl-N',N'-diallyl-(S)-seryl]-dibenzylglycinate 256 (12.0 mg, 
0.22 µmol, 20%) as a colourless oil: [!]!!" -19.8 (c 0.8, CHCl3); 1H NMR (500 MHz, 
CDCl3) δH 8.43 (1H, s, NH), 7.39-7.00 (10H, m, 10 × Ar-H), 5.31-5.23 (2H, m, 
2 × =CH), 4.93-4.89 (4H, m, 2 × CH2=), 4.35 (1H, dd, J 11.0, 4.0 Hz, OCHaHb), 
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3.96-3.93 (1H, dd, J 11.0, 9.5 Hz, OCHaHb), 3.94 (2H, AB, J 13.5 Hz, CH2Ph), 
3.79 (3H, s, OCH3), 3.55 (1 H, dd, J 9.5, 4.0 Hz, CαH), 3.30 (1H, AB, J 13.5 Hz, 
CHaHbPh), 3.19 (1H, AB, J 13.3, CHaHbPh), 3.05-2.92 (4H, m, 2 × NCH2-allyl), 
0.9 (9H, s, C(CH3)3), 0.13 (3H, s, SiCH3), 0.12 (3H, s, SiCH3); 13C NMR (126 MHz, 
CDCl3) δC 172.9 (CONH), 171.7 (CO2CH3), 136.7 (Ar-C), 136.7 (Ar-C), 
136.5 (2 × =CH), 129.7 (2 × Ar-CH), 129.7 (2 × Ar-CH), 128.3 (2 × Ar-CH), 
128.3 (2 × Ar-CH), 127.1 (Ar-CH), 126.9 (Ar-CH), 117.3 (2 × CH2=), 67.4 (Cα+1), 
63.4 (CαH), 61.2 (CH2), 53.8 (2 × NCH2-allyl), 52.5 (OCH3), 41.2 (CH2Ph), 
40.9 (CH2Ph), 26.1 (C(CH3)3), 18.3 (SiC), -5.3 (SiCH3), -5.4 (SiCH3); 
HRMS m/z (ES+) calcd. for C32H46N2O4SiNa [M+Na]+ requires 573.3125, 
found 573.3117; m/z (ES+) 573 ([M+Na]+, 100%).  
 
 
257 
 
Further separation of the material enabled the isolation of methyl (–)-N-[O-(tert-
butyldimethylsilyl)-N',N'-diallyl-(S)-seryl]-N-benzyl-(S)-phenylalaninate 257 (11.0 mg, 
20 µmol, 18%) as a colourless oil: [!]!!" -80.1 (c 0.7, CHCl3); 1H NMR (500 MHz, 
CDCl3) δH 7.30-7.00 (10H, m, 10 × Ar-H), 5.71 (2H, dddd, J 17.2, 10.0, 7.4, 5.5 Hz, 
2 × =CH), 5.20-5.03 (4H, m, 2 × CH2=), 4.60 (1H, AB, J 15.6 Hz, N′CHaHbPh), 
4.13 (1H, dd, J 9.5, 7.5 Hz, OCHaHb), 4.06 (1H, dd, J 7.7, 6.5 Hz, Cα+1H), 4.01 (1H, 
AB, J 15.6 Hz, N′CHaHbPh), 3.93 (1H, dd, J 9.5, 5.3 Hz, OCHaHb), 3.81 (1H, dd, J 7.5, 
5.3 Hz, CαH), 3.50 (3H, s, OCH3), 3.41-3.07 (6H, m, CH2Ph and 2 × NCH2-allyl), 
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0.93 (9H, s, C(CH3)3), 0.12 (3H, s, SiCH3), 0.10 (3H, s, SiCH3); 13C NMR (126 MHz, 
CDCl3) δC 171.4 (CONH), 170.9 (CO2CH3), 138.5 (Ar-C), 136.4 (2 × =CH), 
136.2 (Ar-C), 129.5 (2 × Ar-CH), 128.5 (2 × Ar-CH), 128.4 (2 × Ar-CH), 
128.4 (2 × Ar-CH), 127.6 (Ar-CH), 126.5 (Ar-CH), 117.5 (2 × CH2=), 61.3 (CαH), 
60.2 (Cα+1H), 59.4 (OCH2), 53.6 (2 × NCH2-allyl), 51.8 (OCH3), 51.6 (N′CH2Ph), 
35.2 (CH2Ph), 26.0 (C(CH3)3), 18.4 (SiC), -5.2 (2 × SiCH3); HRMS m/z (ES+) calcd. 
for C32H46N2O4Si [M+H]+ requires 551.3305, found 551.3320; 
m/z (ES+) 573 ([M+Na]+, 100%), 551 ([M+H]+, 5%).  
 
 
258 
 
Yet further separation furnished benzyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-diallyl-
(S)-seryl]-(S)-phenylalaninate 258 (9.0 mg, 16 µmol, 15%) as a colourless oil: [!]!!"!-9.7 (c 0.6, CHCl3); 1H NMR (500 MHz, CDCl3) δH 7.94 (1H, d, J 7.9 Hz, 
CONH), 7.37-7.27 (5H, m, 5 × Ar-H), 7.21-7.03 (5H, m, 5 × Ar-H), 5.61-5.53 (2H, m, 
2 × =CH), 5.14 (2H, ABq, J 12.2 Hz, OCH2Ph), 5.12-5.02 (4H, m, 2 × CH2=), 4.86 (1H, 
ddd, J 7.9, 6.4, 5.9 Hz, Cα+1H), 4.16 (1H, dd, J 11.1, 4.1 Hz, OCHaHb), 3.90 (1H, dd, 
J 11.1, 8.4 Hz, OCHaHb), 3.53 (1H, dd, J 8.4, 4.1 Hz, CαH), 3.21-3.18 (4H, m, 
2 × NCH2-allyl), 3.15 (1H, dd, J 14.0, 5.9 Hz, CHaHbPh), 3.08 (1H, dd, J 14.0, 6.4 Hz, 
CHaHbPh), 0.89 (9H, s, C(CH3)3), 0.06 (6H, s, 2 × SiCH3); 13C NMR (126 MHz, 
CDCl3) δC 171.9 (CONH), 171.4 (CO2Bn), 136.4 (2 × =CH), 136.1 (Ar-C), 
135.3 (Ar-C), 129.4 (2 × Ar-CH), 128.7 (2 × Ar-CH), 128.7 (2 × Ar-CH), 
128.6 (2 × Ar-CH), 128.6 (Ar-CH), 127.1 (Ar-CH), 117.4 (2 × CH2=), 67.3 (OCH2Ph), 
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63.8 (CαH), 61.3 (OCH2), 54.0 (2 × NCH2-allyl), 53.1 (Cα+1H), 38.1 (CH2Ph), 
26.0 (C(CH3)3), 18.2 (SiC), -5.4 (2 × SiCH3); HRMS m/z (ES+) calcd. for 
C31H45N2O4Si [M+H]+ 537.3149, found 537.3161; m/z (ES+) 559 ([M+Na]+, 100%), 
537 ([M+H]+, 10%).  
 
7.4.23 -  
Methyl (–)-N-[N',N'-diallyl-(S)-seryl]-N-allyl-(S)-phenylalaninate  244 
 
 
 
Following GP2: Starting with methyl (–)-N-[O-(tert-butyldimethylsilyl)-N',N'-diallyl-
(S)-seryl]-N-allyl-(S)-phenylalaninate 248 (206 mg, 0.411 mmol), acetic acid (120.0 µL, 
2.06 mmol) and TBAF (1.6 mL, 1 M in THF), the reaction yielded methyl (–)-N-[N',N'-
diallyl-(S)-seryl]-N-allyl-(S)-phenylalaninate 244 (133 mg, 0.345 mmol, 84%) as a 
colourless oil: Rf 0.12 (hexane:ethyl acetate, 70:30); ![!]!!"  -124 (c 1.2, CHCl3); 
IR νmax (neat, cm-1) 3446 (OH), 3078, 2949, 1743 (C=O), 1635 (C=O), 1436, 1274, 
1195, 993; 1H NMR (400 MHz, CDCl3) δH (major rotamer) 7.25-7.06 (5H, m, 
5 × Ar-H), 5.63 (2H, dddd, J 17.3, 10.0, 7.4, 5.4 Hz, 2 × =CH), 5.59-5.50 (1H, m, 
=CH), 5.11-5.03 (4H, m, 2 × CH2=), 5.03-4.92 (2H, m, CH2=), 4.12 (1H, dd, J 10.2, 
5.2 Hz, Cα+1H), 4.00-3.94 (1H, m, N′CHaHb-allyl), 3.88 (1H, dd, J 11.3, 7.3 Hz, 
OCHaHb), 3.69 (1H, dd, J 11.3, 5.0 Hz, OCHaHb), 3.62 (3H, s, OCH3), 3.60 (1H, dd, 
J 7.3, 5.0 Hz, CαH), 3.32 (1H, dd, J 14.0, 5.2, CHaHbPh), 3.22-3.04 (6H, m, CHaHbPh, 
2 × NCH2-allyl and N′CHaHb-allyl), 2.27 (1H, br s, OH); 13C NMR (101 MHz, 
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CDCl3) δC 172.5 (CON), 170.9 (CO2CH3), 138.0 (Ar-C), 136.1 (2 × =CH), 
133.8 (=CH), 129.4 (2 × Ar-CH), 128.8 (2 × Ar-CH), 126.9 (Ar-CH), 118.8 (CH2=), 
118.1 (2 × CH2=), 60.8 (CαH), 60.4 (Cα+1H), 57.8 (OCH2), 53.5 (2 × NCH2-allyl), 
52.2 (OCH3), 51.6 (N′CH2-allyl), 34.7 (CH2Ph); HRMS m/z (ES+) calcd. for 
C22H30N2O4Na [M+Na]+ requires 409.2103, found 409.2090; m/z (ES+) 409 ([M+Na]+, 
100%). 
 
7.4.24 -  
Methyl (–)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-N-allyl-(S)-phenylalanate   
245 
 
 
 
Following GP3: Starting with methyl (–)-N-[N',N'-diallyl-(S)-seryl]-N-allyl-(S)-
phenylalaninate 244 (76.3 mg, 0.197 mmol) and diethylaminosulfur trifluoride 32 (30.0 
µL, 0.265 mmol), to yield methyl (–)-N-[(2R)-3-(diallylamino)-2-fluoropropanoyl]-N-
allyl-(S)-phenylalanate   245 (56 mg, 0.144 mmol, 73%) as a colourless oil: 
Rf 0.1 (hexane:ethyl acetate, 90:10); [!]!!"  -39.2 (c 1.3, CHCl3); IR νmax (neat, 
cm-1) 3076, 2949, 1743 (C=O), 1653 (C=O), 1436, 1222, 1166, 993; 
1H NMR (500 MHz, CDCl3) δH (major rotamer) 7.25-7.09 (5H, m, 5 × Ar-H), 
5.74 (2H, dddd, J 17.0, 10.3, 6.6, 6.6 Hz, 2 × =CH), 5.52-5.44 (1H, m, =CH), 
5.12-5.04 (6H, m, 3 × CH2=), 5.06 (1H, ddd, J 49.7, 8.0, 3.2 Hz, CHF), 4.31 (1H, dd, 
J 10.3, 5.3 Hz, Cα+1H), 3.86-3.82 (2H, m, N′CH2-allyl), 3.64 (3H, s, OCH3), 3.30 (1H, 
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dd, J 14.1, 5.3 Hz, CHaHbPh), 3.17 (1H, dd, J 14.1, 10.3 Hz, CHaHbPh), 3.13-3.03 (4H, 
m, 2 × NCH2-allyl), 2.82 (1H, ddd, J 18.1, 15.0, 8.0 Hz, CHaHbCHF), 2.68 (1H, ddd, 
J 31.8, 15.0, 3.2 Hz, CHaHbCHF); 13C NMR (125 MHz, CDCl3) δC 170.5 (CO2CH3), 
168.5 (d, J 20.4 Hz, CON), 137.6 (Ar-C), 135.3 (2 × =CH), 133.1 (=CH), 
129.4 (2 × Ar-CH), 128.7 (2 × Ar-CH), 126.9 (Ar-CH), 118.4 (CH2=), 
118.1 (2 × CH2=), 88.4 (d, J 180.7 Hz, CHF), 60.8 (Cα+1H), 57.7 (2 × NCH2-allyl), 
54.3 (d, J 21.6 Hz, CH2CHF), 52.4 (OCH3), 50.8 (d, J 4.1 Hz, N′CH2-allyl), 
34.8 (CH2Ph); 19F NMR (470 MHz, CDCl3) δF -185.4 (ddd, J 49.6, 33.5, 19.0 Hz, 
CHF-minor rotamer), -187.2 (ddd, J 49.7, 31.8, 18.1 Hz, CHF-major rotamer); 
HRMS m/z (ES+) calcd. for C22H29FN2O3Na [M+Na]+ requires 411.2060, 
found 411.2058; m/z (ES+) 411 ([M+Na]+, 100%). 
 
7.4.25 - 
Methyl (–)-N-[(2R)-3-amino-2-fluoropropanoyl]-N-allyl-(S)-phenylalanate 
hydrochloride  260 
 
 
 
1,4-Di(phenylphosphino)butane (16.5 mg, 37.3 µmol, 30.0 mol%) was added to a 
solution of tris(dibenzylideneacetone)dipalladium (22.2 mg, 24.2 µmol, 25.0 mol%) in 
THF (5 mL) and stirred for 15 min until the solution turned yellow. This solution was 
added via canula to a solution of methyl (–)-N-[(2R)-3-(diallylamino)-
2-fluoropropanoyl]-N-allyl-(S)-phenylalanate 254 (51.6 mg, 0.133 mmol, 1.0 eq) and 
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2-mercaptosalicylic acid (60.0 mg, 0.389 mmol, 2.9 eq) in THF (7.0 mL) and the 
solution was brought to reflux for 3 h. The reaction was cooled to rt and water (10 mL) 
and HCl (1 M, 0.2 mL) were added. The precipitate was isolated by filtration and 
washed repeatedly with water with the filtrate collected and the solvent removed in 
vacuo to furnish a yellow solid. This solid was reconstituted in water and re-filtered and 
the sample lyophilised to yield methyl (–)-N-[(2R)-3-amino-2-fluoropropanoyl]-N-allyl-
(S)-phenylalanate hydrochloride 260 (41 mg, 0.20 mmol, 93%) as a colourless solid 
which was used without further purification: [!]!!"  -41.7 (c 1.0, D2O); 
1H NMR (500 MHz, D2O) δH (major rotamer) 7.36-7.22 (5H, m, 5 × Ar-H), 5.62 (1H, 
ddd, J 48.0, 7.4, 3.4 Hz, CαHF), 5.58-5.51 (1H, m, =CH), 5.18-5.14 (2H, m, CH2=), 
4.65 (1H, dd, J 10.7, 5.1 Hz, Cα+1H), 3.94 (1H, m, N′CHaHb-allyl), 3.71 (3H, s, OCH3), 
3.41-3.32 (2H, m, CH2CHF), 3.29-3.16 (3H, m, CH2Ph and N′CHaHb-allyl); 
13C NMR (101 MHz, D2O) δC 172.2 (CO2CH3), 167.5 (d, J 19.8 Hz, CONH), 
136.9 (Ar-C), 131.6 (=CH), 129.4 (2 × Ar-CH), 128.8 (2 × Ar-CH), 127.1 (Ar-CH), 
119.3 (CH2=), 84.3 (d, J 179 Hz, CHF), 61.3 (Cα+1H), 53.0 (OCH3), 51.5 (N′CH2-allyl), 
40.0 (d, J 21.3 Hz, CH2CHF), 33.5 (CH2Ph); 19F NMR (376 MHz, D2O) δF -193.9 (ddd, 
J 48.0, 27.9, 20.2 Hz, CHF-minor rotamer), -194.7 (ddd, J 48.0, 26.8, 21.5 Hz, 
CHF-major rotamer); HRMS m/z (ES+) calcd. for C16H22FN2O3 [M+H]+ requires 
309.1614, found 309.1621; m/z (ES+) 331 ([M+Na]+, 50%), 309 ([M+H]+, 100%). 
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7.4.26 -  
Methyl (–)-N-{(2R)-3-[(tert-butoxycarbonyl)amino]-2-fluoropropanoyl}-N-allyl-(S)-
phenylalanate  265 
 
 
 
Diisopropylethylamine (40.0 µL, 0.230 mmol, 3.0 eq) and di-tert-butyl dicarbonate 
(22.0 mg, 0.101 mmol, 1.3 eq) were added to a solution of methyl (–)-N-((2R)-3-amino-
2-fluoropropanoyl)-N-allyl-(S)-phenylalanate hydrochloride 260 (24.0 mg, 69.6 µmol, 
1.0 eq) in aqueous dioxane (2 mL, 25% v/v) and the mixture was stirred at rt for 24 h. 
The reaction was quenched by the addition of saturated aqueous Na2CO3 (2 mL) and the 
aqueous phase extracted with ethyl acetate (2 × 2 mL). The organic extracts were 
combined, dried over Na2SO4, filtered and the solvent removed in vacuo to yield an oil. 
The product was purified by silica gel column chromatography, eluting with hexane and 
ethyl acetate (90:10), to yield methyl (–)-N-{(2R)-3-[(tert-butoxycarbonyl)amino]-
2-fluoropropanoyl}-N-allyl-(S)-phenylalanate 265 (20.1 mg, 49.2 µmol, 71%) as a 
colourless oil: [!]!!"  -52.1 (c 2.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δH (major rotamer) 7.31-7.16 (5H, m, 5 × Ar-H), 5.55-5.46 (1H, m, =CH), 
5.17-5.10 (2H, m, CH2=), 5.15-5.02 (1H, m, CαHF), 4.93 (1H, t, J 6.3 Hz, NHBoc), 
4.40 (1H, dd, J 10.4, 5.1 Hz, Cα+1H), 3.96-3.87 (1H, m, N′CHaHb-allyl), 3.73 (3H, s, 
OCH3), 3.58-3.29 (3H, m, CH2CHF and N′CHaHb-allyl), 3.38 (1H, dd, J 14.2, 5.1 Hz, 
CHaHbPh), 3.24 (1H, dd, J 14.2, 10.4 Hz, CHaHbPh), 1.44 (9H, s, C(CH3)3); 
13C NMR (75 MHz, CDCl3) δC 170.5 (CO2CH3), 167.8 (d, J 20.3 Hz, CONH), 
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156.0 (OCOtBu), 137.5 (Ar-C), 132.8 (=CH), 129.5 (2 × Ar-CH), 128.7 (2 × Ar-CH), 
127.0 (Ar-CH), 119.0 (CH2=), 86.4 (d, J 181 Hz, CHF), 60.9 (Cα+1H), 52.5 (OCH3), 
51.1 (N′CH2-allyl), 41.7 (d, J 23.8 Hz, CH2CHF), 34.8 (CH2Ph), 30.0 (C(CH3)3), 28.5 
(C(CH3)3); 19F NMR (376 MHz, CDCl3) δF -191.5 (ddd, J 47.3, 25.4, 19.6 Hz, 
CHF-minor rotamer), -192.5 (ddd, J 48.0, 22.9, 17.4 Hz, CHF-major rotamer); 
HRMS m/z (ES+) calcd. for C21H29FN2O5Na [M+Na]+ requires 431.1958, 
found 431.1948; m/z (ES+) 431 ([M+Na]+, 100%).  
 
7.4.27 -  
Methyl (–)-N-{(2R)-3-[(tert-butoxycarbonyl)amino]-2-fluoropropanoyl}-N-formyl-
(S)-phenylalanate  267 
 
 
 
Ru(CO)HCl(PPh3)3 (4.7 mg, 4.9 µmol, 10 mol%) was added to a solution of                      
methyl (–)-N-{(2R)-3-[(tert-butoxycarbonyl)amino]-2-fluoropropanoyl}-N-allyl-(S)-
phenylalanate 265 (20 mg, 48.9 µmol, 1.0 eq) in toluene (2 mL) and the mixture was 
brough to reflux for 3 h. The solution was cooled to rt and the solvent removed 
in vacuo. RuCl3 (1.0 mg, 1.7 µmol, 3.5 mol%) and NaIO4 (20.8 mg, 97.8 mmol, 2 eq) in 
aqueous 1,2-dichloroethane (50% v/v, 1 mL) were added to the isomerised product and 
the mixture was stirred at rt for 24 hr. The reaction was quenched by the addition of 
saturated aqueous Na2CO3 (1 mL) and the organics extracted with ethyl 
acetate (2 × 2 mL). The organic phases were combined washed with brine (1 mL) and 
dried over Na2SO4, filtered and the solvent removed in vacuo to yield an oil. The 
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product was purified by silica gel chromatography to yield methyl (–)-N-{(2R)-3-[(tert-
butoxycarbonyl)amino]-2-fluoropropanoyl}-N-formyl-(S)-phenylalanate 267 (11.5 mg, 
29 µmol, 59%) as a colourless oil: [!]!!" -30.2 (c 1.1, CHCl3); 1H NMR (500 MHz, 
CDCl3) δH 8.97 (1H, s, CHO), 7.29-7.10 (5H, m, 5 × Ar-H), 5.49 (1H, dd, J 10.2, 
5.2 Hz, NHBoc), 5.35-5.26 (1H, br m, CHF), 4.74 (1H, m, Cα+1H), 3.76 (3H, s, OCH3), 
3.52 (1H, dd, J 14.2, 5.4 Hz, CHaHbPh), 3.54-3.34 (1H, m, CHaHbCHF), 3.28 (1H, dd, 
J 14.2, 11.1 Hz, CHaHbPh), 3.32-3.23 (1H, m, CHaHbCHF), 1.44 (9H, s, C(CH3)3); 
13C NMR (126 MHz, CDCl3) δC 169.1 (CO2CH3), 168.8 (CHO), 161.3 (d, J 9.6 Hz, 
CONH), 155.7 (OCOtBu), 136.3 (Ar-C), 129.2 (2 × Ar-CH), 128.6 (2 × Ar-CH), 
127.1 (Ar-CH), 87.0 (d, J 186 Hz, CHF), 60.4 (1H, s, Cα+1H), 52.8 (OCH3), 41.8 (d, 
J 23.1 Hz, CH2CHF), 34.3 (CH2Ph), 29.7 (C(CH3)3), 28.3 (C(CH3)3); 
19F NMR (470 MHz, CDCl3) δF -190.5 (br m, CHF-minor rotamer), -191.5 (br m, 
CHF-major rotamer); HRMS m/z (ES+) calcd. for C19H25FN2O6Na [M+Na]+ 419.1594, 
found 419.1588; m/z (ES+) 419 ([M+Na]+, 100%). 
 
7.4.28 - 
Methyl (–)-N-{(2R)-3-[(tert-butoxycarbonyl)amino]-2-fluoropropanoyl}-(S)-
phenylalanate 268 
 
 
 
Saturated aqueous sodium carbonate (0.5 mL) was added to a solution of 
NaHCO3 (1.0 mg, 9.4 µmol, 0.33 eq) and methyl (–)-N-{(2R)-3-[(tert-
butoxycarbonyl)amino]-2-fluoropropanoyl}-N-formyl-(S)-phenylalanate 267 (11.0 mg, 
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28 µmol, 1.0 eq) in aqueous acetone (25% v/v, 1 mL) and the mixture was stirred 
vigorously for 12 h at rt. The mixture was diluted with water (1 mL) and ethyl 
acetate (2 mL), the organic phase was separated and the aqueous layer further extracted 
with ethyl acetate (2 mL). The organic phases were combined, washed with 
brine (1 mL), dried with Na2SO4, filtered and the solvent removed in vacuo. The oil was 
purified by silica gel column chromatography, to yield methyl (–)-N-{(2R)-3-[(tert-
butoxycarbonyl)amino]-2-fluoropropanoyl}-(S)-phenylalanate 268 (4.7 mg, 12 µmol, 
46%) as a colourless solid: [!]!!"  -26.1 (c 0.1, CHCl3); 1H NMR (500 MHz, 
CDCl3) δH 7.34-7.11 (5H, m, 5 × Ar-H), 6.70 (1H, br d, J 4.9 Hz, CONH), 
4.95-4.84 (3H, m, CHF, Cα+1H and NHBoc), 3.82-3.72 (1H, m, CHaHbCHF), 3.75 (3H, 
s, OCH3), 3.54-3.44 (1H, m, CHaHbCHF), 3.19 (1H, dd, J 14.0, 5.7 Hz, CHaHbPh), 
3.12 (1H, dd, J 14.0, 6.5 Hz, CHaHbPh), 1.43 (9H, s, C(CH3)3); 13C NMR (126 MHz, 
CDCl3) δC 171.2 (CO2CH3), 167.9 (d, J 20.7 Hz, CONH), 155.7 (OCOtBu), 
135.3 (Ar-C), 129.1 (2 × Ar-CH), 128.8 (2 × Ar-CH), 127.4 (Ar-C), 90.0 (d, J 194.5 Hz, 
CHF), 52.8 (Cα+1H), 52.6 (OCH3), 42.1 (d, J 21.1 Hz, CH2CHF), 37.7 (CH2Ph), 
29.7 (C(CH3)3), 28.3 (C(CH3)3); 19F NMR (470 MHz, CDCl3) δF -195.3 (ddd, J 48.1, 
23.7, 23.7 Hz, CHF); HRMS m/z (ES+) calcd. for C18H25FN2O5Na [M+Na]+ requires 
391.1645, found 391.1645; m/z (ES+) 391 ([M+Na]+, 100%). 
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Appendix 1.1- Crystallographic information for (R,R)-144 with O.nova telomeric 
DNA 
 
 
PDB ID - 3NYP*  
 
Data collection  
Total number of reflections collected 85447 
Number of unique reflections 23982 
Space Group P21212 
Cell dimensions: a,b and c (Å) 57.80, 44.46, 28.14 
Angle (º) α, β, γ 90.00, 90.00, 90.00 
Maximum resolution (Å) 1.18 
Rmerge 0.051 
I/σI 15.5 
I/σ (highest resolution shell) 5.7 
Completeness (%) 97.7 
Redundancy 3.6 
Refinement  
Resolution range used in refinement (Å) 21.99-1.18 
Number of unique reflections used in 
refinement 23275 
Completeness (%) 94.6 
Rfactor(%) 16.6 
Rfree(%) 18.8 
Number of G-quadruplexes/asymmetric unit 1 
Number of ligands/asymmetric unit 1 
Number of asymmetric units per unit cell 4 
Number of atoms  
DNA 506 
Ligand 36 
Potassium ions 4 
Water 177 
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Appendix 1.2 - Crystallographic information for (S,S)-144 with O. nova 
telomeric DNA 
PDB ID - 3NZ7 **  
 
Data collection  Total number of reflections collected 248167 
Number of unique reflections 25994 
Space Group P21212 
Cell dimensions: a, b and c (Å) 55.57, 42.70, 27.00 
Angle (º) α, β, γ 90.00, 90.00, 90.00 
Maximum resolution (Å) 1.1 
Rmerge 0.073 
I/σI 25.4 
I/σ (highest resolution shell) 6.8 
Completeness (%) 97.1 
Redundancy 5 
Refinement  Resolution range used in refinement (Å) 7.80 - 1.10 
Number of unique reflections used in 
refinement 25901 
Completeness (%) 97 
Rfactor(%) 13.8 
Rfree(%) 15.9 
Number of G-quadruplexes/asymmetric unit 1 
Number of ligands/asymmetric unit 1 
Number of asymmetric units/unit cell 4 
Number of atoms  DNA 506 
Ligand 36 
Potassium ions 4 
Water 188 
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Appendix 1.3 - Crystallographic information for 234 
 
 
 
 
A. Crystal Data  
 
dsdh4 
 
Empirical Formula C36H44N4O6 
Formula Weight 628.77 
Crystal Color, Habit colorless, prism 
Crystal Dimensions 0.200 × 0.020 × 0.020 mm 
Crystal System orthorhombic 
Lattice Type Primitive 
No. of Reflections Used for Unit 
Cell Determination (2θ range) 6233 (81.8 - 139.0 °) 
Lattice Parameters a =  16.681(5) Å 
 b =  17.399(6) Å 
 c =  24.279(8) Å 
 V = 7047(4) Å3 
Space Group P212121(#19) 
Z value 8 
Dcalc 1.185 g/cm3 
F000 2688.00 
μ(CuKα) 6.576 cm-1 
 
B. Intensity Measurements 
 
Diffractometer Radiation CuKα (λ = 1.54187 Å) 
 multi-layer mirror monochromated 
Take-off Angle 2.8 ° 
Detector Aperture 2.0 - 2.5 mm horizontal, 2.0 mm vertical 
Crystal to Detector Distance 21 mm 
Voltage, Current 40kV, 20mA 
Temperature -100.0 °C 
Scan Type ω-2θ 
2θmax 137.0 ° 
No. of Reflections Measured Total: 73332, Unique: 12756 (Rint = 0.1119) 
 Friedel pairs: 5732 
Corrections Lorentz-polarization 
 Absorption (trans. factors: 0.472 - 0.987) 
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C. Structure Solution and Refinement 
 
Structure Solution Direct Methods 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.1213 . P)2  
 + 0.1830 .  P ] 
 where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 137.0° 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 12756 
No. Variables 845 
Reflection/Parameter Ratio 15.10 
Residuals: R1 (I>2.00σ(I)) 0.0707 
Residuals: R (All reflections) 0.0761 
Residuals: wR2 (All reflections) 0.1914 
Goodness of Fit Indicator 1.059 
Flack Parameter (Friedel pairs = 5732) 0.14(17) 
Max Shift/Error in Final Cycle 0.001 
Maximum peak in Final Diff. Map 0.69 e‑/Å3 
Minimum peak in Final Diff. Map -0.38 e‑/Å3
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